Novel DDR1 antibodies and uses thereof
Monoclonal antibodies targeting DDR1 modulate its activity to suppress tumor progression and metastasis, providing a therapeutic strategy for breast and other solid tumors by reducing tumor burden and inhibiting growth.
Patent Information
- Application Number
- JP2024135167
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-12-17
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-12-17
AI Technical Summary
Aberrant expression of tumor discoidin domain receptors 1 (DDR1) contributes to the progression and metastasis of various solid tumors, including breast cancer, and existing treatments fail to effectively target DDR1 for therapeutic intervention.
Development of isolated monoclonal antibodies and antigen-binding fragments that specifically bind to DDR1, modulating its activity by blocking ligand binding and suppressing its function, which are administered alone or in combination with anti-tumor drugs linked via photolabile or enzymatically cleavable linkers.
The antibodies effectively reduce tumor burden, eradicate tumors, and inhibit tumor growth by targeting DDR1, offering a therapeutic approach for breast cancer and other solid tumors, including pancreatic, lung, colon, ovarian, and breast cancer subtypes.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 949,300, filed December 17, 2019, the entire contents of which are incorporated herein by reference.
[0002] Statement Regarding Government-Sponsored Research This invention was made with government support under Grant No. CA220578 awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention.
[0003] Sequence Listing Reference The Sequence Listing was submitted concurrently with the specification as an ASCII text file with the file name P0362WO_ST25.txt, created on December 17, 2020, and 127 kilobytes in size. The information in the electronic format of the Sequence Listing is a part of the specification and is incorporated herein by reference in its entirety.
[0004] 1. Field The present disclosure relates generally to the fields of medicine, oncology, and immunology. More specifically, the present disclosure relates to antibodies that bind to DDR1 and can treat cancer, including breast cancer. [Background technology]
[0005] 2. Description of Related Art Aberrant expression of tumor discoidin domain receptor 1 (DDR1) and 2 (DDR2) proteins is associated with the progression of multiple solid tumor types, including breast cancer (Valiathan et al., 2012, Rammal et al., 2016, Gao et al., 2016, Bayer et al., 2019). Published data support a role for DDR proteins in promoting tumor progression and metastatic potential (Gao et al., 2016, Bayer et al., 2019, Hidalgo-Carcedo et al., 2011, Marcotte et al., 2012). However, genetic ablation of Ddr1 in MMTV-PyMT mice promotes spontaneous tumor formation (Takai et al., 2018), suggesting a stage-dependent tumor DDR1 function in cancer development and progression. Summary of the Invention
[0006] overview Thus, in one aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to DDR1. In certain embodiments, the antibody or antigen-binding fragment, upon binding to DDR1, regulates the activity of DDR1, i.e., inhibits DDR1. In certain embodiments, the antibody or antigen-binding fragment, upon binding to DDR1, specifically blocks the binding of a ligand to DDR1.
[0007] In one aspect, the isolated monoclonal antibody or antigen-binding fragment thereof comprises a light chain (LC) variable region (VL) and a heavy chain (HC) variable region (VH) comprising the CDR amino acid sequences of the clone pairs set forth in Tables 1 and 2, respectively, and variants thereof, wherein one or more of the LC-CDRs and / or one or more of the HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof. In some embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof is a murine antibody, rodent antibody, rabbit antibody, chimeric antibody, humanized antibody, or human antibody. In some embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof may have VL and VH chains with amino acid sequences at least 90% or 95% identical to the sequences of the clone pairs in Tables 3 and 4, respectively. In some embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof may have VL and VH chains that are encoded by nucleic acid sequences that are at least 80% or 90% identical to the sequences of the clone pairs in Tables 8 and 9, respectively. In some embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof may have VL and VH chains that have amino acid sequences that are identical to the sequences of the clone pairs in Tables 3 and 4, respectively. In some embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof may have VL and VH chains that are encoded by nucleic acid sequences that are identical to the sequences of the clone pairs in Tables 8 and 9, respectively.
[0008] The variant may be one in which one or more of the HC-CDRs or LC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof. In certain embodiments, each CDR is defined according to the Kabat definition, the Chothia definition, the IMGT definition, a combination of the Kabat and Chothia definitions, the AbM definition, or the contact definition of a CDR.
[0009] In another aspect, the present disclosure provides an isolated monoclonal antibody or antigen-binding fragment thereof that competes for the same epitope as an antibody having the light chain and heavy chain CDR amino acid sequences of a clone pair from Table 1 and Table 2, respectively.
[0010] In certain embodiments, the isolated monoclonal antibodies described herein are chimeric, humanized, or human antibodies. In certain embodiments, the isolated monoclonal antibodies described herein are of the IgG1, IgG2, IgG3, or IgG4 type. In certain embodiments, the antigen-binding fragments described herein are recombinant ScFv (single-chain variable region fragment) antibodies, Fab fragments, F(ab')2 fragments, or Fv fragments.
[0011] In another aspect, a pharmaceutical composition is provided comprising an isolated monoclonal antibody or antigen-binding fragment thereof provided herein and at least one pharmaceutically acceptable carrier.
[0012] In another aspect, an isolated nucleic acid is provided that encodes the isolated monoclonal antibody or antigen-binding fragment thereof provided herein.
[0013] In another aspect, a vector is provided that comprises an isolated nucleic acid provided herein.
[0014] In another aspect, a host cell is provided comprising the vector provided herein. The host cell can be a mammalian cell. The host cell can be a CHO cell.
[0015] In another aspect, hybridomas are provided that encode or produce the isolated monoclonal antibodies provided herein.
[0016] In another aspect, a method of producing an antibody is provided, which may include culturing a host cell provided herein under conditions suitable for expressing the antibody and recovering the antibody.
[0017] In another aspect, provided is a chimeric antigen receptor (CAR) protein comprising the antigen-binding fragment provided herein.
[0018] In another aspect, an isolated nucleic acid is provided that encodes a CAR protein provided herein.
[0019] In another aspect, engineered cells are provided that contain the isolated nucleic acids provided herein. In certain embodiments, the cells are T cells, NK cells, or myeloid cells. In another aspect, a method for treating or alleviating the effects of cancer in a subject, or a method for treating or alleviating fibrosis (e.g., organ fibrosis) is provided, comprising administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof as defined herein. In treating cancer, the method can reduce or eradicate tumor burden in the subject, reduce the number of tumor cells, reduce tumor size, or eradicate tumors in the subject. In some embodiments, the cancer to be treated is breast cancer.
[0020] The antibody or antigen-binding fragment thereof may be administered locally, intravenously, intraarterially, intratumorally, or subcutaneously. In some embodiments, the method comprises administering to the subject a topoisomerase inhibitor, an anthracycline topoisomerase inhibitor, an anthracycline, daunorubicin, a nucleoside metabolic inhibitor, cytarabine, a hypomethylating agent, low-dose cytarabine (LDAC), a combination of daunorubicin and cytarabine, injectable daunorubicin and cytarabine liposome, Vyxeos®, azacitidine, Vidaza®, decitabine, all-trans retinoic acid (ATRA), arsenic, arsenic trioxide, histamine dihydrochloride, Ceplene®, interleukin-2, aldesleukin, Proleukin®, getumuzumab Ozogamicin, Mylotarg®, FLT-3 inhibitors, midostaurin, Rydapt®, clofarabine, farnesyltransferase inhibitors, decitabine, IDH1 inhibitors, ivosidenib, Tibsovo®, IDH2 inhibitors, enasidenib, Idhifa®, smoothened (SMO) inhibitors, glasdegib, arginase inhibitors, IDO inhibitors, epacadostat, BCL-2 inhibitors, venetoclax, Venclexta®, platinum-conjugated derivatives, oxaliplatin, kinase inhibitors, tyrosine kinase inhibitors, PI3 kinase inhibitors, BTK inhibitors, ibrutinib, IMBRUVICA® The method further comprises administering one or more drugs selected from the group consisting of CALQUENCE® (registered trademark), acalabrutinib, CALQUENCE®, zanubrutinib, PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, LAG3 antibody, ICOS antibody, TIGIT antibody, TIM3 antibody, CD40 antibody, 4-1BB antibody, CD47 antibody, SIRP1α antibody or fusion protein, E-selectin antagonist, antibody that binds to a tumor antigen, antibody that binds to a T cell surface marker, antibody that binds to a myeloid cell or NK cell surface marker, alkylating agent, nitrosourea, antimetabolite, antitumor antibiotic, plant-derived alkaloid, hormone therapy agent, hormone antagonist, aromatase inhibitor, and P-glycoprotein inhibitor.
[0021] In some embodiments, the isolated monoclonal antibody or antigen-binding fragment thereof may comprise an anti-tumor drug linked thereto. The anti-tumor drug may be linked to the antibody via a photolabile linker. The anti-tumor drug may be linked to the antibody via an enzymatically cleavable linker. The anti-tumor drug may be a toxin, a radioisotope, a cytokine, or an enzyme.
[0022] In another embodiment, a method for detecting cancer cells or fibrous tissue in a sample or subject is provided, comprising: (a) contacting a subject or a sample from a subject with an antibody or antigen-binding fragment thereof as defined herein; and (b) detecting binding of the antibody to cancer cells or fibrous tissue in the subject or sample. The sample may be a body fluid or biopsy, or blood, bone marrow, sputum, tears, saliva, mucosa, serum, urine, or feces. Detection may involve immunohistochemistry, flow cytometry, FACS, ELISA, RIA, or Western blot. Some embodiments may further comprise performing steps (a) and (b) again and determining a change in the level of detection compared to the first time. The isolated monoclonal antibody or antigen-binding fragment thereof may further comprise a label, such as a peptide tag, an enzyme, a magnetic particle, a chromophore, a fluorescent molecule, a chemiluminescent molecule, or a dye. The isolated monoclonal antibody or antigen-binding fragment thereof may be conjugated to a liposome or nanoparticle.
[0023] The use of the word "a" or "an," when used in conjunction with the word "comprising" in the claims and / or specification, may mean "one," but may also be consistent with the meanings of "one or more," "at least one," and "one or more than one." The word "about" means plus or minus 5% of the stated numerical value.
[0024] [The present invention 1001] An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to discoidin domain receptor 1 (DDR1) protein, A light chain variable region having LC-LC-CDR1, LC-CDR2, and LC-CDR3 within the light chain variable region selected from SEQ ID NOs: 108 to 128, and A heavy chain variable region having HC-CDR1, HC-CDR2, and HC-CDR3 within the heavy chain variable region selected from SEQ ID NOs: 129 to 149 Contains, or Variants thereof, wherein one or more of the LC-CDRs and / or the HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof. Including, The isolated monoclonal antibody or antigen-binding fragment thereof. [The present invention 1002] LC-LC-CDR1, LC-CDR2, and LC-CDR3 of a clone pair selected from Table 1, and HC-CDR1, HC-CDR2, and HC-CDR3 selected from Table 2 Contains, or Variants thereof, wherein one or more of the LC-CDRs and / or the HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof. Including, 1001. An isolated monoclonal antibody or antigen-binding fragment thereof of the present invention. [The present invention 1003] a light chain variable region having an LC-CDR1 comprising the amino acid sequence QSIGSV (SEQ ID NO: 11), an LC-CDR2 comprising the amino acid sequence GVF, and an LC-CDR3 comprising the amino acid sequence QYIPYGSSP (SEQ ID NO: 12); and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLNRYY (SEQ ID NO: 57), an HC-CDR2 comprising the amino acid sequence ISYGDTT (SEQ ID NO: 58), and an HC-CDR3 comprising the amino acid sequence ARADTGDNGYLGLQL (SEQ ID NO: 59); (DDR1-9), or Variants thereof, wherein one or more of the LC-CDRs and / or the HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof. Including, 1001. An isolated monoclonal antibody or antigen-binding fragment thereof of the present invention. [The present invention 1004] a light chain variable region having an LC-CDR1 comprising the amino acid sequence ESINSW (SEQ ID NO: 41), an LC-CDR2 comprising the amino acid sequence DAS, and an LC-CDR3 comprising the amino acid sequence QSYYIINRSNYGNS (SEQ ID NO: 42); and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLSSYY (SEQ ID NO: 102), an HC-CDR2 comprising the amino acid sequence ITTAGPL (SEQ ID NO: 103), and an HC-CDR3 comprising the amino acid sequence ARGHAGSIYYSYFDL (SEQ ID NO: 104); (DDR1-32), or Variants thereof, wherein one or more of the LC-CDRs and / or the HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof. Including, 1001. An isolated monoclonal antibody or antigen-binding fragment thereof of the present invention. [The present invention 1005] A light chain variable region having an amino acid sequence selected from SEQ ID NOs: 108 to 128, and a heavy chain variable region having an amino acid sequence selected from SEQ ID NOs: 129 to 149. 1001. An isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, comprising: [The present invention 1006] (a) a light chain variable region (DDR1-1K) having the amino acid sequence of SEQ ID NO: 108, and a heavy chain variable region (DDR1-1H) having the amino acid sequence of SEQ ID NO: 129; (b) a light chain variable region (DDR1-3K) having the amino acid sequence of SEQ ID NO: 109, and a heavy chain variable region (DDR1-3H) having the amino acid sequence of SEQ ID NO: 130; (c) a light chain variable region (DDR1-5K) having the amino acid sequence of SEQ ID NO: 110, and a heavy chain variable region (DDR1-5H) having the amino acid sequence of SEQ ID NO: 131; (d) a light chain variable region (DDR1-6K) having the amino acid sequence of SEQ ID NO: 111, and a heavy chain variable region (DDR1-6H) having the amino acid sequence of SEQ ID NO: 132; (e) a light chain variable region (DDR1-9K) having the amino acid sequence of SEQ ID NO: 112, and a heavy chain variable region (DDR1-9H) having the amino acid sequence of SEQ ID NO: 133; (f) a light chain variable region (DDR1-11K) having the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region (DDR1-11H) having the amino acid sequence of SEQ ID NO: 134; (g) a light chain variable region (DDR1-12K) having the amino acid sequence of SEQ ID NO: 114, and a heavy chain variable region (DDR1-12H) having the amino acid sequence of SEQ ID NO: 135; (h) a light chain variable region (DDR1-13K) having the amino acid sequence of SEQ ID NO: 115, and a heavy chain variable region (DDR1-13H) having the amino acid sequence of SEQ ID NO: 136; (i) a light chain variable region (DDR1-14K) having the amino acid sequence of SEQ ID NO: 116, and a heavy chain variable region (DDR1-14H) having the amino acid sequence of SEQ ID NO: 137; (j) a light chain variable region (DDR1-15K) having the amino acid sequence of SEQ ID NO: 117, and a heavy chain variable region (DDR1-15H) having the amino acid sequence of SEQ ID NO: 138; (k) a light chain variable region (DDR1-17K) having the amino acid sequence of SEQ ID NO: 118, and a heavy chain variable region (DDR1-17H) having the amino acid sequence of SEQ ID NO: 139; (l) a light chain variable region (DDR1-20K) having the amino acid sequence of SEQ ID NO: 119, and a heavy chain variable region (DDR1-20H) having the amino acid sequence of SEQ ID NO: 140; (m) a light chain variable region (DDR1-21K) having the amino acid sequence of SEQ ID NO: 120, and a heavy chain variable region (DDR1-21H) having the amino acid sequence of SEQ ID NO: 141; (n) a light chain variable region (DDR1-22K) having the amino acid sequence of SEQ ID NO: 121, and a heavy chain variable region (DDR1-22H) having the amino acid sequence of SEQ ID NO: 142; (o) a light chain variable region (DDR1-23K) having the amino acid sequence of SEQ ID NO: 122, and a heavy chain variable region (DDR1-23H) having the amino acid sequence of SEQ ID NO: 143; (p) a light chain variable region (DDR1-26K) having the amino acid sequence of SEQ ID NO: 123, and a heavy chain variable region (DDR1-26H) having the amino acid sequence of SEQ ID NO: 144; (q) a light chain variable region (DDR1-28K) having the amino acid sequence of SEQ ID NO: 124, and a heavy chain variable region (DDR1-28H) having the amino acid sequence of SEQ ID NO: 145; (r) a light chain variable region (DDR1-29K) having the amino acid sequence of SEQ ID NO: 125, and a heavy chain variable region (DDR1-29H) having the amino acid sequence of SEQ ID NO: 146; (s) a light chain variable region (DDR1-32K) having the amino acid sequence of SEQ ID NO: 126, and a heavy chain variable region (DDR1-32H) having the amino acid sequence of SEQ ID NO: 147; (t) a light chain variable region (DDR1-33K) having the amino acid sequence of SEQ ID NO: 127, and a heavy chain variable region (DDR1-33H) having the amino acid sequence of SEQ ID NO: 148, or (u) a light chain variable region (DDR1-34K) having the amino acid sequence of SEQ ID NO: 128, and a heavy chain variable region (DDR1-34H) having the amino acid sequence of SEQ ID NO: 149 Contains, or and variants thereof, wherein the light chain variable region has an amino acid sequence identity of 80% or more to the amino acid sequence of the parent light chain variable region, and the heavy chain variable region has an amino acid sequence identity of 80% or more to the amino acid sequence of the parent heavy chain variable region, and the variants specifically bind to DDR1 protein. Including, 1001. An isolated monoclonal antibody or antigen-binding fragment thereof of the present invention. [The present invention 1007] A light chain variable region (DDR1-9K) having the amino acid sequence of SEQ ID NO: 112, and a heavy chain variable region (DDR1-9H) having the amino acid sequence of SEQ ID NO: 133. 1001. An isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, comprising: [The present invention 1008] A light chain variable region (DDR1-32K) having the amino acid sequence of SEQ ID NO: 126, and a heavy chain variable region (DDR1-32H) having the amino acid sequence of SEQ ID NO: 147. 1001. An isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, comprising: [The present invention 1009] 1001 or 1002. The isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, wherein said isolated monoclonal antibody is a murine antibody, a rodent antibody, a rabbit antibody, a chimeric antibody, a humanized antibody, or a human antibody. [The present invention 1010] 1009. The isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, wherein said isolated monoclonal antibody is a rabbit antibody or a chimeric antibody. [The present invention 1011] 1009. The isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, wherein said isolated monoclonal antibody is a rabbit antibody or a chimeric antibody. [The present invention 1012] 1005. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 1001 to 1004, wherein the isolated monoclonal antibody is a humanized antibody. [The present invention 1013] A light chain variable region (DDR1-9hu_Lv1 or DDR1-9hu_Lc2) having the amino acid sequence of SEQ ID NO: 150 or 151, and Heavy chain variable region (DDR1-9hu_Hv) having the amino acid sequence of SEQ ID NO: 152 Contains, or and variants thereof, wherein the light chain variable region has an amino acid sequence identity of 80% or more to the amino acid sequence of the parent light chain variable region, and the heavy chain variable region has an amino acid sequence identity of 80% or more to the amino acid sequence of the parent heavy chain variable region, and the variants specifically bind to DDR1 protein. 1001. An isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, comprising: [The present invention 1014] An isolated monoclonal antibody or an antigen-binding fragment thereof according to any one of claims 1001 to 1013, wherein the antigen-binding fragment is an ScFv (single-chain variable region fragment) antibody, a Fab fragment, a F(ab')2 fragment, or an Fv fragment. [The present invention 1015] An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to an epitope specifically bound by any of the isolated monoclonal antibodies or antigen-binding fragments thereof of the present invention 1001 to 1014, or to all or part of the same epitope. [The present invention 1016] An isolated monoclonal antibody or antigen-binding fragment thereof that competes for the same epitope as any of the isolated monoclonal antibodies or antigen-binding fragments thereof of the present inventions 1001 to 1014. [The present invention 1017] An antibody-drug conjugate comprising any one of the isolated monoclonal antibodies or antigen-binding fragments thereof of the present inventions 1001 to 1016 and an anti-tumor drug linked to the antibody or antigen-binding fragment thereof. [The present invention 1018] The antibody-drug conjugate of the present invention 1017, wherein said anti-tumor drug is linked to said antibody via a photolabile linker or an enzymatically cleavable linker. [The present invention 1019] The antibody-drug conjugate of claim 1017 or 1018, wherein said anti-tumor drug is a toxin, a radioisotope, a cytokine, or an enzyme. [The present invention 1020] A pharmaceutical composition comprising any one of the isolated monoclonal antibodies or antigen-binding fragments thereof of the present inventions 1001 to 1014 and a pharmaceutically acceptable carrier. [The present invention 1021] An isolated polynucleotide encoding any one of the isolated monoclonal antibodies or antigen-binding fragments thereof of the present invention 1001 to 1014. [The present invention 1022] A vector comprising the isolated nucleic acid of the present invention. [The present invention 1023] The vector of the present invention 1022, comprising an expression vector capable of expressing the encoded antibody or antigen-binding fragment thereof. [The present invention 1024] A host cell comprising the polynucleotide of the present invention 1021 or the vector of the present invention 1022 or 1023. [The present invention 1025] A host cell of the present invention 1024 which is a mammalian cell. [The present invention 1026] The host cell of the present invention 1025, which is a CHO cell. [The present invention 1027] A hybridoma or engineered cell that encodes and / or produces any of the isolated monoclonal antibodies of the present invention 1001 to 1014. [The present invention 1028] A host cell according to any one of claims 1024 to 1026 of the present invention, capable of expressing the monoclonal antibody or an antigen fragment thereof. A method for producing an antibody, comprising culturing the method comprising culturing the host cell under conditions suitable for expression of the antibody or antigen-binding fragment thereof, and isolating the antibody or antigen-binding fragment thereof. [The present invention 1029] A chimeric antigen receptor (CAR) protein comprising any one of the antibodies or antigen-binding fragments thereof of the present invention 1001 to 1014. [The present invention 1030] An isolated nucleic acid encoding a CAR protein of the present invention. [The present invention 1031] A vector comprising the isolated nucleic acid of the present invention. [The present invention 1032] 1031. The vector of the present invention, capable of expressing said CAR protein. [The present invention 1033] An engineered cell comprising the isolated nucleic acid of the invention 1030 or the vector of the invention 1032. [The present invention 1034] The engineered cell of the present invention 1033, which is a T cell, a NK cell, or a macrophage. [This invention 1035] Administering a therapeutically effective amount of any of the antibodies or antigen-binding fragments thereof of the present invention 1001 to 1014, or the engineered cells of the present invention 1033 or 1034 to a subject. 10. A method of treating or ameliorating the effects of cancer in a subject, comprising: [The present invention 1036] The method of claim 1035, wherein the tumor burden in said subject is reduced or eradicated. [This invention 1037] The method of claim 1036, wherein the number of tumor cells is reduced or the tumor size is reduced. [The present invention 1038] The method of claim 1035, wherein said cancer is a solid cancer or tumor. [This invention 1039] The method of claim 1038, wherein the cancer is selected from pancreatic cancer; lung cancer, including small cell lung cancer and non-small cell lung cancer; colon and colorectal cancer; head and neck cancer; gastric (stomach) cancer; ovarian cancer; breast cancer; kidney cancer; liver cancer; prostate cancer; cervical cancer; brain cancer; skin cancer, including melanoma; and bone cancer. [The present invention 1040] The method of claim 1038, wherein the cancer is breast cancer. [This invention 1041] The method of claim 1040, wherein the breast cancer is of a breast cancer subtype selected from (a) luminal A (ER+ and / or PR+, HER2-), (b) luminal B (ER+ and / or PR+, HER2+), (c) triple negative (ER-, PR-, HER2-), (d) HER2+ / ER- (ER-, PR-, and HER2+), and (e) unclassified (ER-, PR-, HER2-, cytokeratin 5 / 6-, and HER1-). [The present invention 1042] Any of the methods of claims 1035 to 1041, wherein cancer cells of said cancer are identified as expressing or determined to express secreted DDR1 protein and / or DDR1 protein on the surface of said cancer cells. [This invention 1043] The method of any of claims 1035 to 1042, wherein said antibody or antigen-binding fragment thereof is administered intravenously, intraarterially, intratumorally, or subcutaneously. [This invention 1044] The subject may be treated with any of the following drugs: topoisomerase inhibitors, anthracyclines, topoisomerase inhibitors, anthracyclines, daunorubicin, nucleoside metabolic inhibitors, cytarabine, hypomethylating agents, low-dose cytarabine (LDAC), a combination of daunorubicin and cytarabine, injectable daunorubicin and cytarabine liposomes, Vyxeos®, azacitidine, Vidaza®, decitabine, all-trans retinoic acid (ATRA), arsenic, arsenic trioxide, histamine dihydrochloride, Ceplene®, interleukin-2, aldesleukin, Proleukin®, getumuzumab Ozogamicin, Mylotarg®, FLT-3 inhibitors, midostaurin, Rydapt®, clofarabine, farnesyltransferase inhibitors, decitabine, IDH1 inhibitors, ivosidenib, Tibsovo®, IDH2 inhibitors, enasidenib, Idhifa®, smoothened (SMO) inhibitors, glasdegib, arginase inhibitors, IDO inhibitors, epacadostat, BCL-2 inhibitors, venetoclax, Venclexta®, platinum-conjugated derivatives, oxaliplatin, kinase inhibitors, tyrosine kinase inhibitors, PI3 kinase inhibitors, BTK inhibitors, ibrutinib, IMBRUVICA®, a The method of claim 1035, further comprising administering one or more drugs selected from the group consisting of calbrutinib, CALQUENCE®, zanubrutinib, PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, LAG3 antibody, ICOS antibody, TIGIT antibody, TIM3 antibody, CD40 antibody, 4-1BB antibody, CD47 antibody, SIRP1α antibody or fusion protein, E-selectin antagonist, antibody that binds to a tumor antigen, antibody that binds to a T cell surface marker, antibody that binds to a myeloid cell or NK cell surface marker, alkylating agent, nitrosourea, antimetabolite, antitumor antibiotic, plant-derived alkaloid, hormone therapy agent, hormone antagonist, aromatase inhibitor, and P-glycoprotein inhibitor. [This invention 1045] 1045. The method of any of claims 1035 to 1044, wherein said isolated monoclonal antibody or antigen-binding fragment thereof further comprises an anti-tumor drug linked thereto. [The present invention 1046] 1045. The method of claim 1045, wherein said anti-tumor drug is a toxin, a radioisotope, a cytokine, or an enzyme. [This invention 1047] administering to the subject a therapeutically effective amount of any of the antibodies or antigen-binding fragments thereof of the present inventions 1001 to 1014, or the engineered cells of the present invention 1033 or 1034. 20. A method of treating or alleviating the effects of fibrosis in a subject, comprising: [This invention 1048] 1047. The method of claim 1047, wherein the subject has organ fibrosis. [This invention 1049] The method of claim 1048, wherein the subject has renal, hepatic, pulmonary, or cardiac fibrosis. [The present invention 1050] 1049. The method of claim 1049, wherein the subject has pulmonary fibrosis. [This invention 1051] The method of claim 1050, wherein said subject has interstitial lung disease. [This invention 1052] The method of claim 1050, wherein said subject has idiopathic pulmonary fibrosis (IPF) or lung scarring. [This invention 1053] 1. A method for detecting cancer cells or cancer stem cells in a sample or subject, comprising: (a) contacting a subject or a sample from a subject with any one of the antibodies or antigen-binding fragments thereof of the present invention 1001 to 1014; and (b) detecting binding of the antibody to cancer cells or cancer stem cells in the subject or sample; The method comprising: [This invention 1054] 1053. The method of claim 1053, wherein said sample is a body fluid or a biopsy. [This invention 1055] 1054. The method of claim 1054, wherein the sample is blood, bone marrow, sputum, tears, saliva, mucous membrane, serum, urine, or feces. [This invention 1056] 1056. The method of any of claims 1053 to 1055, wherein said detecting comprises immunohistochemistry, flow cytometry, FACS, ELISA, RIA, or Western blot. [This invention 1057] performing steps (a) and (b) again; and determining the change in the level of detection compared to the first time The method of the present invention 1053 further comprising: [This invention 1058] 1058. The method of any of claims 1053 to 1057, wherein said isolated monoclonal antibody or antigen-binding fragment thereof further comprises a label. [This invention 1059] 1058. The method of claim 1058, wherein said label is a peptide tag, an enzyme, a magnetic particle, a chromophore, a fluorescent molecule, a chemiluminescent molecule, or a dye. [The present invention 1060] 1059. The method of any of claims 1035 to 1059, wherein said isolated monoclonal antibody or antigen-binding fragment thereof is conjugated to a liposome or nanoparticle. It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein. Other objects, features, and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description. [Brief explanation of the drawings]
[0025] The drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. [Figure 1] DDR1 confers breast tumor growth in immunocompetent hosts. (Figure 1a) Immunoblot of DDR1, DDR2, and the loading control GAPDH in DDR1 WT / KO breast tumor E0771 cells. (Figure 1b) Cell proliferation of WT / KO E0771 cells measured by MTT assay (n=6). (Figure 1c-d) Quantification of DDR1 WT / KO M-Wnt cell migration (c) and invasion (d) (n=6 random fields). (Figure 1e) Growth of DDR1 WT / KO E0771 tumors in Rag1- / - (n=6, e) hosts. (Figure 1f-h) Growth of WT / KO E0771 (n=6, f), M-Wnt (n=7, g), and AT-3 (n=7, h) tumors in C57BL / 6 mice. (Figure 1i-j) Tumor growth kinetics (i) and weight (j) at endpoint for E0771 DDR1 WT / KO tumors implanted from Rag1- / - mice into C57BL / 6 hosts (n = 8). (Figure 1k) Tumor rechallenge. For the first round of inoculation, mice were challenged with saline buffer or DDR1 KO E0771 cells in one side of the inguinal mammary gland. Thirty days later, mice were rechallenged with DDR1 WT E0771 tumor cells in both sides of the inguinal mammary gland. L, left; R, right. (Figure 1l-m) Tumor curves (Figure 1l) and weights (Figure 1m) from rechallenged mice (n = 6). Values represent mean ± SEM, p values as indicated. [Figure 2]DDR1 excludes antitumor immune cell infiltration. (Figure 2a) Representative images (n=3) of CD8+ and CD4+ T cell staining at the tumor edge (upper panel, indicated by the red dashed line) and the tumor center (lower panel). Scale bar: 50 μm. (Figure 2b-g) Numbers of tumor-infiltrating lymphocytes (TIL) normalized by tumor weight per gram. Cell counts of CD8+ (Figure 2b) and CD4+ (Figure 2c) T cells, cytokine IFN-γ+ CD8+ (Figure 2d) and CD4+ (Figure 2e) T cells, and CD44high CD62Llow activated CD8+ (Figure 2f) and CD4+ (Figure 2g) T cells. (Figure 2h-j) WT / KO E0771 tumor growth in C57BL / 6 hosts with prior treatment with either anti-IgG or anti-CD8 antibodies (n=5). Tumor volume (Figure 2h), image (Figure 2i), and weight (Figure 2j) at endpoint are shown. Scale bar: 1 cm. (Figure 2k-m) Adoptive transfer of CD8+ T cells or medium (sham) into Rag1- / - mice (n=6) burdened with DDR1 WT / KO E0771 tumors. Arrow (Figure 2k) indicates CD8+ T cell transfer on day 17. Tumor image (Figure 2l) and weight (Figure 2m) are shown. Scale bar: 1 cm. Values represent mean ± SEM, p values as indicated. [Figure 3]DDR1-dependent ECM remodeling inhibits antitumor immune infiltration. (Figure 3a) Diagrams (top) and tumor curves of full-length DDR1 from DDR1 KO E0771 tumor cells expressing various DDR1 expression vectors: wild-type (WT), empty vector (EV), kinase domain deletion (ΔKD), and KO E0771 tumor cells carrying only the extracellular domain (ECD). All p values are relative to the KO group. TM: transmembrane domain. (Figure 3b) Diagrams (top) of the ECD consisting of the DS and DS-like (DSL) domains, and the crystal structure (bottom) of the mouse DDR1 DS domain generated by Jmol software. The amino acid residues targeted in the mutational analysis are indicated. (Figure 3c) Collagen binding of WT and point-mutated ECD expressed in KO E0771 cells was assessed by ELISA (n=4). (Figures 3d-k) Individual tumor growth curves of ectopically expressed KO E0771 tumor cells carrying either WT or point-mutated ECD. Tumor incidence is indicated in parentheses for each panel. (Figure 3l) Representative SEM image of WT / KO E0771 tumor cells cultured in vitro. (Figure 3m) Decellularized ECM from E0771 cells inhibits T cell migration in an ECM-dependent manner. Shown on the left is a diagram of a Transwell migration assay. (Figure 3n) WT / KO E0771 tumors transplanted from Rag1- / - mice into C57BL / 6 hosts were analyzed by SHG (gray), CD3 staining (green), To-pro-3 staining (red), and collagen fiber individualization (far right panel). Block arrows indicate tumor edges. Scale bar: 50 µm. (Figure 3o-p) Quantification of tumor fiber alignment (o) and fiber length (p) using CT Fire software. Values represent mean ± SEM, p-values as indicated. [Figure 4]DDR1 is a potential therapeutic target for enhancing antitumor immunity. (Figure 4a) Immunoblot analysis of ectopic human (hu)DDR1 and endogenous mouse DDR1 in cell lysates and medium from E0771-derived cells. (Figure 4b-c) Tumor growth curves (Figure 4b) and weight (Figure 4c) of E0771-derived DDR1 WT, KO, and KO+huDDR1 cells (n=6). Images of tumors are shown above. (Figure 4d-e) Growth curves of individual KO+huDDR1 tumors in C57BL / 6 hosts treated with isotype IgG (Figure 4d) or anti-huDDR1 antibody #9 (Figure 4e). Arrows indicate the start date of antibody administration. (Figure 4f) Survival curves for the isotype IgG and anti-huDDR1 treatment groups. (Figure 4g) KO+huDDR1 tumors were analyzed by SHG (gray), CD3 staining (green), ToxoPro-3 staining (red), and collagen fiber individualization (far right panel). Block arrows indicate tumor edges. Scale bar: 50 μm. (Figures 4h-i) Quantification of tumor fiber parameters: fiber alignment (angle of coefficient of variation, Figure 4h) and fiber length (Figure 4i). (Figure 4j) Correlation between huDDR1 mRNA and the abundance of tumor-infiltrating CD8+ T cells in 1,093 breast cancer patient samples (TIMER). (Figures 4k-m) Correlation between DDR1 mRNA levels and the antitumor immune markers IFNG (Figure 4k), CD8A (Figure 4l), and GZMB (Figure 4m) in 37 TNBC patient samples (GSE88847). (Figure 4n) Model of ECD (red circle) remodeling collagen fibers (curve), forming a barrier to prevent immune cell infiltration. Values represent mean ± SEM, p-values as indicated. [Figure 5]Tumor DDR1 ablation inhibits tumor growth in immunocompetent hosts. (Figure 5a) DDR1 expression in normal (N) tissues and breast tumor (T) samples from the TCGA database. P values are analyzed using the Wilcoxon test. (Figure 5b) Immunoblot of DDR1 in WT / KO cells derived from mouse breast tumor cells M-Wnt and AT-3. (Figures 5c-d) Genomic DNA sequencing of the sgRNA target site in the mouse Ddr1 locus. Both the AT-3 and E0771 KO clones contain a single base pair insertion (Figure 5c) (SEQ ID NO: 312; SEQ ID NO: 313; SEQ ID NO: 314). The M-Wnt DDR1 KO clone has an 8-bp deletion (Figure 5d). The truncation occurred upstream of the PAM sequence. (Figure 5e) Representative images of migration and invasion of DDR1 WT / KO M-Wnt and AT-3 cells (SEQ ID NO: 315, SEQ ID NO: 316). (Figure 5f) In vitro cell proliferation of WT / KO M-Wnt tumor cells. (Figure 5g) M-Wnt tumor growth in nude mice (n = 4). (Figure 5h) Individual tumor growth curves of DDR1 KO E0771 cells inoculated into C57BL / 6 mice at various numbers (0.5, 5, 10, and 20 × 10 cells per mouse, n = 4). (Figures 5i-k) Tumor volume (Figure 5i), images (Figure 5j), and weight (Figure 5k) of M-Wnt DDR1 WT, KO, and 1:1 mixture tumors at the time of inoculation (n = 8). Values represent mean ± SEM, p values as indicated. [Figure 6]Immunodepletion and adoptive transfer of CD8+ cells. (Figures 6a-d) Percentage of T cells from KO and parental controls positive for Ki67 (CD4+ in Figure 6a and CD8+ in Figure 6b), IFNγ (CD8+ in Figure 6c), or Gzmb (CD8+ in Figure 6d). (Figures 6e-f) Flow cytometry of CD4+ and CD8+ T cells from splenocytes of anti-IgG2b-treated or anti-CD8 antibody-treated C57BL / 6 mice (e), and percentage of CD8+ among CD3+ T cells in blood (f, n = 5). (Figure 6g) Number of CD8+ T cells in TILs normalized by tumor weight in Rag1- / - mice (n = 6). (Figures 6h-i) RNA-seq heatmaps for T cell homing and chemokine genes derived from DDR1 WT / KO E0771 tumors transplanted from Rag1- / - mice into C57BL / 6 hosts. ***, p<0.001. Values represent mean±SEM, p-values as indicated. [Figure 7] DDR1-mediated collagen remodeling is required for immune exclusion. (Figure 7a-b) Growth curves (Figure 7a) and tumor weights (Figure 7b) of E0771 DDR1 KO+ECD, KO, KO+DS, and KO+DSL tumors in C57BL / 6 hosts (n=10). (Figure 7c) Co-IP of type I collagen and Flag-tagged ECD WT and mutants. (Figure 7d) Immunoblot of intracellular full-length DDR1 and soluble ECD in conditioned medium from mouse (left) and various human (right) breast cancer cell lines. (Figure 7e) Top 10 biological processes (BPs) based on gene ontology analysis of RNA-seq data from E0771 DDR1 WT and KO tumors transplanted from Rag1- / - mice into C57BL / 6 hosts. Values represent mean ± SEM, p-values as indicated. [Figure 8]Screening for huDDR1 neutralizing antibodies. (Figure 8a) Transwell migration assay of purified CD8+ T cells in the presence of conditioned medium from E0771 cells containing endogenous DDR1 WT, DDR1 KO, and DDR1 KO, as well as ectopic expression of huDDR1. (Figure 8b) Representative neutralizing antibody screening by CD8+ T cell migration assay using conditioned medium from KO or KO+huDDR1 E0771 cells. Control: isotype IgG; anti-huDDR1 antibodies: #3, #9, #14, and #33. (Figure 8c) Body weight measurements of mice treated with control (α-IgG) and anti-huDDR1 antibody #9 (n=5). (Figures 8d-e) KO+huDDR1 E0771 tumors in C57BL / 6 (Figure 8d) and Rag1- / - hosts (Figure 8e) treated with either isotype IgG or anti-huDDR1 #33 antibody. (Figure 8f) KO+huDDR1 tumor centers were analyzed by SHG (gray), CD3 staining (green), To-pro-3 staining (red), and collagen fiber individualization (far right panel). Scale bar: 50 μm. (Figure 8g-i) Correlation between huDDR1 mRNA levels and the immune cytotoxicity marker genes IFNG (Figure 8g), GZMB (Figure 8h), and PRF1 (Figure 8i) in 1,093 breast cancer tumors in the TIMER database. Values represent mean ± SEM, p-values as indicated. [Figure 9] Binding of DDR1-mAb to DDR1 analyzed by ELISA. [Figure 10] Determination of antibody binding affinity to human DDR1 and mouse DDR1 using titration ELISA. [Figure 11] Kinetic binding curve of anti-DDR1 antibody measured using an Octet instrument. [Figure 12]Anti-hECD antibodies inhibit spontaneous tumor growth. To demonstrate the effect of anti-DDR1 antibody treatment on breast cancer development at various stages, MMTV-PyMT mice (C57BL / 6 strain background) were treated with control IgG or anti-DDR1 antibodies for 2 weeks when the average tumor size reached 100 mm3 ("post-tumor"). (Figures 12A-B) Tumor growth kinetics (per mouse, Figure 12A) and tumor incidence (per mouse, Figure 12B) in the MMTV-PyMT spontaneous mammary tumor model on a C57BL / 6 genetic background treated with Ctrl (n = 7) or humanized anti-DDR1#9 antibody (n = 8) in the "post-tumor" scheme. (Figure 12C) Representative images of tumors from the post-tumor treatment group analyzed by SHG (gray), CD3 staining (green), To-pro-3 staining (red), and collagen fiber individualization (far right panel). Scale bar: 50 μm. [Figure 13] Comparison of anti-hECD antibodies and DDR1 kinase inhibitors. E0771 mammary tumors were treated with anti-hECD antibodies, and tumor growth (Figure 13A) and host body weight (Figure 13B) were assessed. The previously published small molecule DDR1 kinase inhibitor 7rh did not reduce tumor growth (Figure 13C). This is consistent with the assertion that DDR1-dependent elimination of antitumor immunity is independent of its kinase activity. (Figure 13D) 7rh had no effect on host body weight. (Figure 13E) Tumors treated with 7rh had substantially lower DDR1 autophosphorylation, a marker of DDR1 tyrosine kinase activity (Gao et al., J Med Chem 2013). [Figure 14] DDR1 is required for the growth of several tumor types. (Figure 14A) CRISPR-based genetic ablation of tumor Ddr1 significantly increased survival of immunocompetent hosts bearing ID8agg ovarian tumors. (Figure 14B-C) Ddr1 KO in B16 melanoma or MC38 colorectal tumors did not affect tumor growth in syngeneic immunocompetent hosts. [Figure 15A]Correlation of DDR1 and anti-tumor immune markers. (Figure 15A) DDR1 mRNA levels in multiple cancers negatively correlated with cytotoxic immune markers such as granzyme B (GZMB), suggesting that DDR1 may antagonize anti-tumor immunity in many cancer types. [Figure 15B] Correlation of DDR1 and anti-tumor immune markers. (FIG. 15B) Analysis of the TCGA breast cancer proteome dataset (NCI CPTAC) showed that DDR1 protein levels also negatively correlated with CD8 and proteins in the cytolytic effector pathway. [Figure 15C] Correlation of DDR1 and anti-tumor immune markers. (FIG. 15C) Analysis of the TCGA breast cancer proteome dataset (NCI CPTAC) showed that DDR1 protein levels also negatively correlated with CD8 and proteins in the cytolytic effector pathway. [Figure 16] High tumor DDR1 protein correlates with immunity in TNBC. (Left) Images of multiplex IHC for DDR1, CD8, and tumor-specific panCK using treatment-naïve DDR1-high (n=7) and DDR1-low (n=5) TNBC tumor samples. Scale bar: 200 mm. Using a treatment-naïve TNBC cohort in multiplex IHC, DDR1-high tumors were shown to exhibit a lower percentage of CD8+ T cells present within the tumor and a higher percentage of CD8+ T cells present at the tumor margin (right) compared to DDR1-low tumors, which had a higher percentage of CD8+ T cells distributed throughout the tumor. [Figure 17] Schematic diagram of the recombinant construct of the DDR1 extracellular (ECD) protein domain for expression in HEK293 cells. DS: N-terminal discoidin domain; DSL: DS-like domain; JM: juxtamembrane domain. [Figure 18A]Determination of DDR1 antibody binding to the ECD and DS or DSL domains using an ELISA method. Recombinant DDR1 extracellular (ECD) protein and domain proteins were coated onto high-binding 96-well plates at a concentration of 2 μg / ml (Figure 18A). Titration of the DDR1-9Hu antibody was used to determine binding curves and EC50s. Deletion of the DS or DSL domain of the DDR1 ECD resulted in decreased binding by the humanized DDR1-9hu antibody. Deletion of the DS domain alone reduced binding with an EC50 of 168 ng / ml versus 83 ng / ml, while deletion of the DSL domain completely abolished DDR1-9 (Figure 18B) and DDR1-14 antibody binding (Figure 18C). [Figure 18B] See legend to Figure 18A. [Figure 18C] See legend to Figure 18A. [Figure 19] Determination of cross-reactivity of a panel of monoclonal antibodies to human DDR2 using an ELISA method. DDR1 or DDR2 ECD protein was coated onto a high-binding plate, and each of the monoclonal antibodies was added at a concentration of 1 μg / ml for binding detection with an HRP-conjugated anti-rabbit antibody (Jackson ImmuneResearch, PA). DETAILED DESCRIPTION OF THE INVENTION
[0026] Description of exemplary embodiments The present inventors have determined that tumor discoidin domain receptor 1 (DDR1) plays an important role in regulating host immunity. DDR1 is a collagen receptor with tyrosine kinase activity. The present inventors have found that DDR1 induces tumor defenses that prevent host immune cells from infiltrating tumor tissue and attacking the tumor itself in a kinase-independent manner. The present inventors have isolated a panel of novel monoclonal antibodies that recognize the DDR1 protein, which can be used to treat cancer. Anti-human DDR1 antibodies are antagonists of DDR1 function and prevent DDR1 from inducing tumor defenses.
[0027] The following description of the present disclosure is intended merely to illustrate various embodiments of the present disclosure. Therefore, the specific modifications discussed should not be construed as limitations on the scope of the present disclosure. It will be apparent to those skilled in the art that various equivalents, changes, and modifications can be made without departing from the scope of the present disclosure. It is understood that such equivalent embodiments are included herein. All references cited herein, including publications, patents, and patent applications, are incorporated herein by reference in their entirety.
[0028] I. Definition It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of "or" means "and / or" unless specifically stated otherwise. Furthermore, the use of the term "including" and other forms, such as "includes" and "included," is not limiting. Also, terms such as "element" or "component" encompass both elements and components that contain one unit and elements and components that contain more than one subunit, unless specifically stated otherwise. Also, the use of the term "moiety" can include part of a moiety or the entire moiety.
[0029] As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise.
[0030] As used herein, when referring to a measurable value, such as an amount, time duration, or the like, the term "about" is intended to encompass a variation of up to ±10% from the specified value. Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and the like used in the specification and claims should be understood in all instances to be modified by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and appended claims are approximations that may vary depending on the desired properties sought to be obtained by the disclosed subject matter. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of at least the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. However, any numerical value inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0031] The term "antibody" refers to an intact immunoglobulin of any isotype, or a fragment thereof that can compete with the intact antibody for specific binding to a target antigen, including, for example, chimeric, humanized, fully human, and bispecific antibodies. "Antibody" is a class of antigen-binding proteins. Intact antibodies generally contain at least two full-length heavy chains and two full-length light chains, but in some cases may contain fewer chains, such as naturally occurring antibodies in camelids, which may contain only heavy chains. Antibodies can be derived from a single source or can be "chimeric," i.e., different portions of the antibody can be derived from two different antibodies, as further described below. Antigen-binding proteins, antibodies, or binding fragments can be produced in hybridomas, by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Unless otherwise indicated, the term "antibody" includes antibodies containing two full-length heavy chains and two full-length light chains, as well as derivatives, variants, fragments, and muteins thereof, examples of which are described below. Additionally, unless expressly excluded, antibodies include monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as "antibody mimetics"), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as "antibody conjugates"), and fragments thereof, respectively. In some embodiments, the term also encompasses peptibodies.
[0032] Naturally occurring antibody structural units typically comprise a tetramer. Each such tetramer typically consists of two identical pairs of polypeptide chains, each pair having one full-length "light" chain (in certain embodiments, approximately 25 kDa) and one full-length "heavy" chain (in certain embodiments, approximately 50-70 kDa). The amino-terminal portion of each chain typically contains a variable region of approximately 100-110 or more amino acids responsible for antigen recognition. The carboxy-terminal portion of each chain typically defines a constant region that may be involved in effector function. Human light chains are typically classified as kappa and lambda light chains. Heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, defining the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. IgG has several subclasses, including, but not limited to, IgG1, IgG2, IgG3, and IgG4. IgM has subclasses, including, but not limited to, IgM1 and IgM2. IgA is similarly subdivided into subclasses, including, but not limited to, IgA1 and IgA2. Within full-length light and heavy chains, the variable and constant regions are typically connected by a "J" region of about 12 or more amino acids, with heavy chains also including a "D" region of about 10 or more amino acids. See, e.g., Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, NY (1989) (incorporated by reference in its entirety for all purposes)). The variable regions of each light / heavy chain pair typically form the antigen-binding site.
[0033] The term "variable region" or "variable domain" refers to a portion of an antibody light and / or heavy chain, typically comprising approximately the amino-terminal 120-130 amino acids in the heavy chain and about the amino-terminal 100-110 amino acids in the light chain. In certain embodiments, the variable regions of different antibodies vary extensively in amino acid sequence, even among antibodies of the same species. The variable regions of an antibody typically determine the specificity of a particular antibody for its target.
[0034] Variable regions typically exhibit the same general structure of relatively conserved framework regions (FRs) connected by three hypervariable regions, also called complementarity-determining regions or CDRs. The CDRs from the two chains of each pair are typically aligned by the framework regions, thereby enabling binding to a specific epitope. From the N-terminus to the C-terminus, both light and heavy chain variable regions typically contain the following domains: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The assignment of amino acids to each domain typically follows the definitions of the Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), Chothia & Lesk, J. Mol. Biol., 196:901-917 (1987), or Chothia et al., Nature, 342:878-883 (1989).
[0035] In certain embodiments, an antibody heavy chain binds to an antigen in the absence of an antibody light chain. In certain embodiments, an antibody light chain binds to an antigen in the absence of an antibody heavy chain. In certain embodiments, an antibody binding region binds to an antigen in the absence of an antibody light chain. In certain embodiments, an antibody binding region binds to an antigen in the absence of an antibody heavy chain. In certain embodiments, an individual variable region specifically binds to an antigen in the absence of other variable regions.
[0036] In certain embodiments, the definitive description of CDR and the identification of the residues comprising antibody binding site are achieved by elucidating the structure of antibody and / or the structure of antibody-ligand complex.In certain embodiments, this can be achieved by any of various techniques known to those skilled in the art, such as X-ray crystallography.In certain embodiments, various analytical methods can be used to identify or estimate CDR regions.Examples of such methods include, but are not limited to, Kabat definition, Chothia definition, AbM definition, IMGT definition, and contact definition.
[0037] The Kabat definition is a standard for numbering residues in antibodies and is typically used to identify CDR regions. See, e.g., Johnson & Wu, Nucleic Acids Res., 28:214-8 (2000). The Chothia definition is similar to the Kabat definition, but takes into account the location of specific structural loop regions. See, e.g., Chothia et al., J. Mol. Biol., 196:901-17 (1986); Chothia et al., Nature, 342:877-83 (1989). The AbM definition uses a suite of integrated computer programs developed by the Oxford Molecular Group to model antibody structure. See, e.g., Martin et al., Proc Natl Acad Sci (USA), 86:9268-9272 (1989); "AbM™, A Computer Program for Modeling Variable Regions of Antibodies," Oxford, UK, Oxford Molecular, Ltd. The AbM definition models the tertiary structure of an antibody from primary sequence using a combination of knowledge databases and ab initio methods, such as those described by Samudrala et al., "Ab Initio Protein Structure Prediction Using a Combined Hierarchical Approach," in PROTEINS, Structure, Function and Genetics Suppl., 3:194-198 (1999). Contact definitions are based on analysis of available complex crystal structures. See, e.g., MacCallum et al., J. Mol. Biol., 5:732-45 (1996).The IMGT definition utilizes a unique numbering system that combines definitions of framework (FR) and CDR regions, structural data from X-ray diffraction studies, and characterization of hypervariable loops, as described by Lefranc MP et al., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," Dev Comp Immunol 27:55-77 (2003). In a preferred embodiment, the CDR sequences are based on the IMGT definition.
[0038] By convention, the CDR regions in the heavy chain are typically referred to as H1, H2, and H3, numbered sequentially from the amino terminus to the carboxy terminus. The CDR regions in the light chain are typically referred to as L1, L2, and L3, numbered sequentially from the amino terminus to the carboxy terminus. In the present disclosure, the CDR regions of the light chain variable region are also referred to as LC-CDR1, LC-CDR2, and LC-CDR3, and the CDR regions of the heavy chain variable region are referred to as HC-CDR1, HC-CDR2, and HC-CDR3.
[0039] The term "light chain" includes full-length light chains and fragments thereof that contain sufficient variable region sequence to confer binding specificity. A full-length light chain contains a variable region domain, VL, and a constant region domain, CL. The variable region domain of the light chain is at the amino terminus of the polypeptide. Light chains include kappa chains and lambda chains.
[0040] The term "heavy chain" includes full-length heavy chains and fragments thereof having sufficient variable region sequence to confer binding specificity. A full-length heavy chain includes a variable region domain, VH, and three constant region domains, CH1, CH2, and CH3. The VH domain is at the amino terminus of the polypeptide, the CH domain is at the carboxyl terminus, and CH3 is closest to the carboxy terminus of the polypeptide. The heavy chain can be of any isotype, including IgG (including IgG1, IgG2, IgG3, and IgG4 subtypes), IgA (including IgA1 and IgA2 subtypes), IgM, and IgE.
[0041] Bispecific or bifunctional antibodies are typically artificial hybrid antibodies with two different heavy / light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods, including, but not limited to, hybridoma fusion or Fab' fragment binding. See, for example, Songsivilai et al., Clin. Exp. Immunol., 79:315-321 (1990); Kostelny et al., J. Immunol., 148:1547-1553 (1992).
[0042] The term "antigen" refers to a substance that can induce an adaptive immune response. Specifically, an antigen is a substance that is targeted by a receptor of the adaptive immune response. Typically, an antigen is a molecule that binds to an antigen-specific receptor but is unable to induce an immune response in the body by itself. Antigens are usually proteins or polysaccharides, but less frequently, lipids. Suitable antigens include, but are not limited to, parts of bacteria (coats, capsules, cell walls, flagella, pili, and toxins), viruses, and other microorganisms. Antigens also include tumor antigens, e.g., antigens generated by mutations in tumors. As used herein, antigens also include immunogens and haptens.
[0043] The term "antigen binding protein" ("ABP"), as used herein, means any protein that binds to a specific target antigen. In the present application, the specific target antigen is the DDR1 protein or a fragment thereof. "Antigen binding proteins" include, but are not limited to, antibodies and antigen-binding fragments thereof. Peptibodies are another example of antigen binding proteins.
[0044] The term "antigen-binding fragment," as used herein, refers to a portion of a protein that can specifically bind to an antigen. In certain embodiments, the antigen-binding fragment is derived from an antibody comprising one or more CDRs, or any other antibody fragment that binds to the antigen but does not comprise an intact native antibody structure. In certain embodiments, the antigen-binding fragment is not derived from an antibody, but rather from a receptor. Examples of antigen-binding fragments include, but are not limited to, diabodies, Fab, Fab', F(ab'), Fv fragments, disulfide-stabilized Fv fragments (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabodies (ds diabodies), single-chain antibody molecules (scFv), scFv dimers (bivalent diabodies), multispecific antibodies, single-domain antibodies (sdAbs), camelid antibodies, or nanobodies, domain antibodies, and bivalent domain antibodies. In certain embodiments, the antigen-binding fragment can bind to the same antigen as the parent antibody. In certain embodiments, the antigen-binding fragment may comprise one or more CDRs from a particular human antibody grafted onto framework regions from one or more different human antibodies. In certain embodiments, the antigen-binding fragment is derived from a receptor and contains one or more mutations. In certain embodiments, the antigen-binding fragment does not bind to the natural ligand of the receptor from which the antigen-binding fragment is derived.
[0045] The term "Fab fragment" contains one light chain and the CH1 and variable regions of one heavy chain. The heavy chain of a Fab molecule cannot form disulfide bonds with another heavy chain molecule.
[0046] The term "Fab' fragment" comprises one light chain and a portion of one heavy chain containing the VH and CH1 domains and the region between the CH1 and CH2 domains, allowing interchain disulfide bonds to form between the two heavy chains of two Fab' fragments to form an F(ab')2 molecule.
[0047] An "F(ab')2 fragment" contains two light chains and two heavy chains containing a portion of the constant region between the CH1 and CH2 domains, such that an interchain disulfide bond is formed between the two heavy chains. Thus, an F(ab')2 fragment consists of two Fab' fragments held together by disulfide bonds between the two heavy chains.
[0048] The "Fc" region comprises two heavy chain fragments comprising the CH1 and CH2 domains of an antibody, held together by two or more disulfide bonds and hydrophobic interactions of the CH3 domain.
[0049] The "Fv region" comprises the variable regions from both the heavy and light chains, but lacks the constant regions.
[0050] A "single-chain antibody" is an Fv molecule in which the heavy and light chain variable regions are linked by a flexible linker to form a single polypeptide chain that forms the antigen-binding region. Single-chain antibodies are described in detail in International Patent Application Publication No. WO 88 / 01649 and U.S. Pat. Nos. 4,946,778 and 5,260,203, the disclosures of which are incorporated by reference.
[0051] A "domain antibody" is an immunologically functional immunoglobulin fragment that contains only the variable region of a heavy chain or the variable region of a light chain. In some instances, two or more VH regions are covalently linked with a peptide linker to create a bivalent domain antibody. The two VH regions of a bivalent domain antibody can target the same or different antigens.
[0052] A "bivalent antigen-binding protein" or "bivalent antibody" comprises two antigen-binding sites. In some cases, the two binding sites have the same antigen specificity. Bivalent antigen-binding proteins and bivalent antibodies may be bispecific (see below). In certain embodiments, a bivalent antibody other than a "multispecific" or "multifunctional" antibody is typically understood to have each of its binding sites identical.
[0053] A "multispecific antigen-binding protein" or "multispecific antibody" is one that targets multiple antigens or epitopes.
[0054] A "bispecific," "dual-specific," or "bifunctional" antigen-binding protein or antibody is a hybrid antigen-binding protein or antibody, respectively, that has two different antigen-binding sites. Bispecific antigen-binding proteins and antibodies are a class of multispecific antigen-binding protein antibodies and can be produced by a variety of methods, including, but not limited to, fusion of hybridomas or linking of Fab' fragments. See, for example, Songsivilai and Lachmann, 1990, Clin. Exp. Immunol. 79:315-321; Kostelny et al., 1992, J. Immunol. 148:1547-1553. The two binding sites of a bispecific antigen-binding protein or antibody bind to two different epitopes that may reside on the same or different protein targets.
[0055] "Binding affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be expressed by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Low-affinity antibodies generally bind antigens slowly and tend to dissociate easily, while high-affinity antibodies generally bind antigens faster and tend to remain bound longer. Various methods for measuring binding affinity are known in the art, any of which can be used for purposes of the present invention. Specific illustrative and exemplary embodiments for measuring binding affinity are described below.
[0056] An antibody that "specifically binds" or is "specific for" a particular polypeptide or epitope on a particular polypeptide is an antibody that binds to a particular polypeptide or an epitope on a particular polypeptide without substantially binding to any other polypeptides or polypeptide epitopes. For example, a DDR1-specific antibody of the present invention is specific for DDR1. In some embodiments, an antibody that binds to DDR1 has a specificity of 100 nM or less, 10 nM or less, 1 nM or less, 0.1 nM or less, 0.01 nM or less, or 0.001 nM or less (e.g., 10 -8 M or less, e.g., 10 -8 M~10 -13 M, e.g., 10 -9 M~10 -13 It has a dissociation constant (Kd) of 1 M.
[0057] When used in the context of antigen binding proteins (e.g., antibodies or antigen-binding fragments thereof) that compete for the same epitope, the term "compete" refers to competition between the antigen binding proteins as determined by an assay in which the antigen binding protein (e.g., antibody or antigen-binding fragment thereof) being tested prevents or inhibits (e.g., reduces) specific binding of a reference antigen binding protein (e.g., a ligand or reference antibody) to a common antigen (e.g., DDR1 or a fragment thereof). Various types of competitive binding assays can be used to determine whether one antigen-binding protein competes with another, such as solid-phase direct or indirect radioimmunoassays (RIAs), solid-phase direct or indirect enzyme immunoassays (EIAs), sandwich competition assays (see, e.g., Stahl et al., 1983, Methods in Enzymology 9:242-253), solid-phase direct biotin-avidin EIAs (see, e.g., Kirkland et al., 1986, J. Immunol. 137:3614-3619), solid-phase direct label assays, solid-phase direct label sandwich assays (see, e.g., Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press), solid-phase direct label RIAs using 1-125 labels (see, e.g., Morel et al., 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press), and the like. These include solid-phase direct biotin-avidin EIA (see, e.g., Cheung, et al., 1990, Virology 176:546-552), and direct labeling RIA (Moldenhauer et al., 1990, Scand. J. Immunol. 32:77-82). Typically, such assays involve the use of purified antigen bound to a solid surface or cells bearing either an unlabeled test antigen-binding protein or a labeled reference antigen-binding protein. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test antigen-binding protein. Typically, the test antigen-binding protein is present in excess.Antigen-binding proteins identified by competitive assays (competitor antigen-binding proteins) include antigen-binding proteins that bind to the same epitope as the reference antigen-binding protein, and antigen-binding proteins that bind to an adjacent epitope sufficiently close to the epitope bound by the reference antigen-binding protein so that steric hindrance occurs. Further details regarding methods for determining competitive binding are provided in the Examples herein. Typically, when a competitor antigen-binding protein is present in excess, it inhibits (e.g., reduces) specific binding of the reference antigen-binding protein to a common antigen by at least 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, or 75% or more. In some cases, binding is inhibited by at least 80-85%, 85-90%, 90-95%, 95-97%, or 97% or more.
[0058] The term "epitope" as used herein refers to a specific group of atoms or amino acids on an antigen to which an antibody binds. An epitope can be either a linear epitope or a conformational epitope. A linear epitope is formed by a continuous sequence of amino acids from an antigen and interacts with an antibody based on its primary structure. On the other hand, a conformational epitope is composed of discontinuous fragments of the antigen's amino acid sequence and interacts with an antibody based on the antigen's 3D structure. Generally, an epitope is approximately 5 or 6 amino acids in length. Two antibodies may bind to the same epitope in an antigen if they exhibit competitive binding to the antigen.
[0059] A "cell," as used herein, may be prokaryotic or eukaryotic. Prokaryotic cells include, for example, bacteria. Eukaryotic cells include, for example, fungi, plant cells, and animal cells.Types of animal cells (e.g., mammalian cells or human cells) include, for example, cells from the circulatory / immune system or organs, such as B cells, T cells (cytotoxic T cells, natural killer T cells, regulatory T cells, helper T cells), natural killer cells, granulocytes (e.g., basophils, eosinophils, neutrophils, and hypersegmented neutrophils), monocytes or macrophages, erythrocytes (e.g., reticulocytes), mast cells, platelets or megakaryocytes, and dendritic cells; cells from the endocrine system or organs, such as thyroid cells (e.g., thyroid epithelial cells, parafollicular cells), parathyroid cells (e.g., thyroid epithelial cells, parafollicular cells), and thyroid cells (e.g., thyroid glandular cells). cells from the nervous system or organs, such as glioblasts (e.g., astrocytes and oligodendrocytes), microglia, magnocellular neuroendocrine cells, astrocytes, Bechtel cells, and pituitary cells (e.g., gonadotrophs, corticotrophs, thyrotrophs, somatotrophs, and lactotrophs); cells from the respiratory system or organs, such as lung cells (type I pneumocytes and type II pneumocytes), Clara cells, goblet cells, and alveolar macrophages; cells from the circulatory system or organs (e.g., cardiac myocytes and peripheral cells); cells from the digestive system or organs, e.g., gastric chief cells, parietal cells, goblet cells, Paneth cells, G cells, D cells, ECL cells, I cells, K cells, S cells, enteroendocrine cells, enterochromaffin cells, APUD cells, and liver cells (e.g., hepatocytes and Kupffer cells); cells from the integumentary system or organs, e.g., bone cells (e.g., osteoblasts, osteocytes, and osteoclasts), dental cells (e.g., cementum cells, cells (e.g., ameloblasts, and ameloblasts), chondrocytes (e.g., chondroblasts and chondrocytes), skin / hair cells (e.g., hair matrix cells, keratinocytes, and melanocytes (nevus cells), muscle cells (e.g., myocytes), adipocytes, fibroblasts, and tenocytes; cells from the urinary system or organs (e.g., podocytes, juxtaglomerular cells, intraglomerular mesangial cells, extraglomerular mesangial cells, kidney proximal tubule brush border cells, and macula densa cells), and cells from the reproductive system or organs (e.g., sperm, Sertoli cells, Leydig cells, eggs, oocytes).The cells may be normal, healthy cells, or diseased or unhealthy cells (e.g., cancer cells). The cells further include mammalian zygotic cells or stem cells, including embryonic stem cells, fetal stem cells, induced pluripotent stem cells, and adult stem cells. Stem cells are cells that can undergo cycles of cell division while maintaining an undifferentiated state and differentiate into specialized cell types. Stem cells may be totipotent stem cells, pluripotent stem cells, multipotent stem cells, oligopotent stem cells, and unipotent stem cells, all of which can be derived from somatic cells. Stem cells may also include cancer stem cells. Mammalian cells may be rodent cells, such as mouse, rat, or hamster cells. Mammalian cells may be lagomorph cells, such as rabbit cells. Mammalian cells may also be primate cells, such as human cells.
[0060] As used herein, the term "chimeric antigen receptor" or "CAR" refers to an artificially constructed hybrid protein or polypeptide containing an antibody antigen-binding site (e.g., a single-chain variable fragment (scFv)) linked to a domain or signaling domain that activates immune cells, e.g., T cells or NK cells, e.g., a T cell signaling or T cell activation domain (see, e.g., Kershaw et al., supra; Eshhar et al., Proc. Natl. Acad. Sci. USA, 90(2):720-724 (1993); and Sadelain et al., Curr. Opin. Immunol. 21(2):215-223 (2009)). CARs can utilize the antigen-binding properties of monoclonal antibodies to redirect immune cell specificity and reactivity to selected targets in a non-MHC-restricted manner. Non-MHC-restricted antigen recognition confers on CAR-expressing immune cells the ability to recognize antigens without relying on antigen processing, thus bypassing a major mechanism of tumor escape. In addition, when expressed in T cells, CARs advantageously do not dimerize with the endogenous T cell receptor (TCR) alpha and beta chains.
[0061] As used herein, "essentially free" in relation to a specific component means that none of the specific components are intentionally formulated in the composition and / or only exist as contaminants or in trace amounts.Therefore, the total amount of the specific component resulting from any unintentional contamination of the composition is much less than 0.05%, preferably less than 0.01%.Most preferred is a composition in which the presence of the specific component cannot be detected using standard analytical methods.
[0062] The term "host cell" means a cell that has been transformed, or is capable of being transformed, with a nucleic acid sequence and thereby expresses a gene of interest. The term includes the progeny of a parent cell, whether or not the progeny is identical in morphology or genetic make-up to the original parent cell, so long as the gene of interest is present.
[0063] The term "identity" refers to the relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. "Percent identity" refers to the percent of identical residues between amino acids or nucleotides in the compared molecules, and is calculated based on the size of the smallest of the molecules being compared. For these calculations, alignment gaps (if any) are preferably addressed by a specific mathematical model or computer program (i.e., an "algorithm"). Methods that can be used to calculate the identity of aligned nucleic acids or polypeptides include those described in Computational Molecular Biology, (Lesk, A. M., ed.), 1988, New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, D. W., ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin, A. M., and Griffin, H. G., eds.), 1994, New Jersey: Humana Press; von Heinje, G., 1987, Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; and Carillo et al., 1988, SIAM J. Applied Math. 48:1073.
[0064] When calculating percent identity, the sequences to be compared are typically aligned in a way that maximizes the sequence identity. One example of a computer program that can be used to determine percent identity is the GCG program package, including GAP (Devereux et al., 1984, Nucl. Acid Res. 12:387, Genetics Computer Group, University of Wisconsin, Madison, Wis.). The computer algorithm GAP is used to align two polypeptides or polynucleotides whose percent sequence identity is to be determined. The sequences are aligned for optimal matching of each amino acid or nucleotide (the "matched span" determined by the algorithm). The gap opening penalty (calculated as 3 times the average diagonal, where "average diagonal" is the average of the diagonal of the comparison matrix used, and "diagonal" is the score or number assigned to each perfect amino acid match by a specific comparison matrix) and gap extension penalty (usually 1 / 10 times the gap opening penalty), and a comparison matrix such as PAM250 or BLOSUM62 are used in conjunction with the algorithm. In certain embodiments, standard comparison matrices are also used by the algorithm (see Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352 for the PAM 250 comparison matrix; Henikoff et al., 1992, Proc. Natl. Acad. Sci. USA 89:10915-10919 for the BLOSUM 62 comparison matrix).
[0065] Examples of parameters that can be used to determine percent identity of polypeptide or nucleotide sequences using the GAP program can be found in Needleman et al., 1970, J. Mol. Biol. 48:443-453.
[0066] A particular alignment scheme for aligning two amino acid sequences may result in matching only a short region of the two sequences, and this small aligned region may have very high sequence identity, even though there is no significant relationship between the two full-length sequences. Thus, the selected alignment method (GAP program) can be adjusted as desired to result in alignment over at least 50 or other consecutive amino acids of the target polypeptide.
[0067] As used herein, the term "bond" refers to association via intramolecular interactions, e.g., covalent, metallic, and / or ionic bonds, or intermolecular interactions, e.g., hydrogen bonds or non-covalent bonds.
[0068] The term "operably linked" refers to an arrangement of elements such that the components so described are configured to perform their normal function. Thus, a given signal peptide operably linked to a polypeptide directs the secretion of the polypeptide from a cell. In the case of a promoter, a promoter operably linked to a coding sequence directs the expression of the coding sequence. A promoter or other control elements need not be contiguous with a coding sequence, so long as they function to direct its expression. For example, intervening untranslated but transcribed sequences can be present between the promoter sequence and the coding sequence, and the promoter sequence would still be considered "operably linked" to the coding sequence.
[0069] Use of the term "or" in the claims is used to mean "and / or," unless expressly indicated to refer only to alternatives or where the alternatives are mutually exclusive, but the present disclosure supports a definition that refers only to alternatives and "and / or." As used herein, "another" can mean at least a second, or more.
[0070] The term "polynucleotide" or "nucleic acid" includes both single-stranded and double-stranded nucleotide polymers. The nucleotides comprising a polynucleotide can be ribonucleotides or deoxyribonucleotides, or modified forms of either type of nucleotide. Such modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2',3'-dideoxyribose, and internucleotide linkage modifications such as phosphorothioates, phosphorodithioates, phosphoroselenoates, phosphorodiselenoates, phosphoroanilothioates, phosphoraniladates, and phosphoramidates.
[0071] The term "polypeptide" or "protein" refers to a polymer having the amino acid sequence of a native protein, i.e., a protein produced by naturally occurring non-recombinant cells, or it includes molecules produced by genetically engineered or recombinant cells and having the amino acid sequence of a native protein or molecules with one or more amino acid deletions, additions, and / or substitutions of the native sequence. The terms also include amino acid polymers in which one or more amino acids are chemical analogs of the corresponding naturally occurring amino acids and polymers. The terms "polypeptide" and "protein" specifically encompass DDR1 antigen-binding proteins, antibodies, or sequences with one or more amino acid deletions, additions, and / or substitutions of the antigen-binding protein. The term "polypeptide fragment" refers to a polypeptide having an amino-terminal deletion, a carboxyl-terminal deletion, and / or an internal deletion compared to the full-length native protein. Such fragments can also contain modified amino acids compared to the native protein. In certain embodiments, the fragments are between about 5 and 500 amino acids in length. For example, the fragment can be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids in length. Useful polypeptide fragments include immunologically functional fragments of antibodies containing the binding domain. In the case of DDR1-binding antibodies, useful fragments include, but are not limited to, the CDR regions, the heavy and / or light chain variable domains, a portion of the antibody chain, or just the variable region thereof containing two CDRs.
[0072] Pharmaceutically acceptable carriers useful in the present invention are conventional. Remington's Pharmaceutical Sciences, by E.W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the fusion proteins disclosed herein. Generally, the nature of the carrier will depend on the particular mode of administration used. For example, parenteral formulations usually contain injectable fluids containing pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solution, aqueous dextrose, glycerol, or the like as a vehicle. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically neutral carriers, the administered pharmaceutical composition may contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents, such as sodium acetate or sorbitan monolaurate.
[0073] As used herein, the term "subject" refers to a human or any non-human animal (e.g., a mouse, rat, rabbit, dog, cat, cow, pig, sheep, horse, or primate). Human includes prenatal and postnatal forms. In many embodiments, the subject is a human. A subject may be a patient, which refers to a human presented to a health care provider for diagnosis or treatment of a disease. The term "subject" is used interchangeably herein with "individual" or "patient." A subject may be suffering from or susceptible to a disease or disorder, but may or may not exhibit symptoms thereof.
[0074] As used herein, the term "therapeutically effective amount" or "effective dose" refers to a dosage or concentration of a drug that is effective for treating a disease or condition. For example, with respect to the use of the monoclonal antibody or antigen-binding fragment thereof disclosed herein to treat cancer, a therapeutically effective amount is a dosage or concentration of the monoclonal antibody or antigen-binding fragment thereof that can reduce tumor volume, eradicate all or part of a tumor, inhibit or delay tumor growth or cancer cell invasion into other organs, inhibit the growth or proliferation of cells that mediate a cancerous condition, inhibit or delay tumor cell metastasis, ameliorate any symptoms or markers associated with a tumor or cancerous condition, prevent or delay the onset of a tumor or cancerous condition, or some combination thereof.
[0075] As used herein, "treatment" or "treating" of a condition includes preventing or alleviating the condition, alleviating the onset or rate of onset of the condition, reducing the risk of developing the condition, preventing or delaying the onset of symptoms associated with the condition, reducing or terminating symptoms associated with the condition, causing complete or partial regression of the condition, curing the condition, or some combination thereof.
[0076] As used herein, a "vector" refers to a nucleic acid molecule that is introduced into a host cell, thereby producing a transformed host cell. A vector can include nucleic acid sequences that enable it to replicate in a host cell, such as an origin of replication. A vector can also include one or more therapeutic genes and / or selectable marker genes and other genetic elements known in the art. A vector can transduce, transform, or infect a cell, causing the cell to express nucleic acids and / or proteins other than those native to the cell. A vector optionally includes materials that assist in achieving entry of the nucleic acid into the cell, such as a viral particle, liposome, protein coating, etc.
[0077] II. DDR1 and DDR1 Antibodies A.DDR1 Receptor tyrosine kinases (RTKs) play an important role in communication between cells and their microenvironment. These molecules are involved in regulating cell growth, differentiation, and metabolism. The DDR1 protein, encoded by the DDR1 gene, is a RTK that is widely expressed in normal and transformed epithelial cells and is activated by various types of collagen. The DDR1 protein belongs to a subfamily of tyrosine kinase receptors that contains a region of homology within its extracellular domain to the Dictyostelium discoideum protein discoidin I. Its autophosphorylation is achieved by all collagens (types I to VI) tested to date. A closely related family member is the DDR2 protein. In situ studies and Northern blot analysis have shown that expression of the DDR1-encoded protein is restricted to epithelial cells, particularly those of the kidney, lung, gastrointestinal tract, and brain. Additionally, the DDR1 protein is significantly overexpressed in several human tumors from the breast, ovary, esophagus, and pediatric brain. This gene is located on chromosome 6p21.3, close to several HLA class I genes. Alternative splicing of this gene results in multiple transcript variants. A representative mRNA sequence of DDR1 is NM_001202521 (SEQ ID NO: 1), and a representative amino acid sequence is NP_001189450 (SEQ ID NO: 2).
[0078] B. Antibody against DDR1 protein Antibodies or antigen-binding fragments thereof according to the present disclosure can be defined first by their binding specificity, in this case to DDR1. One of skill in the art can determine whether a given antibody falls within the scope of the claims by assessing the binding specificity / affinity of such an antibody using techniques well known to those of skill in the art.
[0079] In one aspect, antibodies and antigen-binding fragments that specifically bind to DDR1 are provided. In some embodiments, such antibodies, when bound to DDR1, regulate the activation of DDR1. In certain embodiments, the antibodies or antigen-binding fragments activate DDR1 upon binding to DDR1. In certain embodiments, the antibodies or antigen-binding fragments inhibit the activation of DDR1 upon binding to DDR1. In certain embodiments, the antibodies or antigen-binding fragments can specifically interfere with, block, or reduce the interaction between DDR1 and its binding partner upon binding to DDR1. In certain embodiments, the antibodies or antigen-binding fragments provided herein specifically or selectively bind to human DDR1.
[0080] In some embodiments, the antibody or antigen-binding fragment specifically binds to human DDR1 and / or substantially inhibits binding of human DDR1 to its binding partner by at least about 20%-40%, 40-60%, 60-80%, 80-85%, or more (e.g., by an assay disclosed in the Examples). -7 , 10 -8 , 10 -9 , 10 -10 , 10 -11 , 10 -12 , 10 -13 It has a Kd less than M (tighter binding).
[0081] Although the antibodies of the present disclosure were generated as IgGs, it may be useful to modify the constant regions to alter their function. The constant region of an antibody typically mediates the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system. Thus, the term "antibody" includes intact immunoglobulins of the IgA, IgG, IgE, IgD, and IgM types (and their subtypes), and the light chains of the immunoglobulin may be of the kappa or lambda type. Within the light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 or more amino acids. See generally Fundamental Immunology Ch. 7 (Paul, W., ed., 2002). nd ed. Raven Press, NY (1989).
[0082] In some embodiments, the present disclosure provides an antibody or antigen-binding fragment thereof that specifically binds to a DDR1 protein, wherein the antibody comprises LC-CDR1, LC-CDR2, and LC-CDR3 in the light chain variable region sequence shown in Table 3, and HC-CDR1, HC-CDR2, and HC-CDR3 in the heavy chain variable region sequence shown in Table 4, or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or combinations.
[0083] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises LC-CDR1, LC-CDR2, and LC-CDR3 in the light chain variable region sequence shown in Table 3, and HC-CDR1, HC-CDR2, and HC-CDR3 in the heavy chain variable region sequence shown in Table 4, or a variant thereof, in which one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or combinations, wherein the light chain and heavy chain variable region sequences are those of a clonal pair (e.g., with the same mAb designation) shown in Tables 3 and 4, respectively. Exemplary embodiments of the "clonal pair" LC-CDR1, LC-CDR2, and LC-CDR3 of the light chain variable region sequence and HC-CDR1, HC-CDR2, and HC-CDR3 of the heavy chain variable region sequence are the LC-CDRs and HC-CDRs of the light chain variable region sequence and heavy chain variable region sequence of mAb DDR1-1, respectively.
[0084] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having LC-CDR1, LC-CDR2, and LC-CDR3 selected from the LC-CDR1, LC-CDR2, and LC-CDR3 sequences for each mAb shown in Table 1, and a heavy chain variable region having HC-CDR1, HC-CDR2, and HC-CDR3 selected from the HC-CDR1, HC-CDR2, and HC-CDR3 sequences for each mAb shown in Table 2, or a variant thereof in which one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or combinations. In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having LC-CDR1, LC-CDR2, and LC-CDR3, and a heavy chain variable region having HC-CDR1, HC-CDR2, and HC-CDR3 of the LC-CDRs and HC-CDRs of the clone pairs shown in Table 1 and Table 2, respectively, or a variant thereof, in which one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or combinations.
[0085] (Table 1) CDRs of the light chain amino acid variable region sequence of the DDR1 antibody TIFF2024164067000001.tif190145
[0086] (Table 2) CDRs of the heavy chain amino acid variable region sequence of DDR1 antibody TIFF2024164067000002.tif190157
[0087] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QNIYSN (SEQ ID NO: 3), an LC-CDR2 comprising the amino acid sequence GAS, and an LC-CDR3 comprising the amino acid sequence QSGYYSSSTDIA (SEQ ID NO: 4), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLSRYA (SEQ ID NO: 45), an HC-CDR2 comprising the amino acid sequence IGSSGLT (SEQ ID NO: 46), and an HC-CDR3 comprising the amino acid sequence ARGMWYDDSDDYEDYFNL (SEQ ID NO: 47) (DDR1-1), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0088] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QTISSW (SEQ ID NO: 5), an LC-CDR2 comprising the amino acid sequence YAF, and an LC-CDR3 comprising the amino acid sequence QQGISSSNVDNV (SEQ ID NO: 6), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GIDLSSYA (SEQ ID NO: 48), an HC-CDR2 comprising the amino acid sequence INIGGGT (SEQ ID NO: 49), and an HC-CDR3 comprising the amino acid sequence ARDVAHTLTYFTL (SEQ ID NO: 50) (DDR1-3), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0089] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QTISSW (SEQ ID NO: 7), an LC-CDR2 comprising the amino acid sequence YAF, and an LC-CDR3 comprising the amino acid sequence QCTYGSGSSSSYGCA (SEQ ID NO: 8), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFTLSNNA (SEQ ID NO: 51), an HC-CDR2 comprising the amino acid sequence IYASGRT (SEQ ID NO: 52), and an HC-CDR3 comprising the amino acid sequence ARGDTETDYGIPYFDL (SEQ ID NO: 53) (DDR1-5), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0090] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QSVYSNY (SEQ ID NO: 9), an LC-CDR2 comprising the amino acid sequence ETS, and an LC-CDR3 comprising the amino acid sequence QGGYSEIIENT (SEQ ID NO: 10), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSFSSSYY (SEQ ID NO: 54), an HC-CDR2 comprising the amino acid sequence IYASSGST (SEQ ID NO: 55), and an HC-CDR3 comprising the amino acid sequence AILGADYRLTRLDL (SEQ ID NO: 56) (DDR1-6), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0091] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QSIGSV (SEQ ID NO: 11), an LC-CDR2 comprising the amino acid sequence GVF, and an LC-CDR3 comprising the amino acid sequence QYIPYGSSP (SEQ ID NO: 12), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLNRYY (SEQ ID NO: 57), an HC-CDR2 comprising the amino acid sequence ISYGDTT (SEQ ID NO: 58), and an HC-CDR3 comprising the amino acid sequence ARADTGDNGYLGLQL (SEQ ID NO: 59) (DDR1-9), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or combinations.
[0092] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QSIGSTY (SEQ ID NO: 13), an LC-CDR2 comprising the amino acid sequence KAS, and an LC-CDR3 comprising the amino acid sequence LYGGFGSSTGDA (SEQ ID NO: 14), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSFSSGYY (SEQ ID NO: 60), an HC-CDR2 comprising the amino acid sequence IYTGRTDFT (SEQ ID NO: 61), and an HC-CDR3 comprising the amino acid sequence ARGDYSGGVGGNYWLDL (SEQ ID NO: 62) (DDR1-11), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0093] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QTIYSN (SEQ ID NO: 15), an LC-CDR2 comprising the amino acid sequence QAS, and an LC-CDR3 comprising the amino acid sequence QSYYGADDYT (SEQ ID NO: 16), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GIDLSNTW (SEQ ID NO: 63), an HC-CDR2 comprising the amino acid sequence ITDSGTT (SEQ ID NO: 64), and an HC-CDR3 comprising the amino acid sequence GRDPGDITSGTNDL (SEQ ID NO: 65) (DDR1-12), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0094] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence KSVYNNNA (SEQ ID NO: 17), an LC-CDR2 comprising the amino acid sequence GVS, and an LC-CDR3 comprising the amino acid sequence AGDYSDISDNN (SEQ ID NO: 18), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence SGFSLNNY (SEQ ID NO: 66), an HC-CDR2 comprising the amino acid sequence IFNNGDI (SEQ ID NO: 67), and an HC-CDR3 comprising the amino acid sequence ARTGYRTGGWL (SEQ ID NO: 68) (DDR1-13), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0095] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QSISSY (SEQ ID NO: 19), an LC-CDR2 comprising the amino acid sequence EAS, and an LC-CDR3 comprising the amino acid sequence QNNNGFSGSNFNN (SEQ ID NO: 20), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GIDLSYYA (SEQ ID NO: 69), an HC-CDR2 comprising the amino acid sequence INGRGDT (SEQ ID NO: 70), and an HC-CDR3 comprising the amino acid sequence AREDSAIPFIVGNYYGMDL (SEQ ID NO: 71) (DDR1-14), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0096] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QTIYSS (SEQ ID NO: 21), an LC-CDR2 comprising the amino acid sequence KAS, and an LC-CDR3 comprising the amino acid sequence QQGSSISNVDKNA (SEQ ID NO: 22), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence TFSFNSRYW (SEQ ID NO: 72), an HC-CDR2 comprising the amino acid sequence INNGDIS (SEQ ID NO: 73), and an HC-CDR3 comprising the amino acid sequence AKGGNLAGDCYGL (SEQ ID NO: 74) (DDR1-15), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0097] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QSIGSY (SEQ ID NO: 23), an LC-CDR2 comprising the amino acid sequence EAS, and an LC-CDR3 comprising the amino acid sequence QNNNGMTVSDFNA (SEQ ID NO: 24), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLNRYA (SEQ ID NO: 75), an HC-CDR2 comprising the amino acid sequence IGSSGST (SEQ ID NO: 76), and an HC-CDR3 comprising the amino acid sequence ARDLDDSYGYTYATGMDIRLDL (SEQ ID NO: 77) (DDR1-17), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0098] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QIIDHDH (SEQ ID NO: 25), an LC-CDR2 comprising the amino acid sequence RAS, and an LC-CDR3 comprising the amino acid sequence QNNNGMTVSDFNA (SEQ ID NO: 26), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLSDYA (SEQ ID NO: 78), an HC-CDR2 comprising the amino acid sequence INSRDDT (SEQ ID NO: 79), and an HC-CDR3 comprising the amino acid sequence AREDSSIPFIVGNYYGMDL (SEQ ID NO: 80) (DDR1-20), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0099] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QSVVDKNW (SEQ ID NO: 27), an LC-CDR2 comprising the amino acid sequence EAS, and an LC-CDR3 comprising the amino acid sequence AGDFESGVSG (SEQ ID NO: 28), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLSSYG (SEQ ID NO: 81), an HC-CDR2 comprising the amino acid sequence IYPSGSI (SEQ ID NO: 82), and an HC-CDR3 comprising the amino acid sequence VRYLTGSSDLHL (SEQ ID NO: 83) (DDR1-21), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0100] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence KNIYNNNA (SEQ ID NO: 29), an LC-CDR2 comprising the amino acid sequence GAS, and an LC-CDR3 comprising the amino acid sequence AADYSDISDNN (SEQ ID NO: 30), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLSDYA (SEQ ID NO: 84), an HC-CDR2 comprising the amino acid sequence INNGDIY (SEQ ID NO: 85), and an HC-CDR3 comprising the amino acid sequence ARPGYRTGIWL (SEQ ID NO: 86) (DDR1-22), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0101] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QSVYSNNY (SEQ ID NO: 31), an LC-CDR2 comprising the amino acid sequence AAS, and an LC-CDR3 comprising the amino acid sequence LGGYNDDAN (SEQ ID NO: 32), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFDLRSYYY (SEQ ID NO: 87), an HC-CDR2 comprising the amino acid sequence IHGGEGNT (SEQ ID NO: 88), and an HC-CDR3 comprising the amino acid sequence RGGWTNYF (SEQ ID NO: 89) (DDR1-23), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0102] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence ESVYSNNH (SEQ ID NO: 33), an LC-CDR2 comprising the amino acid sequence AAS, and an LC-CDR3 comprising the amino acid sequence LGGYNDDAN (SEQ ID NO: 34), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFDLSSNYY (SEQ ID NO: 90), an HC-CDR2 comprising the amino acid sequence IYSSNTRT (SEQ ID NO: 91), and an HC-CDR3 comprising the amino acid sequence RGGWTNYL (SEQ ID NO: 92) (DDR1-26), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0103] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QSIDNND (SEQ ID NO: 35), an LC-CDR2 comprising the amino acid sequence RTS, and an LC-CDR3 comprising the amino acid sequence QSYCVNTYGYT (SEQ ID NO: 36), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLSSHD (SEQ ID NO: 93), an HC-CDR2 comprising the amino acid sequence IISSGNT (SEQ ID NO: 94), and an HC-CDR3 comprising the amino acid sequence ARDVYSGASP (SEQ ID NO: 95) (DDR1-28), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0104] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence QSISNH (SEQ ID NO: 37), an LC-CDR2 comprising the amino acid sequence RAS, and an LC-CDR3 comprising the amino acid sequence QSYYIINRSNYANS (SEQ ID NO: 38), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence TFSFNSRYW (SEQ ID NO: 96), an HC-CDR2 comprising the amino acid sequence INNGDIT (SEQ ID NO: 97), and an HC-CDR3 comprising the amino acid sequence AKGGNLAGDCYGL (SEQ ID NO: 98) (DDR1-29), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0105] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence ESINSW (SEQ ID NO: 39), an LC-CDR2 comprising the amino acid sequence DAS, and an LC-CDR3 comprising the amino acid sequence QSYYIINRSNYGNS (SEQ ID NO: 40), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLSSYY (SEQ ID NO: 99), an HC-CDR2 comprising the amino acid sequence ITTAGPL (SEQ ID NO: 100), and an HC-CDR3 comprising the amino acid sequence ARGHAGSIYYSYFDL (SEQ ID NO: 101) (DDR1-32), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0106] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence ETISSR (SEQ ID NO: 41), an LC-CDR2 comprising the amino acid sequence QAS, and an LC-CDR3 comprising the amino acid sequence QGCYYGGGSFYDSA (SEQ ID NO: 42), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLSSYD (SEQ ID NO: 102), an HC-CDR2 comprising the amino acid sequence SWNSGFV (SEQ ID NO: 103), and an HC-CDR3 comprising the amino acid sequence ARLGADDIYYFNL (SEQ ID NO: 104) (DDR1-33), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0107] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence ETISSR (SEQ ID NO: 41), an LC-CDR2 comprising the amino acid sequence QAS, and an LC-CDR3 comprising the amino acid sequence QGCYYGGGSFYDSA (SEQ ID NO: 42), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLSSYD (SEQ ID NO: 102), an HC-CDR2 comprising the amino acid sequence SWNSGFV (SEQ ID NO: 103), and an HC-CDR3 comprising the amino acid sequence ARLGADDIYYFNL (SEQ ID NO: 104) (DDR1-33), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0108] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having an LC-CDR1 comprising the amino acid sequence ENLYKDNY (SEQ ID NO: 43), an LC-CDR2 comprising the amino acid sequence GAS, and an LC-CDR3 comprising the amino acid sequence AGGYDSVVD (SEQ ID NO: 44), and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFDLSSYYY (SEQ ID NO: 105), an HC-CDR2 comprising the amino acid sequence SIYTSSGAT (SEQ ID NO: 106), and an HC-CDR3 comprising the amino acid sequence RGGWCDFNL (SEQ ID NO: 107) (DDR1-34), or a variant thereof, wherein one or more of the LC-CDRs and / or HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof.
[0109] In some embodiments, the LC-CDRs of Table 1 and the HC-CDRs of Table 2 are encoded by polynucleotides of Table 6 and Table 7, respectively, as discussed further below.
[0110] In some embodiments, the LC-CDR and HC-CDR are placed in a suitable context of framework region (FR) sequences to form light chain variable regions and heavy chain variable regions that define the binding specificity of the antibody. In some embodiments, the framework region sequences of the antibody with the identified LC-CDR and HC-CDR are the framework sequences of the original antibody isolate. In some embodiments, the LC-CDR and HC-CDR are used with framework region sequences from different mammalian species, e.g., primates. In some embodiments, the framework sequences are humanized or human framework sequences to form an antibody that specifically binds to a DDR1 protein. In some embodiments, the light chain variable region is, for example, a FR LC 1.FR LC 2.FR LC 3, and FR LC 4 and the LC-CDRs, which, from NH2 to COOH, follow the structure: FR LC 1--LC-CDR1--FR LC 2-LC-CDR2-FR LC 3,-LC-CDR3-FR LC 4. In some embodiments, the heavy chain variable region comprises, for example, FR HC 1.FR HC 2.FR HC 3, and FR HC 4 and HC-CDRs, which, from NH2 to COOH, follow the structure: FR HC 1--HC-CDR1--FR HC 2-HC-CDR2-FR HC 3,-HC-CDR3-FR HC 4. In some embodiments, the framework regions of a parent light chain variable region are replaced with framework regions of a human light chain variable region to form a humanized light chain variable region. In some embodiments, the framework regions of a parent heavy chain variable region are replaced with framework regions of a human heavy chain variable region to form a humanized heavy chain variable region.
[0111] In some embodiments, an isolated antibody or antigen-binding fragment thereof that specifically binds to a DDR1 protein comprises a light chain variable region having a light chain variable region amino acid sequence selected from the sequences shown in Table 3, i.e., SEQ ID NOs: 108 to 128. In some embodiments, an isolated antibody or antigen-binding fragment thereof that specifically binds to a DDR1 protein comprises a heavy chain variable region having a heavy chain variable region amino acid sequence selected from the sequences shown in Table 4, i.e., SEQ ID NOs: 129 to 149.
[0112] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having a light chain variable region amino acid sequence selected from SEQ ID NOs: 108 to 128, and a heavy chain variable region having a heavy chain variable region amino acid sequence selected from SEQ ID NOs: 129 to 149. In various embodiments, any one of the variable light chain amino acid sequences corresponding to SEQ ID NOs: 108 to 128 can be used in combination with any one of the variable heavy chain amino acid sequences corresponding to SEQ ID NOs: 129 to 149.
[0113] In some embodiments, the isolated antibody or antigen-binding fragment thereof comprises a light chain variable region having a light chain variable region amino acid sequence selected from SEQ ID NOs: 108-128 and a heavy chain variable region having a heavy chain variable region amino acid sequence selected from SEQ ID NOs: 129-149. In various embodiments, any one of the variable light chain amino acid sequences corresponding to SEQ ID NOs: 108-128 can be used in combination with any one of the variable heavy chain amino acid sequences corresponding to SEQ ID NOs: 129-149. In some embodiments, the antibody or antigen-binding fragment thereof that specifically binds to DDR1 protein comprises the light chain variable region and heavy chain variable region amino acid sequences of the clone pairs shown in Tables 3 and 4, respectively.
[0114] Table 3: Amino acid sequences of the light chain variable region of anti-DDR1 antibodies TIFF2024164067000003.tif245157TIFF2024164067000004.tif26157
[0115] Table 4: Amino acid sequences of the heavy chain variable region of anti-DDR1 antibodies TIFF2024164067000005.tif185157TIFF2024164067000006.tif89157
[0116] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-1K) having the amino acid sequence of SEQ ID NO: 108 and a heavy chain variable region (DDR1-1H) having the amino acid sequence of SEQ ID NO: 129.
[0117] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-3K) having the amino acid sequence of SEQ ID NO: 109 and a heavy chain variable region (DDR1-3H) having the amino acid sequence of SEQ ID NO: 130.
[0118] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-5K) having the amino acid sequence of SEQ ID NO: 110 and a heavy chain variable region (DDR1-5H) having the amino acid sequence of SEQ ID NO: 131.
[0119] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-6K) having the amino acid sequence of SEQ ID NO: 111 and a heavy chain variable region (DDR1-6H) having the amino acid sequence of SEQ ID NO: 132.
[0120] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-9K) having the amino acid sequence of SEQ ID NO: 112 and a heavy chain variable region (DDR1-9H) having the amino acid sequence of SEQ ID NO: 133.
[0121] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-11K) having the amino acid sequence of SEQ ID NO: 113 and a heavy chain variable region (DDR1-11H) having the amino acid sequence of SEQ ID NO: 134.
[0122] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-12K) having the amino acid sequence of SEQ ID NO: 114 and a heavy chain variable region (DDR1-12H) having the amino acid sequence of SEQ ID NO: 135.
[0123] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-13K) having the amino acid sequence of SEQ ID NO: 115 and a heavy chain variable region (DDR1-13H) having the amino acid sequence of SEQ ID NO: 136.
[0124] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-14K) having the amino acid sequence of SEQ ID NO: 116 and a heavy chain variable region (DDR1-14H) having the amino acid sequence of SEQ ID NO: 137.
[0125] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-15K) having the amino acid sequence of SEQ ID NO: 117 and a heavy chain variable region (DDR1-15H) having the amino acid sequence of SEQ ID NO: 138.
[0126] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-17K) having the amino acid sequence of SEQ ID NO: 118 and a heavy chain variable region (DDR1-17H) having the amino acid sequence of SEQ ID NO: 139.
[0127] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-20K) having the amino acid sequence of SEQ ID NO: 119 and a heavy chain variable region (DDR1-20H) having the amino acid sequence of SEQ ID NO: 140.
[0128] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-21K) having the amino acid sequence of SEQ ID NO: 120 and a heavy chain variable region (DDR1-21H) having the amino acid sequence of SEQ ID NO: 141.
[0129] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-22K) having the amino acid sequence of SEQ ID NO: 121 and a heavy chain variable region (DDR1-22H) having the amino acid sequence of SEQ ID NO: 142.
[0130] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-23K) having the amino acid sequence of SEQ ID NO: 122 and a heavy chain variable region (DDR1-23H) having the amino acid sequence of SEQ ID NO: 143.
[0131] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-26K) having the amino acid sequence of SEQ ID NO: 123 and a heavy chain variable region (DDR1-26H) having the amino acid sequence of SEQ ID NO: 144.
[0132] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-28K) having the amino acid sequence of SEQ ID NO: 124 and a heavy chain variable region (DDR1-28H) having the amino acid sequence of SEQ ID NO: 145.
[0133] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-29K) having the amino acid sequence of SEQ ID NO: 125 and a heavy chain variable region (DDR1-29H) having the amino acid sequence of SEQ ID NO: 146.
[0134] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-32K) having the amino acid sequence of SEQ ID NO: 126 and a heavy chain variable region (DDR1-32H) having the amino acid sequence of SEQ ID NO: 147.
[0135] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-33K) having the amino acid sequence of SEQ ID NO: 127 and a heavy chain variable region (DDR1-33H) having the amino acid sequence of SEQ ID NO: 148.
[0136] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (DDR1-34K) having the amino acid sequence of SEQ ID NO: 128 and a heavy chain variable region (DDR1-34H) having the amino acid sequence of SEQ ID NO: 149.
[0137] In some embodiments, the antibody or antigen-binding fragment thereof is a humanized version of the parent antibody DDR1-9 described in the Examples. The light and heavy chain variable regions are shown in Table 5. The polynucleotide sequences encoding the humanized variable regions are shown in Table 10 below.
[0138] Table 5. Humanized DDR1-9hu antibody amino acid sequence TIFF2024164067000007.tif47156
[0139] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LC-CDR1, LC-CDR2, and LC-CDR3 within the light chain variable region amino acid sequence of SEQ ID NO: 150 (DDR1-9hu_Lv1). In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LC-CDR1, LC-CDR2, and LC-CDR3 within the light chain variable region amino acid sequence of SEQ ID NO: 151 (DDR1-9hu_Lc2). In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HC-CDR1, HC-CDR2, and HC-CDR3 within the heavy chain variable region amino acid sequence of SEQ ID NO: 151 (DDR1-9hu_Lc2). In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LC-CDR1, LC-CDR2, and LC-CDR3 within the light chain variable region amino acid sequence of SEQ ID NO: 150 (DDR1-9hu_Lv1) or SEQ ID NO: 151 (DDR1-9hu_Lc2), and a heavy chain variable region having HC-CDR1, HC-CDR2, and HC-CDR3 within the heavy chain variable region amino acid sequence of SEQ ID NO: 151 (DDR1-9hu_Lc2).
[0140] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 150 (DDR1-9hu_Lv1) or SEQ ID NO: 151 (DDR1-9hu_Lc2), and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 152 (DDR1-9hu_Hv). In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 150 (DDR1-9hu_Lv1) and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 152 (DDR1-9hu_Hv). In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 151 (DDR1-9hu_Lc2), and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 152 (DDR1-9hu_Hv).
[0141] In some embodiments, the antibody or antigen-binding fragment thereof is a variant, wherein the variant light chain and / or heavy chain variable region sequences have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acid substitutions, additions, deletions, or a combination thereof compared to the parent light chain and / or heavy chain variable region sequences, and the variant retains binding specificity for the DDR1 protein and / or other functional properties. In some embodiments, the variant light chain and / or heavy chain variable region sequences have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more conservative or non-conservative amino acid substitutions. In some embodiments, the variant has 1, 2, or 3 amino acid substitutions, additions, deletions, or a combination thereof in one or more LC-CDRs and / or HC-CDRs of the variant light chain variable region or variant heavy chain variable region compared to the parent LC-CDRs or HC-CDRs. In some embodiments, the variant antibody or antigen-binding fragment thereof has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or a combination thereof in the framework region sequences of the light chain variable region and / or heavy chain variable region compared to the parent light chain variable region sequence or heavy chain variable region sequence. In some embodiments, the antibody or antigen-binding fragment thereof has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more conservative or non-conservative amino acid substitutions in the framework region sequences of the light chain variable region and / or heavy chain variable region. The above variations apply to the light chain variable regions of Tables 3 and 5, respectively, and to the heavy chain variable regions of Tables 4 and 5, respectively.
[0142] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the light chain variable region amino acid sequences selected from SEQ ID NOs: 108 to 128 in Table 3 and SEQ ID NOs: 150 and 151 in Table 5. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the heavy chain variable region amino acid sequences selected from SEQ ID NOs: 129 to 149 in Table 4 and SEQ ID NO: 152 in Table 5. In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the light chain variable region amino acid sequences selected from SEQ ID NOs: 108 to 128 in Table 3 and SEQ ID NOs: 150 and 151 in Table 5, and a heavy chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the heavy chain variable region amino acid sequences selected from SEQ ID NOs: 129 to 149 in Table 4 and SEQ ID NO: 152 in Table 5.
[0143] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the light chain variable region amino acid sequence of SEQ ID NO: 112. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the heavy chain variable region amino acid sequence of SEQ ID NO: 133. In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the light chain variable region amino acid sequence of SEQ ID NO: 112, and a heavy chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the heavy chain variable region amino acid sequence of SEQ ID NO: 133.
[0144] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the light chain variable region amino acid sequence of SEQ ID NO: 127. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the heavy chain variable region amino acid sequence of SEQ ID NO: 148. In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the light chain variable region amino acid sequence of SEQ ID NO: 127, and a heavy chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the heavy chain variable region amino acid sequence of SEQ ID NO: 148.
[0145] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region amino acid sequence that has 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the light chain variable region amino acid sequence of SEQ ID NO: 150 or 151. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region amino acid sequence that has 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the heavy chain variable region amino acid sequence of SEQ ID NO: 152. In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the light chain variable region amino acid sequence of SEQ ID NO: 150 or 151, and a heavy chain variable region amino acid sequence having 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the heavy chain variable region amino acid sequence of SEQ ID NO: 152.
[0146] In some embodiments, the light chain variable region present in an antibody or antigen-binding fragment thereof comprises LC-CDR1, LC-CDR2, and LC-CDR3 described herein (e.g., Table 1), or a particular light chain variable region (e.g., Table 3 and Table 5), and is attached to or linked to all or a portion of a light chain constant region to form the light chain of the antibody or antigen-binding fragment. In some embodiments, the light chain constant region is that of the species from which the antibody was isolated, e.g., a rabbit light chain constant region. In some embodiments, the light chain constant region attached to or linked to the light chain variable region is a kappa (κ) or lambda (λ) constant region described herein. In some embodiments, the light chain constant region, if present, can be any one of the known λ subtypes, e.g., λ1, λ2, λ3, or λ4. In some embodiments, the light chain constant region is a lambda light chain constant region sequence. In some embodiments, the light chain constant region is a kappa light chain constant region sequence. In a preferred embodiment, the lambda or kappa constant region is that of a human lambda or human kappa constant region sequence.
[0147] In some embodiments, each of the heavy chain variable regions present in an antibody or antigen-binding fragment thereof comprises an HC-CDR1, HC-CDR2, and HC-CDR3 described herein (e.g., Table 2), or each of the specific heavy chain variable regions (e.g., Tables 4 and 5), and is attached or linked to all or a portion of a heavy chain constant region to form the heavy chain of the antibody or antigen-binding fragment. In some embodiments, the heavy chain constant domain is a rodent, primate, or other mammalian heavy chain constant region. In some embodiments, the heavy chain constant region attached or linked to the heavy chain variable region is a human heavy chain constant region. In some embodiments, the human heavy chain constant region comprises at least one or all of the following: a human CH1, a human hinge, a human CH2, and a human CH3 domain. In some embodiments, the heavy chain constant region comprises an Fc portion, and the Fc portion is a human IgG1, IgG2, IgG3, IgG4, or IgM isotype. In some embodiments, the human heavy chain constant region may have one or more mutations to alter Fc constant region properties, such as stability, glycosylation, and Fc receptor binding, as further described below. In some embodiments, the anti-DDR1 antibody may be modified to reduce at least one constant region-mediated biological effector function compared to the unmodified antibody, for example, reducing binding to one or more Fc receptors (FcγR), such as FcγRI, FcγRIIA, FcγRIIB, FcγRIIIA, and / or FcγRIIIB. FcγR binding can be reduced by mutating the antibody's immunoglobulin constant region segment in specific regions required for FcγR interaction (see, e.g., Canfield and Morrison, 1991, J. Exp. Med. 173:1483-1491, and Lund et al., 1991, J. Immunol. 147:2657-2662). Reducing the FcγR binding ability of an antibody can also reduce other effector functions that depend on FcγR interactions, such as opsonization, phagocytosis, and antigen-dependent cellular cytotoxicity ("ADCC").
[0148] In some embodiments, the antibodies or antigen-binding fragments thereof described herein include antibodies that have been modified to acquire or improve at least one constant region-mediated biological effector function relative to the unmodified antibody, e.g., to enhance FcγR interactions (see, e.g., U.S. Publication No. 2006 / 0134709). For example, an antibody of the disclosure can have a constant region that binds to FcγRI, FcγRIIA, FcγRIIB, FcγRIIIA, and / or FcγRIIIB with higher affinity than the corresponding wild-type constant region.
[0149] Thus, the antibodies of the present disclosure may have altered biological activities that result in increased or decreased opsonization, phagocytosis, or ADCC. For example, modifications in antibodies that reduce ADCC activity are described in U.S. Patent No. 5,834,597. An exemplary ADCC-reducing variant corresponds to "Mutant 3" (also known as "M3") in U.S. Patent No. 5,834,597, in which residues 234 and 237 (using EU numbering) are substituted with alanine. Variants of Mutant 3 (also known as "M3") can be used in many antibody isotypes, such as IgG2. Additional substitutions that can modify FcγR binding and / or ADCC effector function include a K322A substitution or a double L234A and L235A substitution in the Fc region (see, e.g., Hezareh, et al. J. Virol., 2001, 75(24):12161-12168). In some embodiments, antibodies of the present disclosure have low levels of or lack fucose. Antibodies lacking fucose have been correlated with enhanced ADCC activity, particularly at low doses of antibody (see, e.g., Shields et al., J. Biol. Chem., 2002, 277:26733-26740; Shinkawa et al., J. Biol. Chem., 2003, 278:3466-73. Methods of preparing fucose-less antibodies include growth in rat myeloma YB2 / 0).
[0150] In some embodiments, antibodies of the present disclosure can comprise a modified (or variant) CH2 domain or entire Fc domain containing amino acid substitutions that increase binding to FcγRIIB and / or decrease binding to FcγRIIIA compared to the binding of the corresponding wild-type CH2 or Fc region. Variant CH2 or variant Fc domains are described in U.S. Patent Publication No. 2014 / 0377253, which is incorporated herein in its entirety. Variant CH2 or variant Fc domains typically contain one or more substitutions at positions 263, 266, 273, and 305, and the numbering of residues within the Fc domain is that of the EU index as per Kabat. In some embodiments, the anti-DDR1 antibody comprises one or more substitutions relative to the wild-type CH2 domain selected from V263L, V266L, V273C, V273E, V273F, V273L, V273M, V273S, V273Y, V305K, and V305W. In certain embodiments, the one or more substitutions in the CH2 domain are selected from V263L, V273E, V273F, V273M, V273S, and V273Y relative to the CH2 domain of human IgG1. For example, the one or more substitutions in the CH2 domain may be V273E. In another specific embodiment, the anti-DDR1 antibody of the present disclosure comprises a variant CH2 domain comprising the amino acid substitution V263L. Other examples of variant CH2 or variant Fc domains that can confer increased binding to FcγRIIB and / or decreased binding to FcγRIIIA compared to the binding of the corresponding wild-type CH2 or Fc region include those found in Vonderheide, et al. Clin. Cancer Res., 19(5), 1035-1043 (2013), e.g., S267E or S267E / L328F in human IgG1.
[0151] In some embodiments, anti-DDR1 antibodies include modifications that increase or decrease their binding affinity to the fetal Fc receptor, FcRn, for example, by mutating the immunoglobulin constant region segment in specific regions involved in FcRn interaction (see, for example, WO2005 / 123780). In certain embodiments, anti-DDR1 antibodies of the IgG class are mutated so that at least one of amino acid residues 250, 314, and 428 in the heavy chain constant region is substituted alone or in any combination thereof, for example, at positions 250 and 428, or at positions 250 and 314, or at positions 314 and 428, or at specific combinations of positions 250, 314, and 428, and 250 and 428. For position 250, the substituting amino acid residue may be any amino acid residue other than threonine, including, but not limited to, alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, valine, tryptophan, or tyrosine. For position 314, the substituting amino acid residue may be any amino acid residue other than leucine, including, but not limited to, alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine. At position 428, the substituted amino acid residue may be any amino acid residue other than methionine, including, but not limited to, alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, or tyrosine. An exemplary substitution known to modify Fc effector function is the Fc substitution M428L, which may occur in conjunction with the Fc substitution T250Q. Specific combinations of suitable amino acid substitutions are identified in Table 1 of U.S. Patent No. 7,217,797, which is incorporated herein by reference.Such mutations increase binding to FcRn, protecting the antibody from degradation and increasing its half-life.
[0152] In some embodiments, the antibody or antigen-binding fragment thereof is a single-chain antibody comprising the LC-CDR and HC-CDR disclosed herein. In some embodiments, the antibody or antigen-binding fragment thereof is a single-chain antibody comprising the light chain variable region and heavy chain variable region disclosed herein. In certain embodiments, the single-chain antibody comprises the light chain variable region and heavy chain variable region of a clonal pair disclosed herein.
[0153] In some embodiments, an antigen-binding fragment comprising the LC-CDRs and HC-CDRs, or the light chain variable region and heavy chain variable region of the disclosure, is a diabody, Fab, Fab', F(ab'), Fv fragment, disulfide-stabilized Fv fragment (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabody (dsdiabody), single-chain antibody molecule (scFv), scFv dimer (bivalent diabody), multispecific antibody, single domain antibody (sdAb), camelid antibody or nanobody, domain antibody, or bivalent domain antibody, as described herein.
[0154] In some embodiments, the antibody or antigen-binding fragment thereof is a chimeric antibody comprising the LC-CDRs and HC-CDRs, or light chain variable region and heavy chain variable region, disclosed herein, wherein the Fc heavy chain constant region is derived from a species different from the origin of the LC-CDRs and HC-CDRs, or light chain variable region and heavy chain variable region, disclosed herein. In some embodiments, the chimeric antibody comprises a human Fc region.
[0155] In some embodiments, the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof, in which the framework regions of the light chain variable region comprising the LC-CDRs and the heavy chain variable region comprising the HC-CDRs of the present disclosure are replaced with human framework sequences. In some embodiments, the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof, in which the framework regions of the light chain variable region selected from SEQ ID NOs: 108-128 and SEQ ID NOs: 150 and 151 are replaced with human light chain variable region framework sequences. In some embodiments, the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof, in which the framework regions of the heavy chain variable region selected from SEQ ID NOs: 129-140 and SEQ ID NO: 152 are replaced with human heavy chain variable region framework sequences. In some embodiments, the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof, in which the framework region of the light chain variable region selected from SEQ ID NOs: 108-128 and SEQ ID NOs: 150 and 151 is replaced with a human light chain variable region framework sequence, and the framework region of the heavy chain variable region selected from SEQ ID NOs: 129-140 and SEQ ID NO: 152 is replaced with a human heavy chain variable region framework sequence.
[0156] C. Exemplary Epitopes and Competing Antigen-Binding Proteins In another aspect, the present disclosure provides epitopes to which anti-DDR1 antibodies bind. In some embodiments, the epitopes bound by the antibodies described herein are useful. In certain embodiments, the epitopes provided herein can be used to isolate antibodies or antigen-binding proteins that bind to DDR1. In certain embodiments, the epitopes provided herein can be used to generate antibodies or antigen-binding proteins that bind to DDR1. In certain embodiments, the epitopes provided herein or sequences comprising the epitopes can be used as immunogens to generate antibodies or antigen-binding proteins that bind to DDR1. In certain embodiments, the epitopes described herein or sequences comprising the epitopes described herein can be used to disrupt the biological activity of DDR1.
[0157] In some embodiments, antibodies or antigen-binding fragments thereof that bind to any of the epitopes are particularly useful. In some embodiments, the epitopes provided herein, when bound by an antibody, prevent or inhibit the biological activity of DDR1. In some embodiments, the epitopes provided herein, when bound by an antibody, block the interaction between DDR1 and its binding partner.
[0158] In some embodiments, domains / regions containing residues that contact or are buried by antibodies can be identified by mutating specific residues in DDR1 and determining whether the antibody can bind to the mutated DDR1 protein. By making a large number of individual mutations, it is possible to identify residues that play a direct role in binding or that are sufficiently close to the antibody that the mutation can affect binding between the antibody and the antigen. From knowledge of these amino acids, it is possible to elucidate domains or regions of the antigen that contain residues that contact the antigen-binding protein or are covered by the antibody. Such domains may contain the binding epitope of the antigen-binding protein.
[0159] In another aspect, the present disclosure provides antigen binding proteins that compete with one of the exemplified antibodies or antigen-binding fragments that bind to the epitope described herein for specific binding to DDR1. Such antigen binding proteins may also bind to the same epitope as one of the exemplified antibodies or antigen-binding fragments, or overlapping epitopes. Antigen binding proteins that compete with or bind to the same epitope as the exemplified antibodies are expected to exhibit similar functional properties. Exemplary antibodies include those described above, including antibodies having the light and heavy chain variable region CDRs shown in Tables 1 and 2, respectively, the light and heavy chain variable regions shown in Tables 3 and 4, and the light and heavy chain coding regions shown in Tables 8 and 9.
[0160] III. Polynucleotides, Vectors, and Host Cells In another aspect, the present disclosure provides polynucleotides encoding antibodies and antigen-binding fragments thereof that specifically bind to the DDR1 proteins disclosed herein, vectors including expression vectors containing the polynucleotides, and host cells containing the polynucleotides, for example, for expression of the antibodies or antigen-binding fragments thereof.
[0161] In particular, polynucleotide is isolated polynucleotide.Polynucleotide can be operatively linked to one or more heterologous control sequences that control gene expression to produce recombinant polynucleotide that can express target polypeptide.The expression construct that contains the heterologous polynucleotide that encodes relevant polypeptide or protein can be introduced into suitable host cell to express corresponding polypeptide.
[0162] As should be apparent to one of skill in the art, knowledge of a protein sequence provides a description of all polynucleotides that can encode the subject protein sequence, due to knowledge of all possible codons corresponding to the various amino acids. A vast number of nucleic acids encoding the aforementioned polypeptides can be generated by selecting combinations based on possible codon choices, and all such variations are considered to be specifically disclosed for any and all of the polypeptides described herein.
[0163] In some embodiments, the polynucleotide encodes LC-CDR1, LC-CDR2, and / or LC-CDR3 of a light chain variable region disclosed herein, comprising the LC-CDRs set forth in Table 1. In some embodiments, the polynucleotide encodes a variant of LC-CDR1, LC-CDR2, and / or LC-CDR3 of a light chain variable region disclosed herein, comprising the LC-CDRs set forth in Table 1, wherein one or more of the LC-CDRs of the variant have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof, compared to the parent LC-CDR.
[0164] In some embodiments, the polynucleotide encodes the HC-CDR1, HC-CDR2, and / or HC-CDR3 of a heavy chain variable region disclosed herein, comprising the HC-CDRs set forth in Table 2. In some embodiments, the polynucleotide encodes a variant of the HC-CDR1, HC-CDR2, and / or HC-CDR3 of a heavy chain variable region disclosed herein, comprising the LC-CDRs set forth in Table 2, wherein one or more of the HC-CDRs of the variant have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof, compared to the parent HC-CDR.
[0165] In some embodiments, the polynucleotide encoding the LC-CDR1, LC-CDR2, and / or LC-CDR3 of the light chain variable region is selected from the polynucleotides shown in Table 6.
[0166] Table 6: DNA sequences encoding the CDRs of the light chain variable region of the DDR1 antibody TIFF2024164067000008.tif51136TIFF2024164067000009.tif204136
[0167] In some embodiments, the polynucleotide encoding the HC-CDR1, HC-CDR2, and / or HC-CDR3 of the heavy chain variable region is selected from the polynucleotides shown in Table 7.
[0168] Table 7: DNA sequences encoding the CDRs of the heavy chain variable region of the DDR1 antibody TIFF2024164067000010.tif221150TIFF2024164067000011.tif89150
[0169] In some embodiments, the polynucleotide encodes at least one, two, or three LC-CDRs within the light chain variable region of the amino acid sequence of SEQ ID NOs: 108-128 or SEQ ID NO: 150 or 151. In some embodiments, the polynucleotide encodes at least one, two, or three HC-CDRs within the heavy chain variable region of the amino acid sequence of SEQ ID NOs: 129-149 or SEQ ID NO: 153.
[0170] In some embodiments, the polynucleotide encodes at least one, two, or three LC-CDRs within the light chain variable region of the amino acid sequence of SEQ ID NOs: 108-128 or SEQ ID NO: 150 or 151, and at least one, two, or three HC-CDRs within the heavy chain variable region of the amino acid sequence of SEQ ID NOs: 129-149 or SEQ ID NO: 153. In some embodiments, the selected LC-CDRs and HC-CDRs are those of a clone pair.
[0171] In some embodiments, the polynucleotide comprises at least one, two, or three of the polynucleotide sequences of the LC-CDRs of each mAb shown in Table 6.
[0172] In some embodiments, the polynucleotide comprises at least one, two, or three of the polynucleotide sequences of the HC-CDRs of each mAb shown in Table 7.
[0173] In some embodiments, the polynucleotide comprises at least one, two, or three of the polynucleotide sequences of the LC-CDRs of each mAb shown in Table 6 and at least one, two, or three of the polynucleotide sequences of the HC-CDRs of each mAb shown in Table 7, and the selected LC-CDRs and HC-CDRs are those of the clone pairs shown in Tables 6 and 7, respectively.
[0174] In some embodiments, the polynucleotide encodes a light chain variable region having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a light chain variable region amino acid sequence selected from SEQ ID NOs:108-128 in Table 3 and SEQ ID NOs:150-151 in Table 5.
[0175] In some embodiments, the polynucleotide encodes a heavy chain variable region having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a heavy chain variable region amino acid sequence selected from SEQ ID NOs:129-149 in Table 4 and SEQ ID NO:153 in Table 5.
[0176] In some embodiments, the polynucleotide encodes a light chain variable region having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a light chain variable region amino acid sequence selected from SEQ ID NOs:108-128 in Table 3 or SEQ ID NOs:150 and 151 in Table 5, and a heavy chain variable region having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 96%, 97%, 98%, 99% or more sequence identity to a heavy chain variable region amino acid sequence selected from SEQ ID NOs:129-149 in Table 4 and SEQ ID NO:153 in Table 5.
[0177] In some embodiments, the polynucleotide encodes an antibody or antigen-binding fragment comprising a light chain variable region and a heavy chain variable region selected from the following: A light chain variable region (DDR1-1K) having the amino acid sequence of SEQ ID NO: 108, and a heavy chain variable region (DDR1-1H) having the amino acid sequence of SEQ ID NO: 129; A light chain variable region (DDR1-3K) having the amino acid sequence of SEQ ID NO: 109, and a heavy chain variable region (DDR1-3H) having the amino acid sequence of SEQ ID NO: 130; A light chain variable region (DDR1-5K) having the amino acid sequence of SEQ ID NO: 110, and a heavy chain variable region (DDR1-5H) having the amino acid sequence of SEQ ID NO: 131; A light chain variable region (DDR1-6K) having the amino acid sequence of SEQ ID NO: 111, and a heavy chain variable region (DDR1-6H) having the amino acid sequence of SEQ ID NO: 132; A light chain variable region (DDR1-9K) having the amino acid sequence of SEQ ID NO: 112, and a heavy chain variable region (DDR1-9H) having the amino acid sequence of SEQ ID NO: 133; A light chain variable region (DDR1-11K) having the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region (DDR1-11H) having the amino acid sequence of SEQ ID NO: 134; A light chain variable region (DDR1-12K) having the amino acid sequence of SEQ ID NO: 114, and a heavy chain variable region (DDR1-12H) having the amino acid sequence of SEQ ID NO: 135; A light chain variable region (DDR1-13K) having the amino acid sequence of SEQ ID NO: 115, and a heavy chain variable region (DDR1-13H) having the amino acid sequence of SEQ ID NO: 136; A light chain variable region (DDR1-14K) having the amino acid sequence of SEQ ID NO: 116, and a heavy chain variable region (DDR1-14H) having the amino acid sequence of SEQ ID NO: 137; A light chain variable region (DDR1-15K) having the amino acid sequence of SEQ ID NO: 117, and a heavy chain variable region (DDR1-15H) having the amino acid sequence of SEQ ID NO: 138; A light chain variable region (DDR1-17K) having the amino acid sequence of SEQ ID NO: 118, and a heavy chain variable region (DDR1-17H) having the amino acid sequence of SEQ ID NO: 139; A light chain variable region (DDR1-20K) having the amino acid sequence of SEQ ID NO: 119, and a heavy chain variable region (DDR1-20H) having the amino acid sequence of SEQ ID NO: 140; A light chain variable region (DDR1-21K) having the amino acid sequence of SEQ ID NO: 120, and a heavy chain variable region (DDR1-21H) having the amino acid sequence of SEQ ID NO: 141; A light chain variable region (DDR1-22K) having the amino acid sequence of SEQ ID NO: 121, and a heavy chain variable region (DDR1-22H) having the amino acid sequence of SEQ ID NO: 142; a light chain variable region (DDR1-23K) having the amino acid sequence of SEQ ID NO: 122, and a heavy chain variable region (DDR1-23H) having the amino acid sequence of SEQ ID NO: 143; A light chain variable region (DDR1-26K) having the amino acid sequence of SEQ ID NO: 123, and a heavy chain variable region (DDR1-26H) having the amino acid sequence of SEQ ID NO: 144; A light chain variable region (DDR1-28K) having the amino acid sequence of SEQ ID NO: 124, and a heavy chain variable region (DDR1-28H) having the amino acid sequence of SEQ ID NO: 145; A light chain variable region (DDR1-29K) having the amino acid sequence of SEQ ID NO: 125, and a heavy chain variable region (DDR1-29H) having the amino acid sequence of SEQ ID NO: 146; A light chain variable region (DDR1-32K) having the amino acid sequence of SEQ ID NO: 126, and a heavy chain variable region (DDR1-32H) having the amino acid sequence of SEQ ID NO: 147; A light chain variable region (DDR1-33K) having the amino acid sequence of SEQ ID NO: 127, and a heavy chain variable region (DDR1-33H) having the amino acid sequence of SEQ ID NO: 148; A light chain variable region (DDR1-34K) having the amino acid sequence of SEQ ID NO: 128, and a heavy chain variable region (DDR1-34H) having the amino acid sequence of SEQ ID NO: 149; A light chain variable region (DDR1-9hu_Lv) having the amino acid sequence of SEQ ID NO: 150, and a heavy chain variable region (DDR1-9hu_Hv) having the amino acid sequence of SEQ ID NO: 153, and A light chain variable region (DDR1-9hu_Lc2) having the amino acid sequence of SEQ ID NO: 151, and a heavy chain variable region (DDR1-9hu_Hv) having the amino acid sequence of SEQ ID NO: 153.
[0178] In some embodiments, the polynucleotide encoding the light chain variable region is selected from the polynucleotides shown in Table 8.
[0179] Table 8: DNA sequences encoding the light chain variable region of anti-DDR1 antibodies TIFF2024164067000012.tif242154TIFF2024164067000013.tif229154TIFF2024164067000014.tif151154
[0180] In some embodiments, the polynucleotide encoding the heavy chain variable region is selected from the polynucleotides shown in Table 9.
[0181] Table 9: DNA sequences encoding the heavy chain variable regions of anti-DDR1 antibodies TIFF2024164067000015.tif232142TIFF2024164067000016.tif232148TIFF2024164067 000017.tif232146TIFF2024164067000018.tif232146TIFF2024164067000019.tif23292
[0182] In some embodiments, the polynucleotide encoding the humanized light chain variable region and / or the humanized heavy chain variable region of antibody DDR1-9 (DDR1-9hu) is selected from the polynucleotides shown in Table 10.
[0183] Table 10. Humanized DDR1-9hu antibody sequences - nucleic acids TIFF2024164067000020.tif101156
[0184] In some embodiments, the polynucleotide has at least about 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity at the nucleotide level to a reference polynucleotide sequence selected from SEQ ID NOs: 2:58-278 and 301-302, and encodes a corresponding light chain variable region selected from SEQ ID NOs: 108-128 or 150-151.
[0185] In some embodiments, the polynucleotide has at least about 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity at the nucleotide level to a reference polynucleotide sequence selected from SEQ ID NOs:279-299 and SEQ ID NO:300, and encodes a corresponding light chain variable region selected from SEQ ID NOs:129-149 or SEQ ID NO:152.
[0186] In some embodiments, the polynucleotide has at least about 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity at the nucleotide level to the reference polynucleotide sequence of SEQ ID NO:262 or 276 and encodes the corresponding light chain variable region of SEQ ID NO:112 or SEQ ID NO:126.
[0187] In some embodiments, the polynucleotide has at least about 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity at the nucleotide level to the reference polynucleotide sequence of SEQ ID NO: 283 or 297 and encodes the corresponding light chain variable region of SEQ ID NO: 133 or 147.
[0188] In some embodiments, the polynucleotide has at least about 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity at the nucleotide level to the reference polynucleotide sequence of SEQ ID NO:301 or 302 and encodes the corresponding light chain variable region of SEQ ID NO:150 or SEQ ID NO:151.
[0189] In some embodiments, the polynucleotide has at least about 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more sequence identity at the nucleotide level to the reference polynucleotide sequence of SEQ ID NO:300 and encodes the corresponding light chain variable region of SEQ ID NO:152.
[0190] In further embodiments, the nucleic acid of the present disclosure comprises a polynucleotide that hybridizes to a polynucleotide encoding an antibody disclosed herein. In some embodiments, the polynucleotide hybridizes to a polynucleotide selected from SEQ ID NOs: 258-278 and 301-302 and encodes a light chain variable region of an antibody that specifically binds to a DDR1 protein. In some embodiments, the polynucleotide hybridizes to a polynucleotide selected from SEQ ID NOs: 279-299 and 300 and encodes a heavy chain variable region of an antibody that specifically binds to a DDR1 protein.
[0191] Generally, nucleic acids hybridize under moderate or high stringency conditions to nucleic acids encoding the antibodies disclosed herein that also encode antibodies that retain the ability to specifically bind to a DDR1 protein. A first nucleic acid molecule is "hybridizable" to a second nucleic acid molecule if the single-stranded form of the first nucleic acid molecule can anneal to the second nucleic acid molecule under appropriate conditions of temperature and solution ionic strength (Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 3 rded., Cold Spring Harbor Press, Cold Spring Harbor, NY 2001). Temperature and ionic strength conditions determine the "stringency" of hybridization. Typical moderate stringency hybridization conditions are 40% formamide with 5x or 6x SSC and 0.1% SDS at 42°C. High stringency hybridization conditions are 50% formamide, 5x or 6x SSC (0.15M NaCl and 0.015M Na-citrate), 42°C, or optionally, higher temperatures (e.g., 57°C, 59°C, 60°C, 62°C, 63°C, 65°C, or 68°C). Hybridization requires that the two nucleic acids contain complementary sequences, although mismatches between bases are possible, depending on the stringency of the hybridization. The appropriate stringency for nucleic acid hybridization depends on the length of nucleic acid and the degree of complementarity, which are variables well known in the art.The greater the degree of similarity or homology between two nucleotide sequences, the higher the stringency that nucleic acid can hybridize.For the hybrid that is longer than 100 nucleotides, the equation for calculating melting temperature has been derived (see Sambrook et al. above).For hybridization with shorter nucleic acids, such as oligonucleotides, the position of mismatch becomes more important, and the length of oligonucleotide determines its specificity (see Sambrook et al. above).
[0192] In some embodiments, the polynucleotides disclosed herein can be manipulated in various ways to provide expression of the encoded polypeptide, such as the light chain variable region or heavy chain variable region disclosed herein. In some embodiments, the polynucleotide is operably linked to regulatory sequences for expression of the polynucleotide and / or corresponding polypeptide, including, inter alia, transcriptional promoters, leader sequences, transcriptional enhancers, ribosome binding or entry sites, termination sequences, and polyadenylation sequences. Manipulation of the isolated polynucleotide prior to insertion into a vector may be desirable or necessary, depending on the expression vector. Techniques for modifying polynucleotides and nucleic acid sequences using recombinant DNA methods are known in the art. Guidance is provided in Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd Ed., Cold Spring Harbor Laboratory Press, New York (2001), and Current Protocols in Molecular Biology, Ausubel, F. ed., Greene Pub. Associates (1998), updated to 2020.
[0193] In some embodiments, the polynucleotide may be part of an expression vector, wherein the vector and polynucleotide comprise one or more operably linked regulatory sequences for controlling expression of the polynucleotide and / or the encoded polypeptide. The recombinant expression vector may be any vector (e.g., a plasmid or virus) that can be conveniently subjected to recombinant DNA procedures and can result in expression of the polynucleotide sequence. The choice of vector typically depends on the compatibility of the vector with the host cell into which the vector will be introduced. The vector may be a linear or closed circular plasmid. Exemplary expression vectors include, among others, vectors based on T7 or T7lac promoters (pACY: Novagen; pET), vectors based on baculovirus promoters (e.g., pBAC), vectors based on Ef1-α and HTLV promoters (e.g., pFUSE2; Invitrogen, CA, USA), vectors based on CMV enhancers and human ferritin light chain gene promoters (e.g., pFUSE: Invitrogen, CA, USA), vectors based on CMV promoters (e.g., pFLAG: Sigma, USA), and vectors based on dihydrofolate reductase promoters (e.g., pEASE: Amgen, USA).Various vectors can be used for transient or stable expression of the polypeptide of interest.
[0194] In another aspect, the polynucleotide encoding the polypeptide is operably linked to one or more control sequences for expression of the polypeptide in a host cell. Host cells used to express the polypeptide are well known in the art and include, but are not limited to, bacterial cells such as E. coli and yeast cells, insect cells such as Drosophila S2 and Spodoptera Sf9 cells, animal cells such as Chinese hamster ovary (CHO), African green monkey kidney (COS), baby hamster kidney (BHK), mouse myeloma (e.g., NS0 and Sp2 / 0), and human embryonic kidney (HEK), and plant cells. Appropriate culture media and growth conditions for the above-mentioned host cells are known in the art. In some embodiments, host cells and expression vectors are used to express a polypeptide of interest.
[0195] In some embodiments, host cells containing the expression vectors and polynucleotides described herein are cultured in a suitable medium and under culture conditions suitable for expression of the encoded polypeptide, e.g., a polypeptide comprising an amino acid sequence selected from SEQ ID NOs:108-128, SEQ ID NOs:150 and 151, SEQ ID NOs:129-149, and SEQ ID NO:152. In some embodiments, an in vitro expression system can be used with the expression vector to express the polypeptide. In vitro expression systems include those based on E. coli, rabbit reticulocytes, wheat germ, insect cells, and human cells. Whether expressed in a host cell or in vitro, the expressed polypeptide can be isolated or purified as further described herein.
[0196] IV. Methods for preparing antibodies and modifying them In some embodiments, the monoclonal antibodies described herein can be prepared using standard methods, followed by screening, characterization, and functional evaluation. For example, the variable regions can be sequenced and then subcloned into human expression vectors to generate chimeric antibody genes, which can then be expressed and purified. These chimeric antibodies can be tested in antigen binding, signal transduction blockade, and xenograft experiments.
[0197] A. General Method It will be understood that monoclonal antibodies that bind to DDR1 have several uses. These include the detection and diagnosis of cancer, and the production of diagnostic kits for use in cancer therapy. In these contexts, such antibodies may be linked to diagnostic or therapeutic agents and used as capture or competitor agents in competitive assays, or used individually without additional agents attached. The antibodies may be mutated or modified, as further discussed below. Methods for preparing and characterizing antibodies are well known in the art (see, for example, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; U.S. Patent No. 4,196,265).
[0198] Methods for generating monoclonal antibodies (MAbs) generally begin along the same lines as those for preparing polyclonal antibodies. The first step in both of these methods is immunization of a suitable host. As is well known in the art, a given composition for immunization can vary in its immunogenicity. Therefore, it is often necessary to boost the host immune system, which can be achieved by coupling a peptide or polypeptide immunogen to a carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins, such as ovalbumin, mouse serum albumin, or rabbit serum albumin, can also be used as carriers. Means for conjugating polypeptides to carrier proteins are known in the art and include glutaraldehyde, m-maleimidobenocoyl-N-hydroxysuccinimide ester, carbodiimide, and bis-biazotized benzidine. As is also well known in the art, the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response known as adjuvants. Exemplary and preferred adjuvants include complete Freund's adjuvant (a non-specific stimulator of the immune response containing killed Mycobacterium tuberculosis), incomplete Freund's adjuvant, and aluminum hydroxide adjuvant.
[0199] The amount of immunogen composition used to produce polyclonal antibodies varies depending on the nature of the immunogen and the animal used for immunization. Various routes can be used to administer the immunogen (subcutaneous, intramuscular, intradermal, intravenous, and intraperitoneal). Polyclonal antibody production can be monitored by collecting blood from the immunized animal at various times after immunization. A second booster injection may also be administered. The process of boosting and titering is repeated until a suitable titer is obtained. Once a desired level of immunogenicity is achieved, the immunized animal is bled, and the serum can be isolated and stored, and / or the animal can be used to generate MAbs.
[0200] After immunization, somatic cells with the potential to produce antibodies, specifically B lymphocytes (B cells), are selected for use in MAb generation protocols. These cells can be obtained from biopsied spleens or lymph nodes, or from circulating blood. Antibody-producing B lymphocytes from the immunized animal are then fused with immortal myeloma cells, generally from the same species as the immunized animal, or with human or human / mouse chimeric cells. Myeloma cell lines suitable for use in hybridoma-producing fusion procedures preferably do not produce antibodies, have high fusion efficiency, and then possess enzyme deficiencies that render them unable to grow in a specific selective medium that supports only the growth of the desired fused cells (hybridomas). As known to those skilled in the art, any one of a number of myeloma cell lines may be used (Goding, pp. 65-66, 1986; Campbell, pp. 75-83, 1984). Methods for generating hybrids between antibody-producing spleen or lymph node cells and myeloma cells typically involve mixing somatic cells and myeloma cells at a 2:1 ratio in the presence of a substance (chemical or electrical) that promotes cell membrane fusion, although the ratio can vary from about 20:1 to about 1:1, respectively. Fusion methods using Sendai virus have been described by Kohler and Milstein (1975; 1976), and those using polyethylene glycol (PEG), such as 37% (v / v) PEG, have been described by Gefter et al. (1977). Electrically induced fusion methods are also suitable (Goding, pp. 71-74, 1986). The fusion procedure typically involves mixing 1 × 10 somatic cells with myeloma cells. -6 ~1×10 -8Viable hybrids are produced at a low frequency. However, this does not pose a problem because the surviving fused hybrids differentiate from the parent injected cells (especially the injected myeloma cells, which would normally continue to divide indefinitely) by culturing them in selective medium. Selective medium generally contains drugs that block de novo synthesis of nucleotides in tissue culture medium. Exemplary and preferred drugs are aminopterin, methotrexate, and azaserine. Aminopterin and methotrexate block de novo synthesis of both purines and pyrimidines, while azaserine blocks only purine synthesis. When aminopterin or methotrexate is used, the medium is supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium). When azaserine is used, the medium is supplemented with hypoxanthine. Ouabain is added when the B cell source is an Epstein-Barr virus (EBV)-transformed human B cell line to eliminate EBV-transformed cell lines that have not fused to myeloma.
[0201] In some embodiments, the preferred selection medium is HAT or HAT with ouabain. Only cells capable of operating the nucleotide salvage pathway can survive in HAT medium. Myeloma cells are defective in key enzymes in the salvage pathway, such as hypoxanthine phosphoribosyltransferase (HPRT), and are therefore unable to survive. B cells can operate this pathway, but they have a limited lifespan in culture and generally die within about two weeks. Therefore, the only cells that can survive in the selection medium are hybrids formed from myeloma and B cells. When the source of the B cells used for fusion is a lineage of EBV-transformed B cells, as in this case, ouabain is also used for drug selection of the hybrids, because the EBV-transformed B cells are susceptible to drug death, while the myeloma partner used is used to select for resistant EBV-transformed B cells.
[0202] Culture provides a population of hybridomas from which specific hybridomas can be selected. Hybridoma selection is typically performed by culturing cells by single-clone dilution in microtiter plates, followed (approximately 2–3 weeks later) by testing individual clonal supernatants for the desired reactivity. The assay should be sensitive, simple, and rapid, e.g., radioimmunoassay, enzyme-linked immunosorbent assay, cytotoxicity assay, plaque assay, dot immunobinding assay, etc. Selected hybridomas are then serially diluted or single-cell sorted by flow cytometry sorting and cloned into individual antibody-producing cell lines, which can then be expanded indefinitely to provide mAbs. Cell lines can be utilized for MAb production in two basic ways: A sample of the hybridoma can be injected (often intraperitoneally) into an animal (e.g., a mouse). Optionally, the animal is primed with a hydrocarbon, particularly an oil such as pristane (tetramethylpentadecane), prior to injection. When using human hybridomas in this method, it is best to inject them into immunocompromised mice, such as SCID mice, to prevent tumor rejection. The injected animals develop tumors that secrete the specific monoclonal antibodies produced by the fused cell hybrids. The animal's bodily fluids, such as serum or ascites, can then be tapped to provide high concentrations of MAbs. Individual cell lines can also be cultured in vitro, and MAbs are naturally secreted into the culture medium, where they are readily obtained at high concentrations. Alternatively, human hybridoma cell lines can be used in vitro to produce immunoglobulins in the cell supernatant. Cell lines can be adapted for growth in serum-free medium to optimize the ability to recover highly pure human monoclonal immunoglobulins.
[0203] MAbs produced by either means can be further purified, if desired, using filtration, centrifugation, and various chromatographic methods such as FPLC or affinity chromatography. Fragments of the monoclonal antibodies of the present disclosure can be obtained from the purified monoclonal antibodies by methods including digestion with enzymes such as pepsin or papain, and / or by cleavage of disulfide bonds by chemical reduction. Alternatively, monoclonal antibody fragments encompassed by the present disclosure can be synthesized using an automated peptide synthesizer.
[0204] It is also conceivable that a molecular cloning approach could be used to generate monoclonals. For this, RNA could be isolated from hybridoma lines, antibody genes obtained by RT-PCR, and cloned into immunoglobulin expression vectors. Alternatively, combinatorial immunoglobulin phagemid libraries could be prepared from RNA isolated from cell lines, and phagemids expressing the appropriate antibodies could be selected by panning using viral antigens. The advantage of this approach over traditional hybridoma techniques is approximately 10 4 The fact that as many as 200 antibodies can be produced and screened in a single round and that new specificities can be generated by combining heavy and light chains further increases the chances of finding a suitable antibody.
[0205] Other U.S. patents that teach the production of antibodies useful in the present disclosure (each incorporated herein by reference) include U.S. Pat. No. 5,565,332, which describes the production of chimeric antibodies using a combinatorial approach; U.S. Pat. No. 4,816,567, which describes recombinant immunoglobulin preparations; and U.S. Pat. No. 4,867,973, which describes antibody-therapeutic agent conjugates.
[0206] B. Manipulation of Antibody Sequences In various embodiments, one may choose to engineer the sequence of an identified antibody for a variety of reasons, such as improved expression, improved cross-reactivity, or reduced off-target binding. The following is a general description of related techniques for antibody engineering.
[0207] Hybridomas may be cultured, then the cells lysed, and total RNA extracted. Random hexamers may be used with RT to generate cDNA copies of the RNA, followed by PCR using a multiplexed mixture of PCR primers predicted to amplify all human variable gene sequences. PCR products may be cloned into the pGEM-T Easy vector and then sequenced by automated DNA sequencing using standard vector primers. Binding and neutralization assays may be performed using antibodies collected from hybridoma supernatants and purified by FPLC using a Protein G column. Recombinant full-length IgG antibodies may be produced by subcloning heavy and light chain Fv DNA from a cloning vector into an IgG plasmid vector, transfecting them into 293 Freestyle or CHO cells, and purifying and collecting the antibodies from the 293 or CHO cell supernatants.
[0208] The rapid availability of antibodies produced in the same host cell and cell culture process as the final cGMP manufacturing process has the potential to shorten the duration of process development programs. Lonza has developed a general method for the rapid production of small amounts (up to 50 g) of antibodies in CHO cells using pooled transfectants grown in CDACF medium. While somewhat slower than true transient systems, advantages include higher product concentrations and the use of the same host and process as the production cell line. In an example of the growth and productivity of a GS-CHO pool expressing a model antibody in a single-use bioreactor, i.e., a single-use bag bioreactor culture (5 L working volume) operated in fed-batch mode, a harvest antibody concentration of 2 g / L was achieved within 9 weeks of transfection.
[0209] Antibody molecules can include, for example, fragments produced by proteolytic cleavage of mAbs (e.g., F(ab'), F(ab')2), or single-chain immunoglobulins that can be produced, for example, via recombinant means. Such antibody derivatives are monovalent. In one embodiment, such fragments can be combined with each other, or with other antibody fragments or receptor ligands, to form "chimeric" binding molecules. Importantly, such chimeric molecules can contain substituents capable of binding to different epitopes of the same molecule.
[0210] 1. Antigen binding modification In related embodiments, the antibody is a derivative of the disclosed antibodies, e.g., an antibody containing the same CDR sequences as in the disclosed antibodies (e.g., a chimeric or CDR-grafted antibody). Alternatively, one may desire to make modifications, such as introducing conservative changes, into the antibody molecule. When making such changes, the hydropathic amino acid index may be considered. The importance of the hydropathic amino acid index in conferring interactive biological function to a protein is generally understood in the art (Kyte and Doolittle, 1982). It is recognized that the relative hydropathic properties of amino acids contribute to the secondary structure of the resulting protein, which in turn defines the interaction of the protein with other molecules, such as enzymes, substrates, receptors, DNA, antibodies, antigens, etc.
[0211] It is also understood in the art that similar amino acid substitutions can be made effectively based on hydrophilicity. U.S. Pat. No. 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its neighboring amino acids, correlates with the biological properties of the protein. As detailed in U.S. Pat. No. 4,554,101, the following hydrophilicity values are assigned to amino acid residues: basic amino acids: arginine (+3.0), lysine (+3.0), and histidine (-0.5); acidic amino acids: aspartic acid (+3.0±1), glutamic acid (+3.0±1), asparagine (+0.2), and glutamine (+0.2); hydrophilic non-ionic amino acids: serine (+0.3), asparagine (+0.4), and riboflavin (+0.5). 0.2), glutamine (+0.2), and threonine (-0.4); sulfur-containing amino acids: cysteine (-1.0) and methionine (-1.3); hydrophobic non-aromatic amino acids: valine (-1.5), leucine (-1.8), isoleucine (-1.8), proline (-0.5±1), alanine (-0.5), and glycine (0); hydrophobic aromatic amino acids: trypphan (-3.4), phenylalanine (-2.5), and tyrosine (-2.3).
[0212] It is understood that an amino acid can be substituted with another amino acid that has a similar hydrophilicity and produces a biologically or immunologically modified protein. Such changes are preferably substituted with amino acids whose hydrophilicity values are within ±2, particularly preferably within ±1, and even more particularly within ±0.5.
[0213] As outlined above, amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, e.g., their hydrophobicity, hydrophilicity, charge, size, etc. Exemplary substitutions taking into account various characteristics such as those mentioned above are well known to those of skill in the art and include arginine and lysine, glutamic acid and aspartic acid, serine and threonine, glutamine and asparagine, and valine, leucine and isoleucine.
[0214] The present disclosure also contemplates isotype modification. By modifying the Fc region to have a different isotype, different functionalities can be achieved. For example, changing to IgG1 can increase antibody-dependent cellular cytotoxicity, switching to class A can improve tissue distribution, and switching to class M can improve valency.
[0215] The modified antibodies can be produced by any technique known to those skilled in the art, including expression by standard molecular biology techniques or chemical synthesis of the polypeptide. Methods for recombinant expression are covered elsewhere in this document.
[0216] 2.Fc region modification As mentioned above, the antibodies disclosed herein can also be engineered to contain modifications within the Fc region, typically to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding, and / or effector function (e.g., antigen-dependent cellular cytotoxicity). Furthermore, the antibodies disclosed herein can be chemically modified (e.g., one or more chemical moieties can be attached to the antibody) or modified to alter its glycosylation, again altering one or more functional properties of the antibody. Each of these embodiments is described in further detail below. The numbering of residues within the Fc region is that of the EU index of Kabat. The antibodies disclosed herein also include antibodies with modified (or blocked) Fc regions to provide altered effector function. See, e.g., U.S. Pat. No. 5,624,821, WO 2003 / 086310, WO 2005 / 120571, and WO 2006 / 0057702. Such modifications can be used to enhance or suppress various immune system responses, with potential beneficial effects in diagnosis and therapy. Modifications to the Fc region include amino acid changes (substitutions, deletions, and insertions), glycosylation or deglycosylation, and the addition of multiple Fc domains. Modifications to the Fc domain can also alter the half-life of therapeutic antibodies, allowing for less frequent dosing and therefore increased convenience and reduced material use. This mutation has been reported to abolish the heterogeneity of inter-heavy chain disulfide bridges in the hinge region.
[0217] In some embodiments, the hinge region of CH1 is modified to increase or decrease the number of cysteine residues in the hinge region. Exemplary approaches are further described in U.S. Patent No. 5,677,425. The number of cysteine residues in the hinge region of CH1 is altered, for example, to facilitate assembly of the light and heavy chains or to increase or decrease the stability of the antibody. In another embodiment, the antibody is modified to increase its biological half-life. Various approaches are possible. For example, as described in U.S. Patent No. 6,277,375, one or more of the following mutations can be introduced: T252L, T254S, T256F. Alternatively, to increase biological half-life, the antibody can be modified in the CH1 or CL region to include a salvage receptor binding epitope obtained from two loops of the CH2 domain of the IgG Fc region, as described in U.S. Patent Nos. 5,869,046 and 6,121,022. In yet another embodiment, the Fc region is modified by replacing at least one amino acid residue with a different amino acid residue to alter the antibody's effector function. For example, one or more amino acids selected from amino acid residues 234, 235, 236, 237, 297, 318, 320, and 322 can be replaced with a different amino acid residue so that the antibody has altered affinity for an effector ligand while retaining the antigen-binding ability of the parent antibody. The effector ligand for which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in further detail in U.S. Patent Nos. 5,624,821 and 5,648,260.
[0218] In another example, one or more amino acid residues within amino acid positions 231 and 239 are altered to thereby alter the antibody's ability to fix complement. This approach is further described in PCT Publication No. 94 / 29351. In yet another example, the Fc region is modified to increase or decrease the antibody's ability to mediate antibody-dependent cellular cytotoxicity (ADCC) and / or to increase or decrease the antibody's affinity for Fcγ receptors by modifying one or more amino acids at the following positions: 238, 239, 243, 248, 249, 252, 254, 255, 256, 258, 264, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 301, 303, 305, 307, 309, 312, 315, 320, 322, 324, 326, 327, 329, 330, 331, 333, 334, 335, 337, 338, 340, 360, 373, 376, 378, 382, 388, 389, 398, 414, 416, 419, 430, 434, 435, 437, 438, or 439. This approach is further described in PCT Publication No. 00 / 42072. Furthermore, the binding sites on human IgG1 for FcγR1, FcγRII, FcγRIII, and FcRn have been mapped, and variants with improved binding have been described. Specific mutations at positions 256, 290, 298, 333, 334, and 339 have been shown to improve binding to FcγRIII. In addition, the following variant combinations have been shown to improve FcγRIII binding: T256A / S298A, S298A / E333A, S298A / K224A, and S298A / E333A / K334A.
[0219] In one embodiment, the Fc region is modified to reduce the antibody's ability to mediate effector function and / or to increase anti-inflammatory properties by modifying residues 243 and 264. In one embodiment, the Fc region of an antibody is modified by changing residues 243 and 264 to alanine. In one embodiment, the Fc region is modified to reduce the antibody's ability to mediate effector function and / or to increase anti-inflammatory properties by modifying residues 243, 264, 267, and 328. In yet another embodiment, the antibody comprises a particular glycosylation pattern. For example, an aglycosylated antibody (i.e., the antibody lacks glycosylation) can be generated. The glycosylation pattern of an antibody can be modified to, for example, increase the affinity or avidity of the antibody for an antigen. Such modifications can be achieved, for example, by altering one or more glycosylation sites within the antibody sequence. For example, one or more amino acid substitutions can be made that result in the removal of one or more of the variable region framework glycosylation sites, thereby eliminating glycosylation at that site. Such aglycosylation can increase the affinity or avidity of the antibody for the antigen. See, e.g., U.S. Patent Nos. 5,714,350 and 6,350,861.
[0220] Antibodies can also be generated whose glycosylation pattern includes hypofucosylated or nonfucosylated glycans; for example, hypofucosylated or nonfucosylated antibodies have a reduced amount of fucosyl residues on the glycans. Antibodies can also contain increased amounts of glycans with bisecting GlcNac structures. Such glycosylation pattern modifications have been demonstrated to increase the ADCC ability of antibodies. Such modifications can be achieved, for example, by expressing the antibody in a host cell whose glycosylation pathway has been genetically engineered to produce glycoproteins with a particular glycosylation pattern. These cells have been described in the art and can be used as host cells to express the recombinant antibodies of the invention, thereby producing antibodies with modified glycosylation. For example, cell lines Ms704, Ms705, and Ms709 lack the fucosyltransferase gene, FUT8 (α(1,6)-fucosyltransferase), resulting in antibodies expressed in the Ms704, Ms705, and Ms709 cell lines lacking fucose on their carbohydrates. The Ms704, Ms705, and Ms709 FUT8- / - cell lines were generated by targeted disruption of the FUT8 gene in CHO / DG44 cells using two recombinant vectors (see, e.g., U.S. Patent Publication No. 2004 / 0110704). As another example, EP1176195 describes a cell line with a functionally disrupted FUT8 gene encoding a fucosyltransferase; antibodies expressed in such cell lines exhibit hypofucosylation by reducing or eliminating α-1,6-linkage-related enzymes. EP1176195 also describes cell lines with reduced or no enzymatic activity to add fucose to N-acetylglucosamine attached to the Fc region of antibodies, e.g., rat myeloma cell line YB2 / 0 (ATCC CRL 1662). PCT Publication No. 03 / 035835 describes a variant CHO cell line, Lec13 cells, that has a reduced ability to attach fucose to Asn(297)-linked carbohydrates, which also results in hypofucosylation of antibodies expressed in the host cells.Antibodies with modified glycosylation profiles can also be produced in chicken eggs, as described in PCT Publication No. 06 / 089231. Alternatively, antibodies with modified glycosylation profiles can be produced in plant cells, such as Lemna (U.S. Patent No. 7,632,983). Methods for producing antibodies in plant systems are disclosed in U.S. Patent Nos. 6,998,267 and 7,388,081. PCT Publication No. 99 / 54342 describes cell lines engineered to express glycoprotein-modifying glycosyltransferases (e.g., β(1,4)-N-acetylglucosaminyltransferase III (GnTIII)) such that antibodies expressed in the engineered cell lines exhibit increased bisecting GlcNac structures, which results in increased ADCC activity of the antibodies.
[0221] Alternatively, fucosidase enzymes can be used to cleave the fucose residues of antibodies; for example, the fucosidase α-L-fucosidase removes fucosyl residues from antibodies. The antibodies disclosed herein also include those produced in lower eukaryotic host cells, particularly fungal host cells such as yeast and filamentous fungi, which are genetically engineered to produce glycoproteins with mammalian or human-like glycosylation patterns. A particular advantage of these genetically modified host cells over currently used mammalian cell lines is the ability to control the glycosylation profile of glycoproteins produced within the cells, allowing for the production of glycoprotein compositions in which specific N-glycan structures predominate (see, e.g., U.S. Patent Nos. 7,029,872 and 7,449,308). These genetically modified host cells are primarily used to produce antibodies with specific N-glycan structures.
[0222] Additionally, fungi such as yeast or filamentous fungi lack the ability to produce fucosylated glycoproteins, and therefore antibodies produced in such cells will lack fucose unless the cells are modified to further comprise an enzymatic pathway for producing fucosylated glycoproteins (see, e.g., PCT Publication WO 2008 / 112092). In certain embodiments, the antibodies disclosed herein further include antibodies produced in lower eukaryotic host cells and comprising fucosylated and nonfucosylated hybrid and complex N-glycans, including, but not limited to, bisected and hyperantennary species, including N-glycans such as GlcNAc(1-4)Man3GlcNAc2; Gal(1-4)GlcNAc(1-4)Man3GlcNAc2; NANA(1-4)Gal(1-4)GlcNAc(1-4)Man3GlcNAc2. In certain embodiments, the antibody compositions provided herein may comprise an antibody having at least one hybrid N-glycan selected from the group consisting of GlcNAcMan5GlcNAc2; GalGlcNAcMan5GlcNAc2; and NANAGalGlcNAcMan5GlcNAc2. In certain aspects, the hybrid N-glycan is the predominant N-glycan species in the composition. In further aspects, the hybrid N-glycan is a particular N-glycan species that comprises about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99%, or 100% of the hybrid N-glycans in the composition.
[0223] In certain embodiments, the antibody compositions provided herein comprise antibodies having at least one complex N-glycan selected from the group consisting of GlcNAcMan3GlcNAc2; GalGlcNAcMan3GlcNAc2; NANAGalGlcNAcMan3GlcNAc2; GlcNAc2Man3GlcNAc2; GalGlcNAc2Man3GlcNAc2; Gal2GlcNAc2Man3GlcNAc2; NANAGal2GlcNAc2Man3GlcNAc2; and NANA2Gal2GlcNAc2Man3GlcNAc2. In certain aspects, the complex N-glycan is the predominant N-glycan species in the composition. In a further aspect, the complex N-glycan is a specific N-glycan species that comprises about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99%, or 100% of the complex N-glycans in the composition. In certain embodiments, the N-glycan is fucosylated. Generally, the fucose is linked to a GlcNAc at the reducing end of the N-glycan via an α1,3-linkage, an α1,6-linkage, an α1,2-linkage, an α1,3-linkage, or an α1,4-linkage, an α1,4-linkage, with a GlcNAc at the non-reducing end of the N-glycan.
[0224] Thus, in certain embodiments of the above glycoprotein compositions, the glycoform is in an α1,3-linked or α1,6-linked fucose, or is selected from the group consisting of Man5GlcNAc2(Fuc), GlcNAcMan5GlcNAc2(Fuc), Man3GlcNAc2(Fuc), GlcNAcMan3GlcNAc2(Fuc), GlcNAc2Man3GlcNAc2(Fuc), GalGlcNAc2Man3GlcNAc2(Fuc), Gal2GlcNAc2Man3GlcNAc2(Fuc), NANAGal2GlcNAc2Man3GlcNAc2(Fuc), and NANA2Gal2GlcNAc2Man3GlcNAc2(Fuc). )Man3GlcNAc2, GalGlcNAc2(Fuc1-2)Man3GlcNAc2, Gal2GlcNAc2(Fuc1-2)Man3GlcNAc2, NANAGal2GlcNAc2(Fuc1-2)Man3GlcNAc2, and NANA2Gal2GlcNAc2(Fuc1-2)Man3GlcNAc2, or at an α1,2-linked fucose to generate a glycoform selected from the group consisting of Gal(Fuc)GlcNAc2Man3GlcNAc2, Gal2(Fuc1-2)GlcNAc2Man3GlcNAc2, NANAGal2(Fuc1-2)GlcNAc2Man3GlcNAc2, and NANA2Gal2(Fuc1-2)GlcNAc2Man3GlcNAc2.
[0225] In a further embodiment, the antibody comprises N-glycans consisting of high-mannose N-glycans, including, but not limited to, Man8GlcNAc2, Man7GlcNAc2, Man6GlcNAc2, Man5GlcNAc2, and Man4GlcNAc2, or the Man3GlcNAc2 N-glycan structure. In the above further embodiment, the complex N-glycans further include fucosylated and non-fucosylated bisected and multiantennary species. As used herein, the terms "N-glycan" and "glycoform" are used interchangeably and refer to, for example, N-linked oligosaccharides attached by an asparagine-N-acetylglucosamine bond to an asparagine residue in a polypeptide. N-linked glycoproteins contain an N-acetylglucosamine residue attached to the amide nitrogen of an asparagine residue in a protein.
[0226] C. Single chain antibody Single-chain variable fragments (scFvs) are fusions of the variable regions of immunoglobulin heavy and light chains linked together with a short (usually serine or glycine) linker. These chimeric molecules retain the specificity of the original immunoglobulin despite the removal of the constant region and the introduction of a linker peptide. This modification typically maintains specificity without altering specificity. These molecules were historically created to facilitate phage display, where it is very convenient to express the antigen-binding domain as a single peptide. Alternatively, scFvs can be generated directly from subcloned heavy and light chains derived from hybridomas. Single-chain variable fragments lack the constant Fc region found in intact antibody molecules and therefore lack the consensus binding sites (e.g., protein A / G) used to purify antibodies. These fragments can often be purified / immobilized using protein L, as protein L interacts with the variable region of the kappa light chain.
[0227] Flexible linkers are generally composed of helix- and twist-promoting amino acid residues such as alanine, serine, and glycine. However, other residues may function as well. Tang et al. (1996) used phage display as a means to rapidly select tailored linkers for single-chain antibodies (scFv) from protein linker libraries. They constructed a random linker library in which genes for heavy and light chain variable domains were linked by a segment encoding an 18-amino acid polypeptide of variable composition. The scFv repertoire (approximately 5 × 10 6 The tethers (different members) were displayed on filamentous phage and subjected to affinity selection using haptens. The population of selected variants showed a significant increase in binding activity while retaining considerable sequence diversity. 1054 variants were subsequently screened to obtain catalytically active scFvs that were efficiently produced in a soluble form. Sequence analysis revealed the V as the only common feature of the selected tethers. H A conserved proline in the linker of two residues after the C-terminus and abundant arginine and proline at other positions were revealed.
[0228] The recombinant antibodies of the present disclosure may also contain sequences or moieties that allow receptor dimerization or multimerization. Such sequences include sequences derived from IgA that allow the formation of multimers in conjunction with the J chain. Another multimerization domain is the Gal4 dimerization domain. In other embodiments, the chains may be modified with agents such as biotin / avidin, which allow the combination of two antibodies.
[0229] In another embodiment, single-chain antibodies can be produced by linking receptor light and heavy chains using a non-peptide linker or chemical unit. Generally, the light and heavy chains are produced in different cells, purified, and then linked together in an appropriate manner (i.e., the N-terminus of the heavy chain is linked to the C-terminus of the light chain via a suitable chemical bridge).
[0230] Cross-linking reagent is used to form a molecular bridge that connects the functional groups of two different molecules, such as stabilizer and coagulant.However, it is also contemplated that the heteromeric complexes can be made of the same analogue dimer or multimer or different analogues.To link two different compounds step by step, heterobifunctional cross-linking reagents can be used, which eliminates the formation of unnecessary homopolymers.
[0231] Exemplary heterobifunctional crosslinkers contain two reactive groups: one that reacts with primary amine groups (e.g., N-hydroxysuccinimide) and the other that reacts with thiol groups (e.g., pyridyl disulfide, maleimide, halogen, etc.). Through the primary amine reactive group, the crosslinker reacts with a lysine residue on one protein (e.g., a selected antibody or fragment), and through the thiol reactive group, the crosslinker already attached to the first protein can react with a cysteine residue (free sulfhydryl group) on another protein (e.g., a selected agent).
[0232] Preferably, a crosslinker with reasonable stability in blood is used.Many kinds of disulfide bond-containing linkers are known, and they can be successfully used to conjugate targeting and therapeutic / preventive drugs.Containing sterically hindered disulfide bond linkers can be proven to bring greater stability in vivo and prevent the release of targeting peptide before reaching the site of action.Therefore, these linkers are one group of linking agents.
[0233] Another cross-linking reagent is SMPT, a bifunctional cross-linker containing a disulfide bond that is "sterically hindered" by an adjacent benzene ring and a methyl group. The steric hindrance of the disulfide bond is thought to serve to protect the bond from attack by thiolate anions, such as glutathione, which may be present in tissues and blood, thereby helping to prevent detachment of the conjugate prior to delivery of the attached drug to the target site.
[0234] The SMPT crosslinking reagent, like many other known crosslinking reagents, confers the ability to crosslink functional groups such as the SH residue of cysteine or primary amines (e.g., the epsilon-amino group of lysine). Another possible type of crosslinker is a heterobifunctional photoreactive phenyl azide containing a cleavable disulfide bond, such as sulfosuccinimidyl-2-(p-azidosalicylamido)ethyl-1,3'-dithiopropionate. The N-hydroxy-succinimidyl group reacts with primary amino groups, and the phenyl azide (upon photolysis) reacts nonselectively with any amino acid residue.
[0235] In addition to hindered crosslinkers, unhindered linkers can also be used in accordance with the present invention. Other useful crosslinkers that are not thought to contain or generate protected disulfides include SATA, SPDP, and 2-iminothiolane (Wawrzynczak & Thorpe, 1987). The use of such crosslinkers is well understood in the art. Another embodiment involves the use of flexible linkers.
[0236] U.S. Patent No. 4,680,338 describes bifunctional linkers useful for producing conjugates of ligands with amine-containing polymers and / or proteins, particularly for forming antibody conjugates with chelators, drugs, enzymes, detectable labels, and the like. U.S. Patent Nos. 5,141,648 and 5,563,250 disclose cleavable conjugates containing labile bonds that are cleavable under a variety of mild conditions. This linker is particularly useful in that the desired agent can be directly attached to the linker, allowing cleavage to release the active agent. Specific applications include adding free amino or sulfhydryl groups to proteins such as antibodies or drugs.
[0237] U.S. Patent No. 5,856,456 provides peptide linkers for use in connecting polypeptide components to create fusion proteins, such as single-chain antibodies. The linkers are up to about 50 amino acids in length and contain at least one charged amino acid (preferably arginine or lysine) followed by proline, and are characterized by higher stability and reduced aggregation. U.S. Patent No. 5,880,270 discloses aminooxy-containing linkers useful in various immunodiagnostic and separation techniques.
[0238] D. Purification In certain embodiments, the antibodies of the present disclosure may be purified. As used herein, the term "purified" is intended to refer to a composition that can be isolated from other components, and the protein is purified to any degree compared to its naturally achievable state. Thus, a purified protein also refers to a protein that is free from the environment in which it may naturally occur. When the term "substantially purified" is used, this designation refers to a composition in which the protein or peptide forms a major component of the composition, such as constituting about 50%, about 60%, about 70%, about 80%, about 90%, about 95% or more of the protein in the composition.
[0239] Protein purification techniques are well known to those skilled in the art. These techniques involve, at one level, crude fractionation of the cellular milieu into polypeptide and non-polypeptide fractions. After separation of the polypeptide from other proteins, the polypeptide of interest can be further purified using chromatographic and electrophoretic techniques to achieve partial or complete purification (or purification to homogeneity). Analytical methods particularly suitable for the preparation of pure peptides are ion exchange chromatography, exclusion chromatography, polyacrylamide gel electrophoresis, and isoelectric focusing. Other methods for protein purification include precipitation with ammonium sulfate, PEG, antibodies, etc., or heat denaturation followed by centrifugation, gel filtration, reverse-phase, hydroxylapatite, and affinity chromatography, as well as combinations of such and other techniques.
[0240] When purifying the antibody of the present disclosure, it may be desirable to express the polypeptide in a prokaryotic or eukaryotic expression system and extract the protein using denaturing conditions.The polypeptide can be purified from other cellular components using an affinity column that binds to the tagged portion of the polypeptide.As is generally known in the art, it is contemplated that the order of performing various purification steps can be changed or certain steps can be omitted, and still result in a method suitable for preparing substantially purified proteins or peptides.
[0241] Generally, whole antibodies are fractionated using a substance that binds to the Fc portion of the antibody (i.e., Protein A). Alternatively, antigen can be used to simultaneously purify and select suitable antibodies. Such methods often utilize a selection substance bound to a support, such as a column, filter, or beads. The antibodies bind to the support, contaminants are removed (e.g., washed away), and the antibodies are released by applying conditions (salt, heat, etc.).
[0242] Various methods for quantifying the degree of purification of a protein or peptide will be known to those of skill in the art in light of the present disclosure. These include, for example, determining the specific activity of an active fraction or assessing the amount of polypeptide within a fraction by SDS / PAGE analysis. Another way to assess the purity of a fraction is to calculate the specific activity of the fraction and compare it to the specific activity of the initial extract, thus calculating the degree of purity. The actual units used to express the amount of activity will, of course, depend on the particular assay technique chosen when performing the purification and whether the expressed protein or peptide exhibits detectable activity.
[0243] It is known that the migration of polypeptides can vary, sometimes significantly, under different conditions of SDS / PAGE (Capaldi et al., 1977). Therefore, it will be understood that the apparent molecular weight of purified or partially purified expression products may vary under different electrophoretic conditions.
[0244] V. Uses and Compositions of Anti-DDR1 Antibodies A. Therapeutic Methods and Uses 1. Cancer treatment Hyperproliferative diseases can be associated with any disease in which cells begin to proliferate uncontrollably, a typical example being cancer. One of the key components of cancer is disruption of the normal apoptosis cycle of cells, and therefore, agents that disrupt cell growth are important therapeutic agents for treating these diseases. In the present disclosure, the anti-DDR1 antibodies or antigen-binding fragments thereof described herein can be used to reduce the number of cancer cells and thus potentially be used to treat various types of cancer cell lines. In some aspects, the antibodies or antigen-binding fragments thereof of the present disclosure can be used to treat cancers, including solid tumors, particularly cancers that secrete DDR1 protein or portions thereof (such as the DDR1 extracellular domain) and / or have DDR1 present on the surface of cancer cells or cancer stem cells. In some embodiments, cancers or cancer cells that overexpress DDR1 protein are selected for treatment with the antibodies of the present disclosure.
[0245] In some embodiments, cancers and cancer cell types that can be treated according to the present disclosure include, but are not limited to, bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal, gingival, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, pancreas, testis, tongue, cervix, or uterine cancers or cancer cells. In addition, cancers may specifically be of the following histological types, but are not limited to: malignant neoplasms, carcinomas, undifferentiated carcinomas, giant cell carcinoma and spindle cell carcinoma, small cell carcinoma, papillary carcinoma, squamous cell carcinoma, lymphoepithelial carcinoma, basal cell carcinoma, pilomatrix carcinoma, transitional cell carcinoma, papillary transitional cell carcinoma, adenocarcinoma, malignant gastrinoma, cholangiocarcinoma, hepatocellular carcinoma, combined hepatocellular carcinoma and cholangiocarcinoma, trabecular adenoma, adenoid cystic carcinoma, adenocarcinoma of adenomatous polyps, and familial adenocarcinoma. Adenomatous polyposis;Solid tumor;Malignant carcinoid tumor;Bronchioloalveolar adenocarcinoma;Papillary adenocarcinoma;Chromophobe carcinoma;Eosinophilic carcinoma;Eosinophilic adenocarcinoma;Basophilic carcinoma;Clear cell adenocarcinoma;Granular cell carcinoma;Follicle adenocarcinoma;Papillary-follicular adenocarcinoma;Non-encapsulated sclerosing carcinoma;Adrenal cortical carcinoma;Endometrial carcinoma;Cutaneous adenocarcinoma;Apocrine adenocarcinoma;Sebaceous gland carcinoma;Parotid gland carcinoma;Mucous epidermoid carcinoma;Cystadenocarcinoma;Papillary cystadenocarcinoma;Papillary serous cystadenocarcinoma;Mucinous cystadenocarcinoma;Mucinous adenocarcinoma;Signet ring cell carcinoma;Invasive breast Ductal carcinoma;Medullary carcinoma;Lobular carcinoma;Inflammatory carcinoma;Paget's disease of the breast;Acinic cell carcinoma;Adenosquamous carcinoma;Adenosquamous metaplasia;Malignant thymoma;Malignant ovarian stromal tumor;Malignant thecal tumor;Malignant granulosa cell tumor;Malignant androblastoma;Sertoli cell carcinoma;Malignant Leydig cell tumor;Malignant lipid cell tumor;Malignant paraganglioma;Malignant extramammary paraganglioma;Pheochromocytoma;Glomangiosarcoma;Malignant melanoma;Amelanotic melanoma;Superficial spreading melanoma;Malignant melanoma of giant pigmented nevus;Epithelioid cell melanoma;Malignant Blue nevus;Sarcoma;Fibrosarcoma;Malignant fibrous histiocytoma;Myxosarcoma;Liposarcoma;Leiomyosarcoma;Rhabdomyosarcoma;Embryonic rhabdomyosarcoma;Alveolar rhabdomyosarcoma;Stromatous sarcoma;Malignant mixed tumor;Mixed Müllerian tumor;Nephroblastoma;Hepatoblastoma;Carcinosarcoma;Malignant mesenchymal tumor;Malignant Brenner tumor;Malignant Filodes tumor;Synovial sarcoma;Malignant mesothelioma;Dysplastic tumor;Germ cell carcinoma;Malignant teratoma;Malignant ovarian goiter;Choriocarcinoma;Malignant mesonephroma;Angiosarcoma;Malignant hemangioendothelioma;Kaposi's sarcoma;Malignant hemangiopericytoma;Lymphangiosarcoma;Osteosarcoma;Parosteal osteosarcoma; Chondrosarcoma; Malignant chondroblastoma; Mesenchymal chondrosarcoma; Giant cell tumor of bone; Ewing's sarcoma; Malignant odontogenic tumor; Ameloblastic odontoma; Malignant enamel-like splenomegaly; Ameloblastic fibrosarcoma; Malignant pineal tumor; Chordoma; Malignant glioma; Ependymoma; Astrocytoma; Primitive astrocytoma; Fibrous astrocytoma; Astroblastoma; Glioma; Oligodendroglioma; Oligodendroglioma; Primitive neuroectodermal tumor; Cerebellar sarcoma; Ganglioblastoma; Neuroblastoma; Retinoblastoma; Olfactory neurogenic tumor; Malignant meningioma; Neurofibrosarcoma; Malignant neurilemmoma; Malignant Cancers include: granular cell tumor; malignant lymphoma; Hodgkin's disease; lateral granuloma; malignant small lymphocytic lymphoma; malignant large cell diffuse lymphoma; malignant follicular lymphoma; mycosis fungoides; other specified non-Hodgkin's lymphoma; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphocytic leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryocytic leukemia; myeloid sarcoma; and hairy cell leukemia. In certain embodiments, the tumor may include osteosarcoma, angiosarcoma, rhabdomyosarcoma, leiomyosarcoma, Ewing's sarcoma, glioblastoma, neuroblastoma, or leukemia.
[0246] In some embodiments, the antibodies or antigen-binding fragments are used to treat pancreatic cancer, lung cancer, including small cell lung cancer and non-small cell lung cancer, colon and colorectal cancer, head and neck cancer, gastric (stomach) cancer, ovarian cancer, breast cancer, kidney cancer, liver cancer, prostate cancer, cervical cancer, brain cancer, skin cancer, including melanoma, and bone cancer. In some embodiments, the cancer selected for treatment is breast cancer, including various breast cancer subtypes, as discussed further below.
[0247] In some embodiments, subjects selected for treatment with the antibody or antigen-binding fragment thereof have a cancer that secretes DDR1 protein or a portion thereof and / or has DDR1 protein present on the cell surface of the cancer cells. In some embodiments, the method of treating cancer includes determining whether the cancer for treatment secretes DDR1 protein and / or has DDR1 protein expressed on the surface of the cancer cells.
[0248] In some embodiments, the antibody or antigen-binding fragment thereof is used to treat hematological or blood cancers, including, but not limited to, malignant lymphoma, Hodgkin's disease, granulomatous granulomatosis, malignant small lymphocytic lymphoma, malignant large cell diffuse lymphoma, malignant follicular lymphoma, mycosis fungoides, other certain non-Hodgkin's lymphomas, malignant histiocytosis, multiple myeloma, mast cell sarcoma, immunoproliferative small intestinal disease, leukemia, lymphocytic leukemia, plasma cell leukemia, erythroleukemia, lymphosarcoma cell leukemia, myeloid leukemia, basophilic leukemia, eosinophilic leukemia, monocytic leukemia, mast cell leukemia, megakaryocytic leukemia, myeloid sarcoma, and leukemia.
[0249] In some embodiments, a subject selected for treatment with an antibody or antigen-binding fragment thereof has a cancer that secretes DDR1 protein or a portion thereof and / or has DDR1 protein present on the cell surface of the cancer cells. In some embodiments, a method of treating cancer includes determining whether the cancer for treatment secretes DDR1 protein and / or has DDR1 protein expressed on the surface of the cancer cells. Thus, in some embodiments, a method of treating cancer in a subject includes determining the presence of secreted DDR1 protein or the presence of DDR1 protein on the surface of cancer cells in the subject, and if the cancer cells are determined to have secreted DDR1 protein or have DDR1 present on the surface of the cancer cells, treating the cancer in the subject by administering a therapeutically effective amount of an antibody or antigen-binding fragment disclosed herein.
[0250] 2. Breast cancer treatment In some embodiments, the cancer for treatment is breast cancer, which typically originates in the breast, usually the lining of the milk ducts or lobules. There are various types of breast cancer, differing in stage (spread), aggressiveness, and genetic makeup. With the best treatments, 10-year disease-free survival rates vary from 98% to 10%. Treatments are selected from surgery, drugs (chemotherapy), and radiation. In the United States, there were 216,000 cases of invasive breast cancer in 2004, resulting in 40,000 deaths. Worldwide, breast cancer is the second most common cancer after lung cancer (10.4% of all cancer incidence rates, both in men and women) and the fifth leading cause of cancer death. In 2004, breast cancer caused 519,000 deaths worldwide (7% of cancer deaths, nearly 1% of all deaths). Breast cancer is approximately 100 times more common in women than in men, but survival rates are equal for both sexes.
[0251] The first symptom, or subjective sign, of breast cancer is typically a lump that feels different from the surrounding breast tissue. According to the Merck Manual, more than 80% of breast cancer cases are discovered when a woman feels a lump. According to the American Cancer Society, the first medical, or objective, sign of breast cancer detected by a doctor is found by mammography. A lump found in a lymph node located under the arm may also indicate breast cancer. Indications of breast cancer other than a lump may include a change in breast size or shape, skin inversion, nipple inversion, or spontaneous discharge from one nipple. Pain ("mastalgia") is an unreliable tool for determining whether or not breast cancer is present but may indicate other breast health issues.
[0252] When breast cancer cells invade the dermal lymphatic vessels and small lymphatic vessels in the skin of the breast, the condition can resemble skin inflammation and is therefore known as inflammatory breast cancer (IBC). Symptoms of inflammatory breast cancer include pain, swelling, warmth, and redness throughout the breast, as well as an orange peel texture known as "peau d'orange." Another reported symptom complex of breast cancer is Paget's disease of the breast. This syndrome manifests as eczema-like skin changes, such as redness and mild peeling of the skin around the nipple. As Paget's disease progresses, symptoms may include tingling, itching, increased sensitivity, burning, and pain. Nipple discharge may also be present. Approximately half of women diagnosed with Paget's disease also have a breast lump.
[0253] Sometimes, breast cancer can present as metastatic disease, i.e., cancer that has spread beyond the organ of origin. Metastatic breast cancer will cause symptoms that depend on the location of metastasis. Common sites of metastasis include bone, liver, lung, and brain. Unexplained weight loss can sometimes herald occult breast cancer, as can symptoms of fever and chills. Bone or joint pain can be a symptom of metastatic breast cancer, as can jaundice or neurological symptoms. These symptoms are "nonspecific," meaning they can also be symptoms of many other diseases.
[0254] The major identified risk factors are gender, age, childbirth, hormones, a high-fat diet, alcohol consumption, obesity, and environmental factors such as tobacco use, radiation, and shift work. While the etiology of 95% of breast cancer cases is unknown, approximately 5% of new breast cancers are attributable to genetic syndromes. Carriers of the breast cancer susceptibility genes BRCA1 and BRCA2, in particular, have a 30–40% increased risk of breast and ovarian cancer, depending on the portion of the protein in which the mutation occurs. Experts believe that 95% of hereditary breast cancers can be traced back to one of these two genes. Hereditary breast cancer can take the form of site-specific hereditary breast cancer, cancer affecting only the breast, or breast-ovarian and other cancer syndromes. Breast cancer can be inherited from both female and male relatives.
[0255] Breast cancer subtypes are typically classified immunohistochemically. Subtype definitions are generally as follows: Normal (ER+, PR+, HER2+, cytokeratin 5 / 6+, and HER1+) Luminal A (ER+ and / or PR+, HER2-) Luminal B (ER+ and / or PR+, HER2+) Triple negative (ER-, PR-, HER2-) HER2+ / ER- (ER-, PR-, and HER2+) Unclassified (ER-, PR-, HER2-, cytokeratin 5 / 6-, and HER1-)
[0256] In triple-negative breast cancer cells, cancer growth is not driven by estrogen or progesterone, or growth signals derived from the HER2 protein. Similarly, such cancer cells do not respond to hormonal therapies, such as tamoxifen or aromatase inhibitors, or therapies targeting the HER2 receptor, such as Herceptin®. Approximately 10–20% of breast cancers are found to be triple-negative. It is important to identify these types of cancer and focus on therapies that can be used to treat triple-negative breast cancer, so that the cost and toxicity of unlikely treatments can be avoided. Like other forms of breast cancer, triple-negative breast cancer can be treated with surgery, radiation therapy, and / or chemotherapy. One particularly promising approach is "neoadjuvant" therapy, in which chemotherapy and / or radiation therapy are provided before surgery. Another drug therapy is the use of poly(ADP-ribose) polymerase, or PARP, inhibitors.
[0257] While the screening techniques described above are useful for determining the likelihood of cancer, further testing is required to confirm whether a lump detected by screening is cancerous, as opposed to a benign surrogate such as a simple cyst. In clinical settings, breast cancer is typically diagnosed using the "triple test" of a clinical breast exam (a breast examination by an experienced physician), mammography, and fine-needle aspiration cytology. Both mammography and a clinical breast exam, also used for screening, can indicate the approximate likelihood that a lump is cancerous and can also identify any other pathologies. Fine-needle aspiration and cytology (FNAC), performed as an outpatient procedure using local anesthetic, involves attempting to extract a small amount of fluid from the lump. Clear fluid significantly reduces the likelihood that the lump is cancerous, but blood-tinged fluid may be transported for microscopic examination for cancerous cells. Using these three tools in combination, breast cancer can be diagnosed with a high degree of accuracy. Other biopsy options include a core biopsy, in which part of the breast lump is removed, and an excision biopsy, in which the entire lump is removed.
[0258] Breast cancer screening attempts to detect cancer in otherwise healthy individuals. The most common screening method for women is a combination of x-ray mammography and clinical breast examination. For women at higher than normal risk, such as those with a strong family history of cancer, additional tools may include genetic testing or breast magnetic resonance imaging.
[0259] Breast self-examination was a form of screening that was strongly advocated in the past but subsequently failed after several large studies showed that it offered no survival benefit to women and often caused considerable anxiety. This may be because detectable cancers tended to be already relatively advanced, whereas other methods encourage identifying cancers at an early stage when curative treatment is more frequently available.
[0260] X-ray mammography uses x-rays to examine the breasts for featureless masses or lumps. In some countries, regular mammograms are recommended for women over a certain age as a screening tool.
[0261] Genetic testing for breast cancer typically involves testing for mutations in the BRCA genes, a procedure that is generally not recommended except for those at high risk for breast cancer.
[0262] Once the tumor has been localized, the mainstay of breast cancer treatment is surgery, with the possibility of adjuvant hormonal therapy (using tamoxifen or aromatase inhibitors), chemotherapy, and / or radiation therapy. Currently, recommended treatments after surgery (adjuvant therapy) follow a pattern: Depending on clinical criteria (age, cancer type, size, metastasis), patients are roughly divided into high-risk and low-risk cases, and each risk category follows different treatment rules. Treatment possibilities include radiation therapy, chemotherapy, hormonal therapy, and immunotherapy.
[0263] Targeted cancer therapies are treatments that target specific characteristics of cancer cells, such as proteins that allow cancer cells to grow rapidly or in an abnormal way. Targeted therapies are generally less likely than chemotherapy to harm normal, healthy cells. Some targeted therapies are antibodies that act like antibodies naturally produced by one's own immune system. These types of targeted therapies are sometimes called immunotargeted therapies.
[0264] Currently, there are three targeted therapies doctors use to treat breast cancer: Herceptin® (trastuzumab) works against HER2-positive breast cancer by blocking the cancer cells' ability to receive chemical signals that tell them to grow. Tykerb® (lapatinib) works against HER2-positive breast cancer by blocking specific proteins that can cause uncontrolled cell growth. Avastin® (bevacizumab) works by blocking the growth of new blood vessels that cancer cells depend on to grow and function.
[0265] Hormone (anti-estrogen) therapy works in two ways for hormone receptor-positive breast cancer: first, by reducing the amount of the hormone estrogen in the body; and second, by blocking the effects of estrogen in the body. Most of the estrogen in a woman's body is made by the ovaries. Estrogen drives hormone receptor-positive breast cancer to grow. Therefore, reducing the amount of estrogen or blocking its effects can help shrink hormone receptor-positive breast cancer and reduce the risk of hormone receptor-positive breast cancer coming back (recurring). Hormone therapy drugs are not effective against hormone receptor-negative breast cancer.
[0266] There are several types of hormone therapy drugs, including aromatase inhibitors, selective estrogen receptor modulators, and estrogen receptor down-modulators. In some cases, the ovaries and fallopian tubes may be surgically removed to treat hormone receptor-positive breast cancer or as a preventative measure for women at high risk of developing breast cancer. The ovaries may also be temporarily shut off using medications.
[0267] Treatment planning can also involve the use of PCR tests, such as Oncotype DX, or microarray tests that predict the risk of breast cancer recurrence based on gene expression. In February 2007, the first breast cancer predictor test was officially approved by the U.S. Food and Drug Administration. This is a new genetic test that can help predict whether women with early-stage breast cancer will recur in 5 or 10 years, which may affect how aggressively the initial tumors are treated.
[0268] Radiation therapy is also used to help destroy any cancer cells that may remain after surgery. When given in the correct dose, radiation can reduce the risk of recurrence by 50 to 66 percent.
[0269] Thus, in some embodiments, the antibody or antigen-binding fragment thereof is used to treat breast cancer, including each of the above-mentioned breast cancer subtypes. In some embodiments, the antibody or antigen-binding fragment thereof of the present disclosure is used in combination with a second therapeutic agent, and the second therapeutic agent includes one or more of the agents described herein (e.g., radiation, chemotherapeutic agents, hormones, and immunotherapeutic agents). In some embodiments, breast cancer or subtypes thereof determined to have DDR proteins on the cell surface or secrete DDR1 protein are treated with the antibody or antigen-binding fragment.
[0270] 3. Treatment of fibrotic disorders In addition to its expression in cancer, DDR1 protein is also expressed in the kidney, lung, gastrointestinal tract, skin, and brain, among other organs, and is involved in fibrosis of the skin, lung, and liver (Moll, et al. 2019, incorporated herein by reference). Thus, in some embodiments, the anti-DDR1 antibodies or antigen-binding fragments thereof of the present disclosure can be used alone or in combination with other therapies to treat fibrotic disorders. In some embodiments, the fibrotic disorder is organ fibrosis. In some embodiments, the fibrotic disorder is fibrosis of the skin, kidney, liver, lung, or heart. In some embodiments, the fibrotic disorder treated includes, but is not limited to, hypertrophic scarring of the skin, idiopathic pulmonary fibrosis, liver cirrhosis, and renal fibrosis.
[0271] In some embodiments, the fibrotic disorder to be treated is pulmonary fibrosis. In some embodiments, the subject to be treated has interstitial lung disease. In some embodiments, the subject to be treated has idiopathic pulmonary fibrosis (IPF) or lung scarring.
[0272] B. Formulation and Administration In another aspect, the present disclosure provides pharmaceutical compositions comprising anti-DDR1 antibodies and antigens for generating the same. Such compositions comprise a prophylactically or therapeutically effective amount of the antibody or fragment thereof and a pharmaceutically acceptable carrier. In certain embodiments, the term "pharmaceutically acceptable" means approved by a regulatory agency of the U.S. federal or state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, particularly humans. The term "carrier" refers to a diluent, excipient, or vehicle with which a therapeutic agent is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water is a particular carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions. Other suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like.
[0273] If desired, the compositions may also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations, and the like. Oral formulations can contain standard pharmaceutical-grade carriers such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. Examples of suitable pharmaceuticals are described in "Remington's Pharmaceutical Sciences." Such compositions contain a prophylactically or therapeutically effective amount of the antibody or fragment thereof, preferably in purified form, together with an appropriate amount of carrier to provide the form for proper administration to the patient. The formulation should be compatible with the mode of administration, which may be oral, intravenous, intraarterial, buccal, intranasal, nebulized, bronchial inhalation, or delivered by respirator.
[0274] The antibodies of the present disclosure described herein can be formulated for parenteral administration, for example, for injection via intradermal, intravenous, intramuscular, subcutaneous, intratumoral, or even intraperitoneal routes. Alternatively, the antibodies can be administered by direct topical routes to mucous membranes, for example, by nasal drops, inhalation, or nebulizer. Pharmaceutically acceptable salts include acid salts and those formed with inorganic acids, such as hydrochloric or phosphoric acid, or organic acids, such as acetic acid, oxalic acid, tartaric acid, mandelic acid, and the like. Salts formed with free carboxyl groups may be derived from inorganic bases, such as sodium, potassium, ammonium, calcium, or ferric hydroxide, as well as organic bases, such as isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine, procaine, and the like.
[0275] Generally, the components of the composition of the present disclosure are provided separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a sealed container such as an ampoule or sachet indicating the amount of active ingredient.When the composition is administered by infusion, it can be dispensed in an infusion bottle containing sterile pharmaceutical-grade water or saline.When the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the components can be mixed before administration.
[0276] In some embodiments, the compositions of the present disclosure can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxide, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, procaine, etc.
[0277] In some embodiments, the antibody or antigen-binding fragment thereof is administered in an amount effective to treat a disease or disorder, particularly cancer, such as breast cancer. The amount of anti-DDR1 antibody administered will depend on various factors, including, but not limited to, the particular type of cancer being treated, the stage of the cancer being treated, the mode of administration, the frequency of administration, the desired therapeutic effect, and other parameters such as the patient's age, weight, and other characteristics.
[0278] Dosages effective to provide a therapeutic benefit can be estimated initially from in vivo animal models or clinical trials. Suitable animal models for various diseases are known in the art, and the determination of an effective dose to provide a therapeutic benefit for a particular mode and frequency of administration is within the capabilities of one of ordinary skill in the art.
[0279] In some embodiments, an anti-DDR1 antibody or antigen-binding fragment thereof may be administered in the range of 0.0001 to 100 mg / kg body weight. Wide variations in administered dosages are to be expected given the diversity of antibody compositions available and the differing efficiencies of various administration routes. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art. In some embodiments, for treatment of the indications described herein, an effective dose of an antibody of the present disclosure may range from about 0.001 to about 75 mg / kg body weight, 0.005 mg / kg to about 50 mg / kg body weight, about 0.01 mg / kg to about 30 mg / kg body weight, or about 0.01 to 5 mg / kg body weight.
[0280] C. Cell therapy In another aspect, the present disclosure provides an immune cell expressing a chimeric antigen receptor (CAR). In some embodiments, the CAR comprises an antigen-binding fragment provided herein. In some embodiments, the CAR protein comprises, from N- to C-terminus, a leader peptide, an anti-DDR1 heavy chain variable domain, a linker domain, an anti-DDR1 light chain variable domain, a human IgG1-CH2-CH3 domain, a spacer region, a CD28 transmembrane domain, an anti-DDR1 intracellular costimulatory signaling domain, and a CD3ζ intracellular T cell signaling domain.
[0281] Also provided are methods for immunotherapy comprising administering an effective amount of the immune cells of the present disclosure. In one embodiment, a medical disease or disorder is treated by the transfer of an immune cell population that induces an immune response. In certain embodiments of the present disclosure, cancer or infection is treated by the transfer of an immune cell population that induces an immune response. Provided herein are methods for treating or delaying the progression of cancer in an individual, comprising administering to the individual an effective amount of an antigen-specific cell therapy.
[0282] The immune cells can be T cells (e.g., regulatory T cells, CD4+ T cells, CD8+ T cells, or gamma delta T cells), NK cells, invariant NK cells, NKT cells, or macrophages. Also provided herein are methods for producing and manipulating immune cells, and methods for using and administering cells for adoptive cell therapy, where the cells can be autologous or allogeneic. Thus, immune cells can be used as immunotherapy, for example, to target cancer cells.
[0283] Immune cells can be isolated from a subject, particularly a human subject.Immune cells can be obtained from a healthy human subject, a healthy volunteer, or a healthy donor.Immune cells can be obtained from a target subject, for example, a subject suspected of having a specific disease or condition, a subject suspected of having a predisposition to a specific disease or condition, or a subject undergoing treatment for a specific disease or condition.Immune cells can be collected from any location present in a subject, including but not limited to blood, umbilical cord blood, spleen, thymus, lymph node, and bone marrow.Immune cells isolated can be used directly or can be stored for a certain period of time, such as by freezing.
[0284] Immune cells can be enriched / purified from any tissue in which they reside, including blood (including blood collected by blood banks or umbilical cord blood banks), spleen, bone marrow, tissues removed and / or exposed during surgical procedures, and tissues obtained via biopsy procedures. The tissues / organs from which immune cells are enriched, isolated, and / or purified can be isolated from both living and non-living subjects, with non-living subjects being organ donors. In certain embodiments, immune cells are isolated from blood, such as peripheral blood or umbilical cord blood. In some aspects, immune cells isolated from umbilical cord blood have enhanced immunoregulatory capabilities, as measured by CD4 or CD8 positive T cell suppression. In certain aspects, immune cells are isolated from pooled blood, particularly pooled spinal cord blood, for enhanced immunoregulatory capabilities. Pooled blood can be from two or more sources, such as 3, 4, 5, 6, 7, 8, 9, 10, or more sources (e.g., donor subjects).
[0285] The population of immune cells can be obtained from the subject who needs treatment or the subject who suffers from the disease associated with the decrease of immune cell activity.Therefore, the cells are autologous to the subject who needs treatment.Alternatively, the population of immune cells can be obtained from a donor, preferably a histocompatibility-matched donor.The population of immune cells can be collected from peripheral blood, umbilical cord blood, bone marrow, spleen, or any other organ / tissue in which immune cells exist in the subject or donor.The immune cells can be isolated from a pool of subjects and / or donors, for example, from pooled spinal cord blood.
[0286] When immune cell population is obtained from a donor different from the subject, the donor is preferably allogeneic, but the obtained cells can be introduced into the subject and be subject-compatible.Allogeneic donor cells can be human leukocyte antigen (HLA) compatible or not.To achieve subject compatibility, allogeneic cells can be treated to reduce immunogenicity.
[0287] Immune cells can be genetically engineered to express antigen receptors, such as engineered TCRs and / or chimeric antigen receptors (CARs). For example, host cells (e.g., autologous or allogeneic T cells) are modified to express T cell receptors (TCRs) with antigen specificity for cancer antigens. In certain embodiments, NK cells are engineered to express TCRs. NK cells can be further engineered to express CARs. Multiple CARs and / or TCRs, such as those for different antigens, can be added to a single cell type, such as T cells or NK cells.
[0288] Suitable modification methods are known in the art. See, for example, Sambrook et al., supra, and Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and John Wiley & Sons, NY, 1994. For example, cells can be transduced to express T cell receptors (TCRs) with antigen specificity for cancer antigens using the transduction techniques described in Heemskerk et al. (2008) and Johnson et al. (2009).
[0289] In some embodiments, the cells contain one or more nucleic acids introduced via genetic engineering that encode one or more antigen receptors, and the genetically engineered products of such nucleic acids. In some embodiments, the nucleic acids are heterologous, i.e., not normally present in cells or samples obtained from the cells, e.g., obtained from another organism or cell, e.g., not normally found in the engineered cell and / or the organism from which such cells are derived. In some embodiments, the nucleic acids are not naturally occurring, such as nucleic acids not found in nature (e.g., chimeras).
[0290] D. Combination Therapy It may also be desirable to provide a combination therapy using the antibodies of the present disclosure in conjunction with an additional anti-cancer therapy. These therapies are provided in a combined amount effective to achieve a reduction in one or more disease parameters. This process may involve contacting the cells / subject with both agents / therapies simultaneously, for example, by using a single composition or pharmacological formulation containing both agents, or by contacting the cells / subject with two different compositions or formulations at the same time (one composition containing the antibody and another composition containing the other agent).
[0291] Alternatively, the antibody can precede or follow the other treatment by intervals ranging from minutes to weeks. Generally, no significant time period should elapse between each delivery time, so that the treatments can still exert a beneficially combined effect on the cells / subject. In such cases, it is contemplated to contact the cells with both modalities within about 12-24 hours of each other, within about 6-12 hours of each other, or with only about a 12-hour delay. In some situations, it may be desirable to extend the treatment period significantly, with tens of days (2, 3, 4, 5, 6, or 7) to several weeks (1, 2, 3, 4, 5, 6, 7, or 8) elapsed between each administration.
[0292] It is also contemplated that administration of more than one of the anti-DDR1 antibodies or other therapies may be desirable. Various combinations can be used, where the antibody is "A" and the other therapy is "B," examples of which are provided below: A / B / AB / A / BB / B / AA / A / BB / A / AA / B / BB / B / B / AB / B / A / B A / A / B / BA / B / A / BA / B / B / AB / B / A / AB / A / B / AB / A / A / BB / B / B / A A / A / A / BB / A / A / AA / B / A / AA / A / B / AA / B / B / BB / A / B / BB / B / A / B
[0293] Other combinations are contemplated. Using the methods and compositions of the present invention, target cells or sites can be contacted with an antibody and at least one other therapeutic agent to kill cells, inhibit cell growth, inhibit metastasis, inhibit angiogenesis, or otherwise reverse or reduce the malignant phenotype of tumor cells. These therapeutic agents are provided in a combined amount effective to kill or inhibit the growth of cancer cells. This process can include contacting the cells / sites / subjects with the agents / therapies simultaneously.
[0294] Specific agents contemplated for combination therapy with the antibodies of the present disclosure include chemotherapy and hematopoietic stem cell transplantation. Chemotherapy may include cytarabine (ara-C) and an anthracycline (most often daunorubicin), high-dose cytarabine alone, all-trans retinoic acid (ATRA) in addition to induction chemotherapy, usually in addition to an anthracycline, histamine dihydrochloride (Ceplene) and interleukin-2 (Proleukin) after completion of consolidation therapy, gemtuzumab ozogamicin (Mylotarg) for relapsed AML patients aged 60 years or older who are not suitable for high-dose chemotherapy, clofarabine, and targeted therapies such as kinase inhibitors, farnesyltransferase inhibitors, decitabine, and MDR1 (multidrug resistance protein) inhibitors, or arsenic trioxide for relapsed acute promyelocytic leukemia (APL).
[0295] In certain embodiments, the agents for combination therapy are topoisomerase inhibitors, anthracycline topoisomerase inhibitors, anthracyclines, daunorubicin, nucleoside metabolic inhibitors, cytarabine, hypomethylating agents, low-dose cytarabine (LDAC), a combination of daunorubicin and cytarabine, injectable daunorubicin and cytarabine liposomes, Vyxeos®, azacitidine, Vidaza®, decitabine, all-trans retinoic acid (ATRA), arsenic, arsenic trioxide, histamine dihydrochloride, Ceplene®, interleukin-2, aldesleukin, Proleukin®, getumuzumab Ozogamicin, Mylotarg®, FLT-3 inhibitors, midostaurin, Rydapt®, clofarabine, farnesyltransferase inhibitors, decitabine, IDH1 inhibitors, ivosidenib, Tibsovo®, IDH2 inhibitors, enasidenib, Idhifa®, smoothened (SMO) inhibitors, glasdegib, arginase inhibitors, IDO inhibitors, epacadostat, BCL-2 inhibitors, venetoclax, Venclexta®, platinum-conjugated derivatives, oxaliplatin, kinase inhibitors, tyrosine kinase inhibitors, PI3 kinase inhibitors, BTK inhibitors, ibrutinib, IMBRUV The combination therapy is one or more drugs selected from the group consisting of ICA®, acalabrutinib, CALQUENCE®, zanubrutinib, PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, LAG3 antibody, ICOS antibody, TIGIT antibody, TIM3 antibody, CD40 antibody, 4-1BB antibody, CD47 antibody, SIRP1α antibody or fusion protein, E-selectin antagonist, antibody that binds to a tumor antigen, antibody that binds to a T cell surface marker, antibody that binds to a myeloid cell or NK cell surface marker, alkylating agent, nitrosourea agent, antimetabolite, antitumor antibiotic, plant-derived alkaloid, hormone therapy agent, hormone antagonist, aromatase inhibitor, and P-glycoprotein inhibitor. In some embodiments, the drug used in the combination therapy is a drug that has previously been used as therapy for a particular indication, such as a particular type of cancer.In some embodiments, the specific indication is breast cancer and the agent used in combination with the antibody or antigen-binding agent thereof is an agent that is accepted for the treatment of breast cancer.
[0296] VI. Antibody Conjugates The antibodies of the present disclosure can be linked to at least one agent to form an antibody conjugate. To increase the effectiveness of antibody molecules as diagnostic or therapeutic agents, it is common practice to link, covalently bind, or complex at least one desired molecule or moiety to the antibody molecule. Such a molecule or moiety can be, but is not limited to, at least one effector or reporter molecule. Effector molecules include molecules with desired activity, such as cytotoxic activity. Non-limiting examples of effector molecules that can be attached to antibodies include toxins, antitumor agents, therapeutic enzymes, radionuclides, antiviral agents, chelators, cytokines, growth factors, and oligo- or polynucleotides. In contrast, a reporter molecule is defined as any moiety that can be detected using an assay. Non-limiting examples of reporter molecules that can be conjugated to antibodies include ligands such as enzymes, radiolabels, haptens, fluorescent labels, phosphorescent molecules, chemiluminescent molecules, chromophores, photoaffinity molecules, colored particles, or biotin.
[0297] Antibody-drug conjugates have emerged as a revolutionary approach for the development of cancer therapeutics. Antibody-drug conjugates (ADCs) contain a monoclonal antibody (MAb) covalently linked to a cell-killing drug. This approach combines the high specificity of MAbs for antigen targets with a potent cytotoxic drug, resulting in "armed" MAbs that deliver their payload (drug) to tumor cells where the antigen is concentrated. Targeted delivery of the drug also minimizes its exposure in normal tissues, resulting in reduced toxicity and an improved therapeutic index. The FDA approval of two ADC drugs, ADCETRIS® (brentuximab vedotin) in 2011 and KADCYLA® (trastuzumab emtansine or T-DM1) in 2013, validated this approach. Currently, there are more than 30 ADC drug candidates in various stages of clinical trials for cancer treatment (Leal et al., 2014). As antibody engineering and linker-payload optimization become increasingly mature, the discovery and development of new ADCs increasingly relies on the identification and validation of new targets amenable to this approach and the generation of targeted MAbs. Two criteria for ADC targets are upregulated / high levels of expression in tumor cells and robust internalization.
[0298] Antibody conjugates are also preferably used as diagnostic agents.Antibody diagnostics are generally divided into two categories: those for use in in vitro diagnostics such as various immunoassays, and those for use in in vivo diagnostic protocols generally known as "antibody-directed imaging diagnostics".Many suitable imaging agents and their attachment methods to antibodies are known in the art (see, for example, U.S. Patent Nos. 5,021,23, 4,938,948 and 4,472,509).The imaging moiety used can be paramagnetic ions, radioisotopes, fluorescent dyes, NMR detectable substances and X-ray imaging agents.
[0299] In some embodiments, the moiety that binds to an antibody or antigen-binding fragment thereof is a paramagnetic ion, which may be selected from chromium(III), manganese(II), iron(III), iron(II), cobalt(II), nickel(II), copper(II), neodymium(III), samarium(III), ytterbium(III), gadolinium(III), vanadium(II), terbium(III), dysprosium(III), holmium(III), and / or erbium(III), among others, with gadolinium being particularly preferred. Ions useful in other contexts, such as x-ray imaging, include, but are not limited to, lanthanum(III), gold(III), lead(II), and especially bismuth(III).
[0300] In the case of radioisotopes for therapeutic and / or diagnostic use, the isotope may be astatine 211 , 14 carbon, 51 chromium, 36 chlorine, 57 cobalt, 58 Cobalt, Copper 67 , 152 Eu, gallium 67 , 3 Hydrogen, iodine 123 , iodine 125 , iodine 131 ,indium 111 , 59 iron, 32 Phosphorus, rhenium 186 ,rhenium 188 , 75 selenium, 35 Sulfur, Technetium 99m and / or yttrium 90 may be selected from: 125 I is often preferred for use in certain embodiments, and technetium 99m and / or indium 111Radiolabeled monoclonal antibodies of the present disclosure are also often preferred due to their low energy and suitability for long-distance detection. Radiolabeled monoclonal antibodies of the present disclosure can be produced according to methods well known in the art. For example, monoclonal antibodies can be iodinated by contact with sodium iodide and / or potassium iodide and a chemical oxidizing agent such as sodium hypochlorite, or an enzymatic oxidizing agent such as lactoperoxidase. Monoclonal antibodies according to the present disclosure can also be iodinated with technetium by a ligand exchange process, for example, by reducing the pertechnate with a stannous solution, chelating the reduced technetium on a Sephadex column, and applying the antibody to the column. 99m Alternatively, direct labeling techniques may be used, for example, by incubating the antibody with a reducing agent such as pertechnate or SNCl2, a buffer such as sodium-potassium phthalate solution, and the antibody. Intermediate functional groups often used to attach radioisotopes that exist as metal ions to antibodies are diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).
[0301] Fluorescent labels contemplated for use as conjugates include Alexa350, Alexa430, AMCA, BODIPY630 / 650, BODIPY650 / 665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy3, Cy5,6-FAM, fluorescein isothiocyanate, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin, ROX, TAMRA, TET, tetramethylrhodamine, and / or Texas Red.
[0302] Another type of antibody conjugate contemplated by the present disclosure is primarily intended for in vitro use, in which the antibody is linked to a secondary binding ligand and / or enzyme (enzyme tag) that generates a colored product upon contact with a chromogenic substrate. Examples of suitable enzymes include urease, alkaline phosphatase, (horseradish) hydrogen peroxidase, or glucose oxidase. Preferred secondary binding ligands are biotin and avidin and streptavidin compounds. The use of such labels is well known to those skilled in the art and is described, for example, in U.S. Patent Nos. 3,817,837, 3,850,752, 3,939,350, 3,996,345, 4,277,437, 4,275,149, and 4,366,241.
[0303] Yet another known method for site-specifically binding a molecule to an antibody involves reacting the antibody with a hapten-based affinity label. Essentially, the hapten-based affinity label reacts with amino acids in the antigen-binding site, thereby destroying this site and blocking specific antigen reaction. However, this may not be advantageous because it results in loss of antigen binding by the antibody conjugate.
[0304] Molecules containing azide groups can also be used to form covalent bonds to proteins via reactive nitrene intermediates generated by low-intensity ultraviolet light (Potter and Haley, 1983). In particular, 2- and 8-azido analogs of purine nucleotides have been used as site-directed optical probes to identify nucleotide-binding proteins in crude cell extracts (Owens & Haley, 1987; Atherton et al., 1985). 2- and 8-azido nucleotides have also been used to map nucleotide-binding domains in purified proteins (Khatoon et al., 1989; King et al., 1989; Dholakia et al., 1989) and can be used as antibody binders.
[0305] Several methods for binding or conjugating antibodies to their conjugate moieties are known in the art. Some attachment methods involve, for example, the use of metal chelate complexes with organic chelators such as diethylenetriaminepentaacetic anhydride (DTPA), ethylenetriaminetetraacetic acid, N-chloro-p-toluenesulfonamide, and / or tetrachloro-3α-6α-diphenylglycouril-3 (U.S. Pat. Nos. 4,472,509 and 4,938,948) attached to the antibody. Monoclonal antibodies may also be reacted with enzymes in the presence of coupling agents such as glutaraldehyde or periodate. Conjugates with fluorescein markers are prepared in the presence of these coupling agents or by reaction with isothiocyanates. In U.S. Pat. No. 4,938,948, imaging of breast tumors is achieved using monoclonal antibodies, and a detectable imaging moiety is attached to the antibody using a linker such as methyl-p-hydroxybenzimidate or N-succinimidyl-3-(4-hydroxyphenyl)propionate.
[0306] In another embodiment, immunoglobulins are derivatized by selectively introducing sulfhydryl groups into the Fc region of the immunoglobulin using reaction conditions that do not alter the antibody binding site. Antibody conjugates produced according to this method have been disclosed to exhibit improved longevity, specificity, and sensitivity (U.S. Patent No. 5,196,066, incorporated herein by reference). Site-specific conjugation of effector or reporter molecules, in which the reporter or effector molecule is conjugated to a carbohydrate residue in the Fc region, has also been disclosed in the literature (O'Shannessy et al., 1987). This approach has been reported to produce antibodies with diagnostic and therapeutic potential that are currently undergoing clinical evaluation.
[0307] VII. Immunodetection Methods In still further embodiments, the present disclosure relates to immunodetection methods for binding, purifying, removing, quantifying, and otherwise generally detecting DDR1-associated cancers. While such methods can be applied in the traditional sense, another use is in the quality control and monitoring of vaccines and other viral stocks, where antibodies according to the present disclosure can be used to assess the amount or integrity (i.e., long-term stability) of H1 antigen in the virus. Alternatively, the methods can be used to screen various antibodies for appropriate / desired reactivity profiles.
[0308] Some immunodetection methods include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), immunoradiometric assays, fluorescent immunoassays, chemiluminescent assays, bioluminescent assays, and Western blots, to name a few. Competitive assays for the detection and quantification of DDR1 are also provided. The steps of various useful immunodetection methods are described in scientific literature, such as Doolittle and Ben-Zeev (1999), Gulbis and Galand (1993), De Jager et al. (1993), and Nakamura et al. (1987). Generally, immunoconjugation methods involve obtaining a sample suspected of containing a DDR1-associated cancer and, optionally, contacting the sample with a first antibody according to the present disclosure under conditions effective to allow the formation of an immune complex.
[0309] These methods include methods for detecting or purifying DDR1 or DDR1-associated cancer cells from a sample. The antibody is preferably linked to a solid support, such as in the form of a column matrix, and a sample suspected of containing DDR1-associated cancer cells is applied to the immobilized antibody. Unwanted components are washed off the column, leaving DDR1-expressing cells immunocomplexed to the immobilized antibody, and then the organisms or antigens are collected by removing them from the column.
[0310] The immunobinding method also includes a method for detecting and quantifying the amount of DDR1-associated cancer cells or related components in a sample, and detecting and quantifying any immune complexes formed during the binding process. Herein, a sample suspected of containing DDR1-associated cancer cells is obtained, the sample is contacted with an antibody or component thereof that binds to DDR1, and then the amount of immune complexes formed under specific conditions is detected and quantified. For antigen detection, the biological sample analyzed may be any sample suspected of containing DDR1-associated cancer, such as a tissue section or specimen, a homogenized tissue extract, a biological fluid including blood and serum, or a secretion such as feces or urine.
[0311] Contacting a selected biological sample with an antibody under effective conditions and for a period of time sufficient to allow the formation of immune complexes (primary immune complexes) generally involves simply adding an antibody composition to the sample and incubating the mixture for a period of time sufficient for the antibody to form immune complexes, i.e., bind to DDR1. After this time, the sample-antibody composition, such as a tissue section, ELISA plate, dot blot, or Western blot, is generally washed to remove any non-specifically bound antibody species, allowing only specifically bound antibodies within the primary immune complexes to be detected.
[0312] Generally, the detection of immune complex formation is well known in the art and can be achieved by applying a number of approaches.These methods are generally based on the detection of labels or markers, such as radioactive, fluorescent, biological and enzymatic tags.Patents relating to the use of such labels include U.S. Patent Nos. 3,817,837, 3,850,752, 3,939,350, 3,996,345, 4,277,437, 4,275,149 and 4,366,241.Of course, as known in the art, additional advantages can be found through the use of secondary binding ligands, such as second antibody and / or biotin / avidin ligand binding arrangement.
[0313] The antibody used for detection may itself be linked to a detectable label, which can then be simply detected, thereby determining the amount of primary immune complexes in the composition. Alternatively, the first antibody that becomes bound within the primary immune complex can be detected by a second binding ligand that has binding affinity for the antibody. In these cases, the second binding ligand can be linked to a detectable label. The second binding ligand is often itself an antibody, which can therefore be referred to as a "secondary" antibody. The primary immune complex is contacted with a labeled secondary binding ligand or antibody for a period of time and under effective conditions to allow the formation of secondary immune complexes. The secondary immune complex is then generally washed to remove any non-specifically bound labeled secondary antibody or ligand, and the remaining label in the secondary immune complex is then detected.
[0314] Another method involves detecting primary immune complexes using a two-step approach. As described above, a second binding ligand, such as an antibody having binding affinity for the antibody, is used to form secondary immune complexes. After washing, the secondary immune complexes are contacted with a third binding ligand or antibody having binding affinity for the second antibody, again under effective conditions, for a period of time sufficient to allow the formation of immune complexes (tertiary immune complexes). The third ligand or antibody is linked to a detectable label, allowing the detection of the tertiary immune complexes thus formed. This system can provide signal amplification if desired.
[0315] One immunodetection method uses two different antibodies. A first biotinylated antibody is used to detect the target antigen, and then a second antibody is used to detect the biotin bound to the complexed biotin. In this method, the sample to be tested is first incubated in a solution containing the first-step antibody. If the target antigen is present, some of the antibody binds to the antigen, forming a biotinylated antibody / antigen complex. The antibody / antigen complex is then amplified by incubation in successive solutions of streptavidin (or avidin), biotinylated DNA, and / or complementary biotinylated DNA, each step adding additional biotin moieties to the antibody / antigen complex. The amplification steps are repeated until a suitable level of amplification is achieved, at which point the sample is incubated in a solution containing the second-step antibody against biotin. This second-step antibody is labeled with an enzyme that can be used to detect the presence of the antibody / antigen complex, for example, by histoenzymology using a chromogenic substrate. With suitable amplification, macroscopically visible conjugates can be produced.
[0316] Another known method of immunodetection utilizes immuno-PCR (polymerase chain reaction) methodology. The PCR method is similar to the Cantor method up to the incubation with biotinylated DNA, but instead of using multiple rounds of streptavidin and biotinylated DNA incubation, the DNA / biotin / streptavidin / antibody complex is washed with a low pH or high salt buffer, which releases the antibody. The resulting wash solution is then used to perform a PCR reaction with suitable primers and appropriate controls. At least theoretically, the enormous amplification power and specificity of PCR can be exploited to detect single antigen molecules.
[0317] A. ELISA Immunoassay, in its simplest and most direct sense, is a binding assay.A particular preferred immunoassay is various types of enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA) that are known in the art.Immunohistochemical detection using tissue sections is also particularly useful.However, it is easy to understand that detection is not limited to such techniques, and Western blotting, dot blotting, FACS analysis, etc. can also be used.
[0318] In one exemplary ELISA, the antibodies of the present disclosure are immobilized on a selected surface exhibiting protein affinity, such as the wells of a polystyrene microtiter plate. A test composition suspected of containing DDR1-associated cancer cells is then added to the wells. After binding and washing to remove nonspecifically bound immune complexes, the bound antigen can be detected. Detection can be achieved by adding another anti-DDR1 antibody linked to a detectable label. This type of ELISA is a simple "sandwich ELISA." Detection can also be achieved by adding a second anti-DDR1 antibody, followed by a third antibody with binding affinity for the second antibody, where the third antibody is linked to a detectable label.
[0319] In another exemplary ELISA, a sample suspected of containing DDR1-associated cancer cells is fixed to the well surface and then contacted with the anti-DDR1 antibody of the present disclosure. After binding and washing to remove non-specifically bound immune complexes, the bound anti-DDR1 antibody is detected. If the initial anti-DDR1 antibody is linked to a detectable label, the immune complex can be detected directly. Again, the immune complex can be detected using a second antibody that has binding affinity for the first anti-DDR1 antibody, and the second antibody is linked to a detectable label.
[0320] Regardless of the format employed, ELISAs share certain features in common, such as coating, incubating, and binding, washing to remove non-specifically bound species, and detection of bound immune complexes, which are described below.
[0321] When coating a plate with either an antigen or an antibody, the wells of the plate are generally incubated with a solution of the antigen or antibody overnight or for a specified period of time. The wells of the plate are then washed to remove incompletely adsorbed material. Any remaining available surfaces of the wells are then "coated" with a nonspecific protein that is antigenically neutral with respect to the test antiserum. These include solutions of bovine serum albumin (BSA), casein, or milk powder. The coating allows for blocking of nonspecific adsorption sites on the immobilizing surface, thereby reducing the background caused by nonspecific binding of the antiserum to the surface.
[0322] In ELISA, it is more common to use secondary or tertiary detection means rather than direct treatment. Thus, after binding a protein or antibody to a well, coating it with a non-reactive material to reduce background, and washing to remove unbound material, the immobilized surface is contacted with the biological sample to be tested under conditions effective to allow immune complex (antigen / antibody) formation. Next, detection of the immune complex requires a labeled secondary binding ligand or antibody, and the secondary binding ligand or antibody in conjunction with a labeled tertiary antibody or third binding ligand.
[0323] By "under conditions effective to allow immune complex (antigen / antibody) formation" is meant that the conditions preferably include diluting the antigen and / or antibody with a solution such as BSA, bovine gamma globulin (BGG), or phosphate buffered saline (PBS) / Tween. These additives also tend to aid in the reduction of nonspecific background.
[0324] "Appropriate" conditions also mean that the incubation is at a temperature or for a period of time sufficient to allow effective binding. The incubation step is typically for about 1 to 2 to 4 hours, preferably at a temperature of about 25°C to 27°C, or may be overnight at about 4°C.
[0325] Following all incubation steps in an ELISA, the contacted surface is washed to remove uncomplexed material. A preferred washing procedure involves washing with a solution such as PBS / Tween or borate buffer. After specific immune complex formation between the test sample and the originally bound substance and subsequent washing, the occurrence of minute amounts of immune complexes can be determined.
[0326] To provide a means of detection, the second or third antibody has an associated label to allow detection. Preferably, this is an enzyme that generates color when incubated with an appropriate chromogenic substrate. Thus, for example, one may wish to contact or incubate the first and second immune complexes with urease, glucose oxidase, alkaline phosphatase, or hydrogen peroxidase-conjugated antibodies for a period of time and under conditions favorable for the development of further immune complex formation (e.g., incubation for 2 hours at room temperature in a PBS-containing solution, such as PBS-Tween).
[0327] After incubation with the labeled antibody and washing to remove unbound material, the amount of label is quantified by incubation with a chromogenic substrate, such as urea, bromocresol purple, 2,2'-azino-di(3-ethyl-benzthiazoline-6-sulfonic acid (ABTS), or HO, if peroxidase is used as the enzyme label. Quantitation is then achieved by measuring the degree of color produced, for example, using a visible spectrum spectrophotometer.
[0328] B. Western Blot Western blot (alternatively, protein immunoblot) is an analytical technique used to detect specific proteins in a given sample of tissue homogenate or extract. It uses gel electrophoresis to separate native or denatured proteins by polypeptide length (denaturing conditions) or by protein 3D structure (native / non-denaturing conditions). The proteins are then transferred to a membrane (typically nitrocellulose or PVDF) where they are probed (detected) using antibodies specific to the target protein.
[0329] Samples can be taken from whole tissues or cell cultures. Often, solid tissues are first mechanically disintegrated using a blender (for larger sample volumes), a homogenizer (for smaller volumes), or by sonication. Cells may also be liberated by one of the mechanical methods mentioned above. However, it should be noted that bacterial, viral, or environmental samples can also be sources of proteins, and therefore Western blotting is not limited to cellular studies alone. Various detergents, salts, and buffers can be used to promote cell lysis and solubilize proteins. Protease and phosphatase inhibitors are often added to prevent digestion of the sample by its own enzymes. Tissue preparation is often performed at low temperatures to avoid protein denaturation.
[0330] Proteins in a sample are separated using gel electrophoresis. Protein separation can be by isoelectric point (pI), molecular weight, charge, or a combination of these factors. The nature of the separation depends on the sample processing and the properties of the gel. This is a very useful method for determining proteins. It is also possible to use two-dimensional (2D) gels, which spread proteins from a single sample in two dimensions. Proteins are separated according to their isoelectric point (pH with a neutral net charge) in the first dimension and according to molecular weight in the second dimension.
[0331] To make proteins accessible to antibody detection, they are transferred from the gel onto a membrane made of nitrocellulose or polyvinylidene fluoride (PVDF). The membrane is placed on top of the gel, and a stack of filter paper is placed on top of it. The entire stack is placed in a buffer solution and allowed to migrate to the paper by capillary action, carrying the proteins along with it. Another method for transferring proteins, called electroblotting, uses an electric current to draw the proteins from the gel onto a PVDF or nitrocellulose membrane. The proteins migrate from the gel onto the membrane while maintaining their internal structure. As a result of this blotting process, the proteins are exposed on a thin surface layer for detection (see below). Both types of membranes are chosen for their nonspecific protein-binding properties (i.e., they bind all proteins equally well). Protein binding is based on hydrophobic interactions as well as charged interactions between the membrane and the protein. Nitrocellulose membranes are less expensive than PVDF but are much more fragile and less resistant to repeated probing. The uniformity and overall effectiveness of protein transfer from the gel to the membrane can be confirmed by staining the membrane with Coomassie Brilliant Blue or Ponceau S dye. Once transferred, proteins are detected using a labeled or unlabeled primary antibody, followed by indirect detection using labeled Protein A or a secondary labeled antibody that binds to the Fc region of the primary antibody.
[0332] C. Immunohistochemistry In some embodiments, the antibodies of the present disclosure may be used in conjunction with both fresh-frozen and / or formalin-fixed, paraffin-embedded tissue blocks prepared for immunohistochemistry (IHC) studies. Methods for preparing tissue blocks from these particulate specimens have been successfully used in previous IHC studies of various prognostic factors and are well known to those skilled in the art (Brown et al., 1990; Abbondanzo et al., 1990; Allred et al., 1990).
[0333] Briefly, frozen sections can be prepared by rehydrating 50 ng of frozen "pulverized" tissue in phosphate-buffered saline (PBS) at room temperature, pelleting the particles by centrifugation, resuspending the particles in viscous embedding medium (OCT), re-inverting the capsule and / or pellet by centrifugation, flash-freezing in isopentane at -70°C, cutting the plastic capsule and / or removing the frozen tissue cylinder, securing the tissue cylinder to a cryostat microtome chuck, and / or cutting 25-50 serial sections from the capsule. Alternatively, the whole frozen tissue sample can be used to cut the serial sections.
[0334] Permanent sections can be prepared by a similar method, including rehydrating a 50 mg sample in a plastic microcentrifuge tube, pelleting, resuspending in 10% formalin and fixing for 4 hours, washing / pelleting, resuspending in warm 2.5% agar, pelleting, chilling in ice water to harden the agar, removing the tissue / agar block from the tube, infiltrating and / or embedding the block in paraffin, and / or cutting up to 50 serial permanent sections. Again, the entire tissue sample can be substituted.
[0335] D. Immunodetection Kit In yet another embodiment, the present disclosure also contemplates an immunodetection kit for use with the above-mentioned immunodetection method.Antibodies can be used to detect DDR1-associated cancer cells, so the antibodies can be included in the kit.Thus, the immunodetection kit includes, in suitable container means, a first antibody that binds to DDR1, and optionally an immunodetection reagent.
[0336] In certain embodiments, the antibody may be pre-bound to a solid support, such as a column matrix and / or the wells of a microtiter plate. The immunodetection reagents of the kit may take any one of a variety of forms, including a detectable label associated with or bound to a given antibody. Detectable labels associated with or bound to a secondary binding ligand are also contemplated. An exemplary secondary ligand is a secondary antibody that has binding affinity for the first antibody.
[0337] Further suitable immunodetection reagents for use in the present kits include two-component reagents comprising a second antibody having binding affinity for the first antibody and a third antibody having binding affinity for the second antibody, the third antibody being linked to a detectable label. As noted above, several exemplary labels are known in the art, and all such labels may be used in connection with the present disclosure.
[0338] The kit may further comprise an appropriately aliquoted composition of DDR1, whether labeled or unlabeled, so that it can be used to generate a standard curve for the detection assay. The kit may contain the antibody-labeled conjugate either in fully conjugated form, in the form of an intermediate, or in separate portions that are conjugated by the user of the kit. The components of the kit may be packaged either in aqueous medium or in lyophilized form.
[0339] The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe, or other container means into which the antibody may be placed, or preferably dispensed. The kits of the present disclosure will also typically include a means for containing the antibody, antigen, and any other reagent containers in close confinement for commercial sale. Such containers may include injection- or blow-molded plastic containers into which the desired vials are retained.
[0340] E. Flow Cytometry and FACS The antibodies of the present disclosure can also be used in flow cytometry, or FACS. Flow cytometry is a laser- or impedance-based technology used in many detection assays, including cell counting, cell sorting, biomarker detection, and protein engineering. This technology suspends cells in a fluid stream and passes them through an electronic detection device, allowing for simultaneous multiparametric analysis of the physical and chemical properties of up to thousands of particles per second. Flow cytometry is routinely used in the diagnosis of disorders, particularly blood cancers, but also has many other applications in basic research, clinical practice, and clinical trials.
[0341] Fluorescence-activated cell sorting (FACS) is a specialized type of cytometry. It provides a method for sorting a heterogeneous mixture of biological cells, one cell at a time, into two or more containers based on the specific light scattering and fluorescence properties of each cell. Generally, this technique involves a cell suspension entrained in the center of a narrow stream of rapidly flowing liquid. The flow is positioned so that there is a large separation between cells relative to its diameter. A vibrating mechanism breaks the stream of cells into individual droplets. Just before the stream breaks into droplets, it passes through a fluorescence measurement station where the fluorescence of each cell is measured. An electrically charged ring is positioned at the point where the stream breaks into droplets. A charge is placed on the ring just before the fluorescence intensity is measured, and an opposite charge is trapped on the droplets as they disintegrate from the stream. The charged droplets then fall through an electrostatic deflection system that diverts the droplets into containers based on their charge.
[0342] In certain embodiments, for use in flow cytometry or FACS, antibodies of the present disclosure are labeled with a fluorophore and then bound to cells of interest that are analyzed by flow cytometry or sorted by a FACS machine. [Example]
[0343] VIII. Working Examples The following examples are included to demonstrate preferred embodiments of the invention. Those of skill in the art should understand that the techniques disclosed in the examples which follow represent techniques the inventors have discovered to work well in the practice of the invention, and as such can be considered to constitute preferred modes for its practice. However, those skilled in the art will, in light of the present disclosure, understand that many changes can be made in the specific embodiments which are disclosed and still obtain like or similar results without departing from the spirit and scope of the invention.
[0344] Example 1 - Materials and Methods CRISPR KO. DDR1 was knocked out in M-WNT, AT-3, and E0771 using the DDR1 sgRNA CRISPR / Cas9 All-in-One Lentivector Set (ABM; catalog no. K4331005) according to the manufacturer's instructions. Briefly, lentiviral packaging was performed by co-transfecting HEK293T cells with the DDR1 KO vector and two helper vectors (psPAX2 and pMD2.G) using Lipofectamine 2000 (Life Technologies, catalog no. 11668027). After two days, lentivirus-containing supernatants were collected and used to infect target tumor cells. Single clones were picked and expanded after antibiotic selection. Genomic DNA of all selected KO clones was extracted and sequenced to verify the desired mutations. The sgRNA sequences were as follows: sgRNA1, AAGCAGTGATGGAGATG (SEQ ID NO: 303); sgRNA2, TGTGTTCCCCAAAGAAG (SEQ ID NO: 304); sgRNA3, GACCATGCAGTTATCTG (SEQ ID NO: 305). A scrambled sgRNA sequence was used as a control.
[0345] Western blotting. For cell lysate preparation, cells were lysed with Laemmli buffer. Protein concentration was assessed using a BCA protein assay kit (Pierce, 23225). Proteins were then run by SDS-PAGE and transferred to membranes according to established protocols. The primary antibodies were anti-DDR1 (dilution: 1:1000; CST, 5583S) and anti-GAPDH (dilution: 1:5000; CST, 2118S).
[0346] To recover proteins in the conditioned medium, the medium was collected, centrifuged at 6,000 rpm, and then passed through a 0.45 μm pore filter to remove any cellular debris. The medium was subjected to SDS-PAGE and subsequently immunoblotted with anti-DDR1 ECD antibody (dilution: 1:1000; R&D, AF2396).
[0347] qRT-PCR. RNA extraction and RT-qPCR were performed as previously described (Sun et al., 2018). Briefly, RNA was reverse transcribed using the ImProm-II Reverse Transcription System (Promega, A3800), and real-time PCR was set up using Luminaris Color HiGreen qPCR Master Mix (Thermo Fisher Scientific, K0364). Relevant primers were generated through Primer Premier software. The primer sequences are as follows:
[0348] TIFF2024164067000021.tif32128
[0349] MTT. Tumor cells were seeded into 96-well plates and cultured for the indicated period before analysis. On the day of harvest, MTT solution (3 mg / ml) was added to each well, and the plate was incubated for 1 hour. The medium was then removed, and the purple precipitate was dissolved with 100 μl of DMSO. The absorbance at 570 nm was measured for each well.
[0350] Tumor cell migration and invasion. For cell migration, tumor cells were suspended in serum-free culture medium and then seeded on top of the transwell chamber. Medium containing 10% FBS was placed at the bottom of the chamber. Cells were cultured for 12 hours and then analyzed.
[0351] For cell infiltration, Matrigel matrix (Corning, 354483) was filled into the insert according to the manufacturer's instructions and incubated at 37°C for 30 minutes. Tumor cells were seeded into the upper chamber of the insert using 10% FBS-containing medium in the lower chamber. The cells were then incubated at 37°C for 20 hours. The upper cells in the upper chamber were gently removed, and the lower cells in the upper chamber were stained with crystal violet, and six random fields were counted under a standard microscope.
[0352] Mouse treatments and tumor studies. All animal experiments were approved by the Institutional Animal Care and Use Committee at the George Washington University. Eight-week-old WT C57BL / 6 (Jackson Lab, 000664), Rag1 - / - (Jackson Lab, 002216) or nude (Jackson Lab, 002019) mice were used for tumor studies. E0771, AT-3, and M-Wnt cells were administered at 5 × 10 per inoculation, respectively. 5 , 2 × 10 5 , and 2 × 10 5 The cells were injected into the mouse mammary fat pad in a volume of 100 μl. The tumor volume (0.5 × length × width) was 2 ) was measured using a caliper on the indicated days. At the time of tumor harvest, tumors were weighed and samples were used for immunophenotyping and IHC.
[0353] For the tumor transplantation assay, first, tumor cells were transfected with Rag1 - / - The tumor volume was approximately 200-300 mm 3When tumor tissue size reached 100 μg (typically 20 days after inoculation), 60 mg of tumor organoids were transplanted into WT C57BL / 6 mice. On day 12, tumor samples were collected for immunostaining.
[0354] For tumor rechallenge experiments, WT C57BL / 6 mice were first inoculated with 0.5 million DDR1 KO E0771 tumor cells or PBS alone into one side of the inguinal mammary fat pad. Thirty days later, the same mice were inoculated with 0.5 million DDR1 WT E0771 tumor cells into both sides of the mammary fat pad. Tumor volumes were measured as described above.
[0355] For in vivo treatment with DDR1 antibodies, a 100mm diameter 3 Once larger, both the home-made control IgG and the anti-huDDR1 ECD antibody were injected locally into the tumor at 10 mg / kg every other day until the end of the experiment.
[0356] Decellularization. E0771 cells were seeded at 2,000 cells per insert into inserts with a 5 μm pore size (Costar, Corning Inc., 3422) and cultured in DMEM + 10% FBS + 1% PS medium for 2 days. The resulting ECM from DDR1 WT or KO cells was washed with PBS and decellularized by incubation in PBS containing 0.5% Triton X-100 and 20 mM NH4OH at 37 °C for 5 minutes. The decellularized ECM was washed three times with PBS, followed by rinsing three times with distilled water, and immediately used in T cell migration experiments.
[0357] In vitro CD8 + T Cell Isolation and Migration Assay. EasySep™ Mouse CD8 + CD8 was isolated using a negative isolation kit (Stemcell, 19853) according to the manufacturer's instructions. + T cells were isolated from splenocytes of naive C57BL / 6 mice. +T cell migration assays were performed using 6.5 mm polycarbonate membranes and 5 μm pore size inserts (Costar, Corning Inc., 3422). + T cells were added to the upper chamber and allowed to migrate for 2 hours at 37°C with tumor-conditioned medium in the bottom chamber in the presence of recombinant CCL21 (100 ng / ml, R&D Systems, 4576C025CF). + T cells were quantified by flow cytometry. For huDDR1 antibody neutralization, antibodies were first co-incubated with conditioned medium at 37°C for 1 hour, then the procedure described above was followed.
[0358] Second-harmonic generation and immunofluorescence. Mouse breast tumor tissue was embedded and stored in optimal cutting temperature (OCT) compound at -80°C. Samples were cooled to -20°C for at least 2 hours before sectioning, and 20-μm-thick sections were cut using a cryostat. Slides were thawed, incubated at 37°C for 30 minutes, and then transferred to boiling antigen unmasking solution (Vector Labs, H-3300) for 10 minutes. Samples were incubated with CD3e (BD, 553057) primary antibody and Alexa-488 (Life Technologies) secondary antibody. Each tumor section was filled with fluorescent G medium (VWR) and mounted on a microscope cover slip (No. 1.5).
[0359] All samples were imaged using a Leica TCS SP8 multiphoton confocal microscope, and a 20x HC PL Apo, NA 0.7 oil immersion objective was used throughout the experiment.
[0360] The excitation wavelength was adjusted to 840 nm (Erikson et al., 2007), and a narrow bandpass emission filter of 420 ± 5 nm was used to detect the collagen SHG signal. The SHG signal is generated when two incident light photons interact with the non-centrosymmetric structure of collagen fibers, resulting in photons with a wavelength half that of the incident photon. Images of 1024 × 1024 pixels were acquired using LAS X software. Collagen measurements were performed using CT Fire software (freely available at loci.wisc.edu / software / ctfire). For collagen from tumor margin analysis, a 60 μm area was taken from the tumor border.
[0361] Immunohistochemistry (IHC) staining. Mouse breast tumor tissue was fixed overnight at 4°C in 10% buffered formalin (Fisher Scientific, 23-427098). Fixed tumor samples were embedded in paraffin and cut into 4-μm sections for staining. Samples were deparaffinized and rehydrated in PBS. Sections were boiled in antigen unmasking solution (Vector Labs, H-3300) for 20 minutes and then blocked with 10% normal goat serum in PBS for 1 hour. CD8 (Biorbyt, orb10325) and CD4 (Sino Biological Inc., 50134-R001) primary antibodies were incubated overnight at 4°C. Primary antibody detection was performed using the ABC peroxidase detection system (Vector Labs, PK-6105) according to the manufacturer's instructions, with DAB (Vector Labs, SK-4105) as the substrate.
[0362] CD8 + T cell depletion and adoptive transfer. CD8 + For T cell depletion, C57BL / 6 mice were administered 200 μg / mouse of anti-mouse CD8 (clone 2.43, BioxCell, BE0061) or IgG2b isotype control (clone LTF-2, BioxCell, BE0090) intraperitoneally 2 days before tumor inoculation and then twice weekly.
[0363] CD8+ For adoptive transfer of T cells, 17 days after tumor inoculation, purified CD8 + T cells (>90%) were 5 × 10 6 Rag1 bearing E0771 mammary tumors at a concentration of 100 cells / mouse - / - transferred to the mouse.
[0364] Picrosirius Red Staining. Fixed breast tumor samples were prepared and sectioned as previously described (Sun et al., 2018). Briefly, paraffin-embedded tumor tissues were cut into 4 μm slides and stained with a Picrosirius Red Staining Kit (Abcam, catalog no. ab150681). Sections were deparaffinized, hydrated in distilled water, and Picrosirius Red solution was applied to the slides for 1 hour. Slides were then rinsed in acetic acid solution and dehydrated in absolute alcohol. Mounted slides were then examined under a standard microscope, and positive collagen fiber signals were quantified using ImageJ software.
[0365] ELISA. Type I collagen was diluted to a concentration of 50 μg / ml in PBS and added to a 96-well microtiter plate (50 μl / well). The plate was sealed, incubated overnight at room temperature, washed three times with wash buffer (R&D, WA126), and then blocked with 200 μl of reagent diluent (R&D, DY995) for 1 hour. After three washes, 100 μl of conditioned medium or recombinant ECD (used as a standard, Sino Biological, 10730-H08H) was added to the plate for 2 hours at room temperature. Subsequently, after three washes, 100 μl of diluted anti-DDR1 N-terminal antibody (1:500, R&D, AF2396) was added and incubated for 2 hours. After 1 hour of reaction with the biotin-conjugated antibody, streptavidin-HRP was added to each well at a dilution of 1:2000 (R&D, 893975) and incubated in the dark for 20 minutes. 100 μl of substrate solution (R&D, DY999) was added and incubated for another 20 minutes. After adding 50 μl of stop solution (R&D, DY994), the plate was analyzed at 450 nm in an ELISA reader.
[0366] Flow cytometry. Cells were stained for viability using Ghost Dye™ Violet 450 (Tonbo Biosciences, 13-0863-T100) at a dilution of 1:1000 in PBS for 20 minutes at 4°C in the dark, followed by washing with PBS. Samples were blocked with anti-CD16 / 32 (clone 2.4G2, Tonbo Biosciences, 70-0161-U100) at a dilution of 1:100. The antibody was incubated for 30 minutes at 4°C in the dark. The following commercially available antibodies were used: CD45-BV645 (Invitrogen, 64-0451-82), CD3-eflor660 (eBiosciences, 50-0032-82), CD4-FITC (eBiosciences, 35-0042-U500), CD8-APC-Cy™7 (BD, 557654), CD44-BV786 (Biolegend, 103059), and CD62L-Pacific Blue (Biolegend, 104424). Data were acquired on a BD FACSCelesta flow cytometer and analyzed using FACSDiva or FlowJo software (BD).
[0367] Scanning electron microscopy. Both WT and DDR1 KO E0771 cells were cultured at 0.1 × 10 6 Cells were seeded at a density of 100 μg / cm2 and cultured in DMEM (10% FBS) for 2 days to allow even adhesion to the surface of glass coverslips. Cells were then fixed in a 2.5% glutaraldehyde and 1% paraformaldehyde solution, followed by rinsing with OsO₄ and water. The samples were then dehydrated through a gradient of alcohols and critical point dried. Once mounted on an SEM stub, the coverslips were coated with iridium and observed under a scanning electron microscope (Model FEI) equipped with an ETD detector at a 10 ms dwell time and a magnification of 12,000.
[0368] Screening and generation of anti-DDR1 monoclonal antibodies (mAbs). Human DDR1 extracellular domain (ECD) protein (Sino Biological, 10730-H08H) was used to immunize rabbits and generate anti-huDDR1 monoclonal antibodies using a previously described method (Gui et al., 2019b). Briefly, New Zealand White rabbits were administered 0.5 mg of recombinant human DDR1 ECD protein by intraperitoneal (ip) injection for a priming immunization and a series of 3–4 booster immunizations at 3-week intervals. Memory B cells were isolated from PBMCs, and single B cells were cultured in 96-well cell culture plates for 10–14 days for antibody production. Cell culture supernatants were analyzed for DDR1 binding using ELISA, and positive hits were selected for antibody gene cloning and sequence analysis.
[0369] Positive cells from B cell culture wells were lysed, total RNA was isolated, and cDNA was synthesized using SuperScript Reverse Transcriptase II (Invitrogen) according to the manufacturer's recommendations. The DNA sequences of the antibody variable regions from both the heavy and light chains were amplified by polymerase chain reaction (PCR) using a set of designed primers and cloned into vectors for sequencing each antibody variable region. The cloned antibody variable sequences from both the heavy and light chains were fused to the constant regions of IgG1 heavy and kappa light chains, respectively, and constructed into mammalian expression vectors for full-length recombinant antibody expression in human embryonic kidney (HEK) 293 (HEK293F) cells (Life Science Technologies). Monoclonal antibodies were purified from HEK293 cell culture medium to greater than 95% purity using Protein-A affinity resin, using a previously described method (O'Donnell et al., 2019). The purified antibodies were screened for neutralizing function in cell culture assays and antitumor activity in mouse tumor models.
[0370] Statistics. Student's t-test was used to compare mean differences between two groups. One-way analysis of variance (ANOVA) and post-hoc multiple comparisons were used to compare mean differences between multiple groups. Survival curves were analyzed by log-rank (Mantel-Cox) analysis. Pearson correlation analysis and all other statistics were performed with Graphpad Prism. P<0.05 was considered significant. Data are presented as mean ± SEM.
[0371] Example 2 - Results We specifically deleted Ddr1 in multiple mouse breast tumor cells with basal-like / TNBC characteristics (E0771, AT-3, and M-Wnt; Figure 1a, Figure 5b-d). Knockout (KO) tumor cells did not exhibit any significant defects in cell proliferation, migration, or invasion in vitro (Figure 1b-d, Figure 5e-f). In addition, Ddr1-KO tumors in immunocompromised hosts grew at the same rate as wild-type (WT) control mice (Figure 1e and Figure 5g). In stark contrast, Ddr1-KO tumors in immunocompetent hosts (C57BL / 6) completely regressed 2 weeks after inoculation in all three breast tumor models tested (Figure 1f-h). This growth defect of KO tumors in immunocompetent hosts was observed after implantation of increased numbers of KO tumor cells (0.5–20 × 10 per inoculation). 6 cells (Fig. 5h) and in immunocompromised hosts (Rag1 - / -Initial growth in WT and subsequent retransplantation into immunocompetent naive mice did not rescue the growth defect (Figure 1i-j). Furthermore, co-transplantation using a mixture of equal numbers of parental WT and KO tumor cells resulted in robust tumor growth in immunocompetent hosts (Figure 5i-k), demonstrating the dominant role of tumor DDR1. When WT tumor cells were injected into either the same or contralateral mammary gland into immunocompetent mice previously challenged with KO tumor cells, no significant growth of the rechallenged parental tumor was observed (Figure 1k-m). This indicates that KO tumor cells can vaccinate the host against WT tumors. Collectively, these data strongly suggest that tumor DDR1 plays a distinct role in tumor growth in immunocompetent hosts.
[0372] Immunohistochemistry (IHC) was performed to identify CD4 + and CD8 + We showed that T cells were restricted to the peripheral regions of parental tumors after retransplantation from immunocompromised to immunocompetent hosts (Fig. 2a). In contrast, these lymphocytes were abundant at both the periphery and center of Ddr1-KO tumors (Fig. 2a). In support, flow cytometry revealed that tumor-infiltrating CD8 + and CD4 + We demonstrated that the total number of T cells (normalized by tumor weight) was substantially elevated in the KO tumor group compared to the parental control (Figure 2b-c). + and CD4 + CD44 T cells were also more abundant in KO tumors than in their WT counterparts (Figure 2d-e). Furthermore, effector and helper T cells were more strongly activated (CD44 T cells) in KO tumors compared to their parental controls. 高 CD62L 低 However, when normalized to the corresponding total T cell counts, KO and parental controls showed no significant differences in CD4 T cell positivity for Ki67 (Fig. 6a-b), IFNγ, or Gzmb (Fig. 2c-d). + or CD8 +There was no difference in the percentage of T cells, indicating that tumor DDR1 likely confers tumor exclusion of T cells without attenuating T cell proliferation or antitumor activity per se.
[0373] To confirm the role of tumor DDR1 in antagonizing antitumor immunity, we investigated the role of tumor DDR1 in antagonizing antitumor immunity in immune-competent mice by neutralizing antibodies. + Ddr1-KO tumors depleted T cells, similar to our findings in immunocompromised hosts (Fig. 1e). + They grew as robustly as isogenic WT controls in cell-depleted hosts (Figures 2h-j, 2e-f). In reciprocal experiments, we observed that purified CD8 + T cells were adoptively transferred into immunodeficient mice, and the growth of parental and KO tumors was compared. Unlike sham-treated immunodeficient hosts, the transplanted CD8 + Mice bearing T cells produced KO tumors that were significantly smaller than the parental tumors (Figure 2k-m, Figure 6g). Collectively, these results support the notion that tumor DDR1, while not necessarily required for intrinsic growth of breast tumors, plays an important role in suppressing T cell infiltration.
[0374] Intratumoral T cell trafficking is a highly dynamic, multistep process that involves extravasation through blood vessels, tumor-induced chemotaxis, and crossing ECM-based physical barriers (Slaney et al., 2014, Sackstein et al., 2017, Ager et al., 2016). CD31-based histological analysis did not reveal significant immunovascular changes between WT and KO tumors (data not shown), nor did RNA-seq reveal any differences in mRNA levels of T cell homing genes or chemokine-coding genes that could explain the enhanced immune infiltration in the Ddr1-KO group (Figure 6h-i). Given the affinity of DDR1 for collagen, we sought to test an alternative model in which tumor DDR1-collagen interactions render tumors less accessible to immune cells. To this end, we first determined whether the immunoregulatory function of DDR1 depends on its kinase activity by transfecting DDR1-KO tumor cells with the following constructs (Figure 3a): (1) empty vector (EV), (2) full-length mouse DDR1 (FL), (3) ΔKD, a truncated DDR1 lacking the intracellular kinase domain (KD) but retaining its transmembrane (TM) domain, and (4) ECD only. The growth defect of KO tumors in immunocompetent hosts was rescued to a similar extent by ectopically expressed FL DDR1 and two truncated variants, ΔKD and ECD (Figure 3a). Further deletion analysis showed that the N-terminal discoidin homology domain (DS, Figure 3b), which is involved in collagen binding, completely rescued tumor growth of DDR1 KO cells (Figure 7a-b). Taken together, these data clearly demonstrate that tumor DDR1 suppresses antitumor immunity in a kinase-independent manner.
[0375] Based on the collagen-DS domain crystal structure (Letinger, 2014; Carafoli et al., 2012; Carafoli & Hohenester, 2013), we mutated several key collagen-binding amino acid residues in mouse DDR1 (W54, T58, D71, K113, E114, and S176, Figure 3b) that correspond to W53, T57, D70, K112, E113, and S175 in human DDR1. We also mutated R33, a residue distal to the collagen-binding pocket responsible for DDR1 transmembrane signaling. The collagen-binding affinities of the WT and mutant ECDs were verified in vitro by ELISA and co-IP (Figures 3c and 7c), and their ability to rescue KO tumor growth was assessed in vivo (Figures 3d-k). As expected, R33A, located outside the collagen-binding region of the ECD, retained the ability to bind collagen and support tumor growth (10 / 10 tumors for WT ECD and 6 / 6 for R33A, Figure 3c-e). In contrast, W54A completely lost the ability to bind collag...
Claims
1. 1. An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to discoidin domain receptor 1 (DDR1) protein, comprising: A light chain variable region having an LC-LC-CDR1, LC-CDR2, and LC-CDR3 in the light chain variable region selected from SEQ ID NOs: 108-128; and A heavy chain variable region having HC-CDR1, HC-CDR2, and HC-CDR3 within the heavy chain variable region selected from SEQ ID NOs: 129 to 149. Contains or and variants thereof, wherein one or more of the LC-CDRs and / or the HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof. Including, The isolated monoclonal antibody or antigen-binding fragment thereof.
2. LC-LC-CDR1, LC-CDR2, and LC-CDR3 of a clone pair selected from Table 1, and HC-CDR1, HC-CDR2, and HC-CDR3 selected from Table 2 Contains or and variants thereof, wherein one or more of the LC-CDRs and / or the HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof. Including, 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1.
3. a light chain variable region having an LC-CDR1 comprising the amino acid sequence QSIGSV (SEQ ID NO:11), an LC-CDR2 comprising the amino acid sequence GVF, and an LC-CDR3 comprising the amino acid sequence QYIPYGSSP (SEQ ID NO:12); and a heavy chain variable region having an HC-CDR1 comprising the amino acid sequence GFSLNRYY (SEQ ID NO:57), an HC-CDR2 comprising the amino acid sequence ISYGDTT (SEQ ID NO:58), and an HC-CDR3 comprising the amino acid sequence ARADTGDNGYLGLQL (SEQ ID NO:59); (DDR1-9), or and variants thereof, wherein one or more of the LC-CDRs and / or the HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof. Including, 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1.
4. a light chain variable region having an LC-CDR1 comprising the amino acid sequence ESINSW (SEQ ID NO: 41), an LC-CDR2 comprising the amino acid sequence DAS, and an LC-CDR3 comprising the amino acid sequence QSYYIINRSNYGNS (SEQ ID NO: 42); and a heavy chain variable region having a HC-CDR1 comprising the amino acid sequence GFSLSSYY (SEQ ID NO: 102), a HC-CDR2 comprising the amino acid sequence ITTAGPL (SEQ ID NO: 103), and a HC-CDR3 comprising the amino acid sequence ARGHAGSIYYSYFDL (SEQ ID NO: 104); (DDR1-32), or and variants thereof, wherein one or more of the LC-CDRs and / or the HC-CDRs have one, two, or three amino acid substitutions, additions, deletions, or a combination thereof. Including, 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1.
5. A light chain variable region having an amino acid sequence selected from SEQ ID NOs: 108 to 128, and a heavy chain variable region having an amino acid sequence selected from SEQ ID NOs: 129 to 149. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising:
6. (a) a light chain variable region (DDR1-1K) having the amino acid sequence of SEQ ID NO: 108, and a heavy chain variable region (DDR1-1H) having the amino acid sequence of SEQ ID NO: 129; (b) a light chain variable region (DDR1-3K) having the amino acid sequence of SEQ ID NO: 109, and a heavy chain variable region (DDR1-3H) having the amino acid sequence of SEQ ID NO: 130; (c) a light chain variable region (DDR1-5K) having the amino acid sequence of SEQ ID NO: 110, and a heavy chain variable region (DDR1-5H) having the amino acid sequence of SEQ ID NO: 131; (d) a light chain variable region (DDR1-6K) having the amino acid sequence of SEQ ID NO: 111, and a heavy chain variable region (DDR1-6H) having the amino acid sequence of SEQ ID NO: 132; (e) a light chain variable region (DDR1-9K) having the amino acid sequence of SEQ ID NO: 112, and a heavy chain variable region (DDR1-9H) having the amino acid sequence of SEQ ID NO: 133; (f) a light chain variable region (DDR1-11K) having the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region (DDR1-11H) having the amino acid sequence of SEQ ID NO: 134; (g) a light chain variable region (DDR1-12K) having the amino acid sequence of SEQ ID NO: 114, and a heavy chain variable region (DDR1-12H) having the amino acid sequence of SEQ ID NO: 135; (h) a light chain variable region (DDR1-13K) having the amino acid sequence of SEQ ID NO: 115, and a heavy chain variable region (DDR1-13H) having the amino acid sequence of SEQ ID NO: 136; (i) a light chain variable region (DDR1-14K) having the amino acid sequence of SEQ ID NO: 116, and a heavy chain variable region (DDR1-14H) having the amino acid sequence of SEQ ID NO: 137; (j) a light chain variable region (DDR1-15K) having the amino acid sequence of SEQ ID NO: 117, and a heavy chain variable region (DDR1-15H) having the amino acid sequence of SEQ ID NO: 138; (k) a light chain variable region (DDR1-17K) having the amino acid sequence of SEQ ID NO: 118, and a heavy chain variable region (DDR1-17H) having the amino acid sequence of SEQ ID NO: 1039; (l) a light chain variable region (DDR1-20K) having the amino acid sequence of SEQ ID NO: 119, and a heavy chain variable region (DDR1-20H) having the amino acid sequence of SEQ ID NO: 140; (m) a light chain variable region (DDR1-21K) having the amino acid sequence of SEQ ID NO: 120, and a heavy chain variable region (DDR1-21H) having the amino acid sequence of SEQ ID NO: 141; (n) a light chain variable region (DDR1-22K) having the amino acid sequence of SEQ ID NO: 121, and a heavy chain variable region (DDR1-22H) having the amino acid sequence of SEQ ID NO: 142; (o) a light chain variable region (DDR1-23K) having the amino acid sequence of SEQ ID NO: 122, and a heavy chain variable region (DDR1-23H) having the amino acid sequence of SEQ ID NO: 143; (p) a light chain variable region (DDR1-26K) having the amino acid sequence of SEQ ID NO: 123, and a heavy chain variable region (DDR1-26H) having the amino acid sequence of SEQ ID NO: 144; (q) a light chain variable region (DDR1-28K) having the amino acid sequence of SEQ ID NO: 124, and a heavy chain variable region (DDR1-28H) having the amino acid sequence of SEQ ID NO: 145; (r) a light chain variable region (DDR1-29K) having the amino acid sequence of SEQ ID NO: 125, and a heavy chain variable region (DDR1-29H) having the amino acid sequence of SEQ ID NO: 146; (s) a light chain variable region (DDR1-32K) having the amino acid sequence of SEQ ID NO: 126, and a heavy chain variable region (DDR1-32H) having the amino acid sequence of SEQ ID NO: 147; (t) a light chain variable region (DDR1-33K) having the amino acid sequence of SEQ ID NO: 127, and a heavy chain variable region (DDR1-33H) having the amino acid sequence of SEQ ID NO: 148, or (u) a light chain variable region (DDR1-34K) having the amino acid sequence of SEQ ID NO: 128, and a heavy chain variable region (DDR1-34H) having the amino acid sequence of SEQ ID NO: 149 Contains or and variants thereof, which specifically bind to a DDR1 protein, wherein the light chain variable region has an amino acid sequence identity of 80% or more to the amino acid sequence of the parent light chain variable region, and the heavy chain variable region has an amino acid sequence identity of 80% or more to the amino acid sequence of the parent heavy chain variable region. Including, 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1.
7. A light chain variable region (DDR1-9K) having the amino acid sequence of SEQ ID NO: 112, and a heavy chain variable region (DDR1-9H) having the amino acid sequence of SEQ ID NO:
133. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising:
8. A light chain variable region (DDR1-32K) having the amino acid sequence of SEQ ID NO: 126, and a heavy chain variable region (DDR1-32H) having the amino acid sequence of SEQ ID NO:
147. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising:
9. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 or 2, wherein the isolated monoclonal antibody is a murine antibody, a rodent antibody, a rabbit antibody, a chimeric antibody, a humanized antibody, or a human antibody.
10. 10. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 9, wherein the isolated monoclonal antibody is a rabbit antibody or a chimeric antibody.
11. 10. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 9, wherein the isolated monoclonal antibody is a rabbit antibody or a chimeric antibody.
12. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein the isolated monoclonal antibody is a humanized antibody.
13. A light chain variable region having the amino acid sequence of SEQ ID NO: 150 or 151 (DDR1-9hu_Lv1 or DDR1-9hu_Lc2), and Heavy chain variable region having the amino acid sequence of SEQ ID NO: 152 (DDR1-9hu_Hv) Contains or and variants thereof, which specifically bind to a DDR1 protein, wherein the light chain variable region has an amino acid sequence identity of 80% or more to the amino acid sequence of the parent light chain variable region, and the heavy chain variable region has an amino acid sequence identity of 80% or more to the amino acid sequence of the parent heavy chain variable region. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising:
14. The antigen-binding fragment may be an ScFv (single chain variable region fragment) antibody, a Fab fragment, an F(ab') 2 The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 13, which is a Fv fragment or an Fv fragment.
15. An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to an epitope specifically bound by the isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 1 to 14 or to all or a portion of the same epitope.
16. An isolated monoclonal antibody or antigen-binding fragment thereof that competes for the same epitope as the isolated monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 14.
17. 17. An antibody-drug conjugate comprising the isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 1 to 16 and an anti-tumor drug linked to the antibody or antigen-binding fragment thereof.
18. The antibody-drug conjugate of claim 17, wherein the anti-tumor drug is linked to the antibody via a photolabile linker or an enzymatically cleavable linker.
19. The antibody-drug conjugate of claim 17 or 18, wherein the anti-tumor drug is a toxin, a radioisotope, a cytokine, or an enzyme.
20. A pharmaceutical composition comprising the isolated monoclonal antibody or antigen-binding fragment thereof of any one of claims 1 to 14 and a pharma- ceutically acceptable carrier.
21. An isolated polynucleotide encoding the isolated monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 14.
22. A vector comprising the isolated nucleic acid of claim 21.
23. The vector of claim 22, comprising an expression vector capable of expressing the encoded antibody or antigen-binding fragment thereof.
24. 24. A host cell comprising a polynucleotide according to claim 21 or a vector according to claim 22 or 23.
25. 25. The host cell of claim 24 which is a mammalian cell.
26. 26. The host cell of claim 25, which is a CHO cell.
27. A hybridoma or engineered cell encoding and / or producing the isolated monoclonal antibody of any one of claims 1 to 14.
28. A host cell according to any one of claims 24 to 26, capable of expressing said monoclonal antibody or an antigenic fragment thereof. A method for producing an antibody, comprising culturing The method comprises culturing the host cell under conditions suitable for expression of the antibody or antigen-binding fragment thereof, and isolating the antibody or antigen-binding fragment thereof.
29. A chimeric antigen receptor (CAR) protein comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14.
30. 30. An isolated nucleic acid encoding the CAR protein of claim 29.
31. A vector comprising the isolated nucleic acid of claim 30.
32. 32. The vector of claim 31 , capable of expressing the CAR protein.
33. 33. An engineered cell comprising the isolated nucleic acid of claim 30 or the vector of claim 32.
34. 34. The engineered cell of claim 33, which is a T cell, a NK cell, or a macrophage.
35. Administering to a subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, or an engineered cell according to claim 33 or 34. A method of treating or ameliorating the effects of cancer in a subject, comprising:
36. 36. The method of claim 35, wherein the method reduces or eradicates tumor burden in the subject.
37. 37. The method of claim 36, wherein the number of tumor cells is reduced or the tumor size is reduced.
38. 36. The method of claim 35, wherein the cancer is a solid cancer or tumor.
39. 39. The method of claim 38, wherein the cancer is selected from pancreatic cancer; lung cancer, including small cell lung cancer and non-small cell lung cancer; colon and colorectal cancer; head and neck cancer; gastric (gastric) cancer; ovarian cancer; breast cancer; kidney cancer; liver cancer; prostate cancer; cervical cancer; brain cancer; skin cancer, including melanoma; and bone cancer.
40. 39. The method of claim 38, wherein the cancer is breast cancer.
41. 41. The method of claim 40, wherein the breast cancer is a breast cancer subtype selected from: (a) Luminal A (ER+ and / or PR+, HER2-), (b) Luminal B (ER+ and / or PR+, HER2+), (c) Triple Negative (ER-, PR-, HER2-), (d) HER2+ / ER- (ER-, PR-, and HER2+), and (e) Unclassified (ER-, PR-, HER2-, Cytokeratin 5 / 6-, and HER1-).
42. A method according to any one of claims 35 to 41, wherein cancer cells of the cancer are identified as or determined to express secreted DDR1 protein and / or DDR1 protein on the surface of the cancer cells.
43. The method of any one of claims 35 to 42, wherein the antibody or antigen-binding fragment thereof is administered intravenously, intraarterially, intratumorally, or subcutaneously.
44. The subject may be treated with any of the following drugs: topoisomerase inhibitors, anthracyclines topoisomerase inhibitors, anthracyclines, daunorubicin, nucleoside metabolic inhibitors, cytarabine, hypomethylating agents, low dose cytarabine (LDAC), a combination of daunorubicin and cytarabine, injectable daunorubicin and cytarabine liposomes, Vyxeos®, azacitidine, Vidaza®, decitabine, all-trans retinoic acid (ATRA), arsenic, arsenic trioxide, histamine dihydrochloride, Ceplene®, interleukin-2, aldesleukin, Proleukin®, getumuzumab Ozogamicin, Mylotarg®, FLT-3 inhibitors, midostaurin, Rydapt®, clofarabine, farnesyltransferase inhibitors, decitabine, IDH1 inhibitors, ivosidenib, Tibsovo®, IDH2 inhibitors, enasidenib, Idhifa®, smoothened (SMO) inhibitors, glasdegib, arginase inhibitors, IDO inhibitors, epacadostat, BCL-2 inhibitors, venetoclax, Venclexta®, platinum complex derivatives, oxaliplatin, kinase inhibitors, tyrosine kinase inhibitors, PI3 kinase inhibitors, BTK inhibitors, ibrutinib, IMBRUVICA®, a 36. The method of claim 35, further comprising administering one or more drugs selected from the group consisting of calabrutinib, CALQUEENCE®, zanubrutinib, PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, LAG3 antibody, ICOS antibody, TIGIT antibody, TIM3 antibody, CD40 antibody, 4-1BB antibody, CD47 antibody, SIRP1α antibody or fusion protein, E-selectin antagonist, antibody that binds to a tumor antigen, antibody that binds to a T cell surface marker, antibody that binds to a myeloid cell or NK cell surface marker, alkylating agent, nitrosourea agent, antimetabolite, antitumor antibiotic, plant-derived alkaloid, hormone therapy agent, hormone antagonist, aromatase inhibitor, and P-glycoprotein inhibitor.
45. The method of any one of claims 35 to 44, wherein the isolated monoclonal antibody or antigen-binding fragment thereof further comprises an anti-tumor drug linked thereto.
46. 46. The method of claim 45, wherein the anti-tumor drug is a toxin, a radioisotope, a cytokine, or an enzyme.
47. Administering to said subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, or an engineered cell according to claim 33 or 34. A method of treating or alleviating the effects of fibrosis in a subject, comprising:
48. 48. The method of claim 47, wherein the subject has organ fibrosis.
49. 49. The method of claim 48, wherein the subject has renal, hepatic, pulmonary, or cardiac fibrosis.
50. 50. The method of claim 49, wherein the subject has pulmonary fibrosis.
51. 51. The method of claim 50, wherein the subject has interstitial lung disease.
52. 51. The method of claim 50, wherein the subject has idiopathic pulmonary fibrosis (IPF) or lung scarring.
53. 1. A method for detecting cancer cells or cancer stem cells in a sample or subject, comprising: (a) contacting a subject or a sample from a subject with an antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, and (b) detecting binding of the antibody to cancer cells or cancer stem cells in the subject or sample. The method comprising:
54. 54. The method of claim 53, wherein the sample is a body fluid or a biopsy.
55. 55. The method of claim 54, wherein the sample is blood, bone marrow, sputum, tears, saliva, mucosa, serum, urine, or feces.
56. The method of any one of claims 53 to 55, wherein said detection comprises immunohistochemistry, flow cytometry, FACS, ELISA, RIA, or Western blot.
57. performing steps (a) and (b) again; and determining the change in the detection level compared to the first time 54. The method of claim 53, further comprising:
58. The method of any one of claims 53-57, wherein the isolated monoclonal antibody or antigen-binding fragment thereof further comprises a label.
59. 59. The method of claim 58, wherein the label is a peptide tag, an enzyme, a magnetic particle, a chromophore, a fluorescent molecule, a chemiluminescent molecule, or a dye.
60. 60. The method of any one of claims 35-59, wherein the isolated monoclonal antibody or antigen-binding fragment thereof is conjugated to a liposome or nanoparticle.
Citation Information
Patent Citations
Novel Anti-DDR1 antibody having Anti-tumor activity
WO2013027802A1
